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ABSTRACT 
Neo-adjuvant chemo-radio therapy (pCRT) has been accepted as a standard care in 
the treatment of patients with locally advanced rectal cancer. The multimodality 
treatment has been established to improve tumour downstaging, pathological 
complete response, and local disease control. However, the response of individual 
tumors to the treament is not uniform and ranges from complete response to 
complete resistance. The discovery of new molecular markers that predict the 
tumour response is surely of wide interest for personalizing the therapy and reducing 
time, costs and side effects in the patients with resistant tumours. Many potential 
biomarkers have been evaluated in order to predict the response to pCRT, and to 
implement targeted therapeutics. However, single-marker or multi-markers analyses, 
based on pre-treatment tissue biopsies, often obtained conflicting results 
demonstrating the heterogeneity of the individual tumour response. Moreover, the 
prediction of histopathological response to neo-adjuvant treatment is complicated by 
the interaction and the involvement of the microenvironment in modulating the 
sensitivity to pCRT.  In this study, we developed blood-based methods of biomarker 
analysis in order to evaluate the histopathological response to treatment in a broad 
contest that can take into account not only the signalling pathway of tumour cells 
but also the microenvironment as a part of a unique system. Indeed, the non-invasive 
nature and the dynamism for which different molecules could be detected according 
with physiological and pathological states has given us the possibility to monitor the 
response along the administration of the treatment. In particular, we focused on two 
different kind of circulating molecules: the cell-free DNA (cfDNA) and the 
circulating low molecular weight (LMW) peptides. In particular, we investigated the 
presence, the quantity of cfDNA and its integrity (cfDNA integrity = non apototic 
cfDNA / total cfDNA) along the chemo-radio treatment.  For this purpose we 
measured the cfDNA concentration and cfDNA integrity in a prospective study of 
locally advanced rectal cancer patients plasma collected before the pCRT, after two 
weeks from initiation of the pCRT and after the pCRT. We evaluated the association 
of these markers with the histological response to the chemo-radio therapy, 
demonstrating a different kinetic of cfDNA integrity in association with the tumour 
response.   
Then we studied the LMW peptidome circulating in plasma, in order to find 
evidences of possible differences in the peptide profile that could reflect the tumour 
response. To overcome the technical difficulties in harvesting LMW species, we 
have employed the mesoporous chip-based technology, developed by the 
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Nanomedicine Department of The Methodist Hospital Research Institute in 
Houston, Texas.  This mesoporous device, in combination with matrix-assisted laser 
desorption/ionization - time of flight mass spectrometry (MALDI-TOF MS), allows 
the isolation and the detection of small peptides from the large proteins. We 
analyzed plasma of rectal cancer patients, with positive or negative response to the 
therapy, at the same time points as the cfDNA: before, during, after the chemo-radio 
therapy. Multivariate analyses of the LMW peptide profile at different time points 
identified combinations of peptides that revealed high discriminating capacity of the 
different tumour responses. In particular, before the pCRT, a pattern of five ionic 
species showed a sensitivity and a specificity of 80% and after the pCRT, a pattern 
of other five specific ionic species showed a sensitivity of 80% and a specificity of 
85% to cluster patients on the basis of histopathologic response to pCRT. Moreover 
the identification of the amino acids sequences of the response-specific ionic species 
revealed the presence of protein fragments that could be directly or indirectly 
valuable for further investigation on the resistance mechanisms of the rectal tumour 
to the neo-adjuvant chemo-radio therapy. 
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RIASSUNTO 
La radiochemioterapia neoadiuvante (pCRT) è un protocollo standard accettato per 
il trattamento di pazienti con cancro rettale localmente avanzato. Il trattamento 
preoperatorio multimodale è stato introdotto per la riduzione dello stadio del tumore, 
per l’aumento della risposta completa patologica e per il controllo locale della 
malattia. Tuttavia la risposta patologica al trattamento non è uniforme e varia da una 
risposta completa alla resistenza totale. La scoperta di nuovi marcatori molecolari in 
grado di predire la risposta del tumore è sicuramente di grande interesse al fine di 
personalizzare la terapia, riducendo così i tempi, i costi e gli effetti collaterali nei 
pazienti con tumori resistenti. Molti potenziali biomarcatori sono stati valutati con 
l’obiettivo di prevedere la risposta alla pCRT, e di attuare terapie mirate. Finora 
molti studi su singolo o multi-marcatore sono stati eseguiti prevalentemente su 
biopsie di tessuto pre-trattamento. I risultati ottenuti, tuttavia, erano spesso 
contrastanti dimostrando l'eterogeneità individuale della risposta tumorale al 
trattamento. Inoltre, la predizione della risposta istopatologica alla pCRT è 
complicata dall’interazione e dal coinvolgimento del microambiente che può 
modulare la sensibilità del tumore al trattamento. In questo studio, abbiamo 
sviluppato metodi di analisi di biomarcatori su sangue, al fine di valutare la risposta 
del tumore al trattamento in un contesto più ampio, che rende conto non solo 
dell’ambiente strettamente tumorale, ma che prende in considerazione anche il 
microambiente come parte di un sistema unico. Infatti, la natura non invasiva del 
materiale biologico analizzato e il dinamismo per cui molecole differenti possono 
essere rilevate secondo lo stato fisiologico e patologico dell’organismo, ci hanno 
permesso di monitorare la risposta lungo il tempo di somministrazione del 
trattamento. In particolare, ci siamo concentrati su due diversi tipi di molecole 
circolanti: il DNA libero da cellule (cfDNA) e i peptidi a basso peso molecolare 
(Low Molecular Weight, LMW). In particolare, abbiamo studiato la presenza, la 
quantità e l’integrità del cfDNA durante il trattamento radio-chemioterapico. A 
questo scopo abbiamo misurato la concentrazione e l'integrità del cfDNA (cfDNA 
integrity=cfDNA apoptotico/cfDNA totale) in uno studio prospettico di plasma di 
pazienti con carcinoma rettale localmente avanzato, raccolto prima della pCRT, 
dopo due settimane dall'inizio del trattamento e dopo la pCRT. Abbiamo valutato 
l'associazione di questi marcatori con la risposta istologica alla chemio-radio terapia, 
dimostrando la presenza di diversa cinetica nell’integrità del cfDNA, in associazione 
con la risposta tumorale. 
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Nel plasma, abbiamo quindi studiato il peptidoma circolante a basso peso 
molecolare, al fine di trovare potenziali differenze nel profilo peptidico che 
potessero riflettere la risposta tumorale. Per superare le difficoltà tecniche nella 
rilevazione dei peptidi circolanti a basso peso molecolare, abbiamo utilizzato una 
strategia basata sull’esclusione dimensionale di un chip di silice mesoporosa (MSC), 
sviluppato dal Dipartimento Nanomedicina del The Methodist Hospital Research 
Institute di Houston, Texas. Questo dispositivo mesoporoso, in combinazione con 
l’utilizzo dello spettrometro di massa MALDI-TOF MS (Matrix-Assisted Laser 
Desorption/Ionization-Time Of Flight Mass Spectrometry), consente l'efficiente 
rimozione di grandi proteine e l'isolamento del peptidoma circolante da campioni di 
fluidi corporei. Abbiamo analizzato il plasma di pazienti con cancro rettale, 
prelevato in diversi tempi (prima, durante, dopo la chemio-radio terapia) e 
stratificati secondo la risposta positiva o negativa alla pCRT. L'analisi multivariata 
del profilo peptidico nei diversi tempi di analisi ha identificato combinazioni di 
peptidi che evidenziavano un’elevata capacità discriminante della risposta tumorale. 
In particolare, il modello di regressione logistica ha evidenziato, prima della pCRT, 
una combinazione di cinque specie ioniche capace di identificare i pazienti che non 
rispondono al trattamento, con una sensibilità e una specificità del 80%; mentre la 
stessa analisi con i campioni raccolti dopo la pCRT, ha identificato un'altra 
combinazione di cinque specie ioniche che evidenziano una sensibilità del 80% e 
una specificità del 85%. Inoltre, l'identificazione delle sequenze amminoacidiche di 
alcune tra le specie ioniche discriminanti la risposta alla pCRT, hanno rivelato la 
presenza di frammenti proteici che possono essere direttamente o indirettamente 
utili per ulteriori indagini sui meccanismi di resistenza del tumore rettale alla radio-
chemio terapia neo-adiuvante. 
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INTRODUCTION 
 
1 RECTAL CANCER 
Rectal and colon tumours are commonly referred as one disease named Colon-
Rectal Cancer (CRC). This definition originates from the common anatomic 
localization; indeed rectum is the continuation of the part of the large bowel of colon 
and it shows similar morphology and configuration. Furthermore colon and rectal 
tumours share many features; they have similar aetiology and type of precancerous 
lesions. However, the issue whether colon and rectal tumours should be considered 
as a single or two distinct entities is still debated because they showed some 
different features at both clinical management and molecular level. Differences have 
been found at the age of tumour formation, the gender of the patients, the clinical 
behaviour, and the therapeutic strategies (Li M. et al., 2007).  In this contest rectal 
cancer will be presented as CRC for the features that share with colon cancer, 
highlighting on the distinctive characteristics of rectal cancer.  
 
1.1 EPIDEMIOLOGY AND AETIOLOGY 
CRC incidence and mortality rates vary markedly around the world. Globally, CRC 
is the third most commonly diagnosed cancer in males and the second in females, 
with over 1.2 million new cases and 608,700 deaths estimated to have occurred in 
2008.  CRC presents a serious public healthcare issue for the population of Europe, 
as it is the most common newly diagnosed cancer and the second most common 
cause of cancer deaths in Europe. It has been estimated that in 2006, 412.000 people 
were diagnosed with CRC in Europe, and more than 200.000 of them die of the 
disease (Ferlay J. et al., 2006; Zavoral M. et al., 2009). In Italy, CRC is the second 
more common tumour in women (12%, 145.027) preceded only by breast cancer, 
while in men is the third type of neoplasm (15%, 152.660) preceded by prostate 
cancer and bladder cancer (Epidemiologia 2010 suppl.2). Colorectal tumour 
includes different anatomic part of the digestive tract. In particular, adeno-carcinoma 
of the rectum contributes to 28% of the total colon and rectal cancer burden, 
resulting the seventh tumour type most commonly diagnosed in both females and 
males (Julien L.A. et al., 2010). Globally, the incidence of CRC varies over 10-fold. 
The highest incidence rates are in Australia and New Zealand, Europe and North 
America, and the lowest rates are found in Africa and South-Central Asia (Jemal A. 
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et al., 2011). Incidence rates in most western countries have been stable or increased 
slightly during the last 15 years. In contrast, CRC incidence rates have rapidly 
increased in several areas historically at low risk, including Spain, and a number of 
countries within Eastern Asia and Eastern Europe. 
Although the incidence of CRC is generally higher in both the gender, rectal 
tumours show a higher prevalence in males. The risk of the rectal disease is around 
17,2% in males and 9,3 % in females. CRC mortality is about 25% higher in men 
than in women, and both colonic adenomas and CRCs appear to have a more 
proximal distribution in women, particularly in postmenopausal women. Incidence 
of CRC increases with the age, as the majority of cases are diagnosed in patients 
more than 50 years of age.  Large bowel cancer is uncommon before the age of 40; 
the incidence begins to increase significantly between the ages of 40 and 50, and 
age-specific incidence rates increase in each succeeding decade thereafter. Lifetime 
incidence of CRC in patients at average risk is about 5%, with 90% of cases 
occurring after age 50. Interestingly, rectal cancer is rare under the age of 45. About 
two-third of patients with rectal cancer are over 65 years of age.  
Death rates from CRC have declined progressively since the mid 1980s in the 
United States and in many other western countries. This improvement in outcome 
can be attributed, at least in part, to detection of CRC at early stages and to use of 
more effective treatments. The good prognosis of patients with CRC decreased from 
90% in locally confined tumours, to 63% in the infiltrating and non-metastatic 
tumours, until 5% in the case of metastatic tumours (Li F.Y. et al., 2009). 
1.1.1 Risk factors 
Colorectal cancer presents a family’s or hereditary derivation in 20% of cases 
whereas the remaining 80% occurs sporadically. Although cancer of the rectum and 
colon follow a common scheme of neoplastic progression, they seem to have distinct 
characteristics and, in particular, the impact of family or hereditary derivation is 
very low in rectal cancer.  Studies on migrants suggest that colorectal cancer risk is 
determined largely by environmental exposure. Rates in migrants moving from low-
risk to high-risk countries tend to increase to the rates of the host countries within 
the migrating generation itself (Zampino M.L., 2004). 
 Several risk factors have been identified increasing person’s chance in developing 
colorectal cancer. Diet is the most important exogenous factor identified up to now 
in the aetiology of colorectal cancer. It has been estimated that 70% of colorectal 
cancers could be prevented by nutritional intervention. Various promoting and 
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protective factors have been identified. There are many evidences that diets rich in 
vegetables protect against this type of cancer; vegetables contain a large quantity of 
micronutrients (carotenoids, folate, ascorbate), bioactive compound (phenols, 
flavonoids, isothiocyanates) with anti-carcinogenic properties. Diets with high fiber 
content may be cause lower exposure of the rectal epithelium to carcinogens derived 
from the environment, as the dietary fibers favour transit through the bowel. 
Furthermore the role of fibers as a protective factor for CRC was confirmed in 
European large cohort (Vainio H. et al., 2006).  On the other hand, several 
epidemiological studies reported the negative effect of the red meat intake. The 
mechanism by which the red meat and processed meat increase the colorectal cancer 
risk include the effect of the fat on bile acid production that increase the possibility 
of cellular membrane damage. Furthermore, carcinogens can be produced when the 
meat is processed and cooked. Overcooking the meats or cooking with high 
temperatures contributes to formation of heterocyclic amines, strong oxidants that 
might react with DNA by inducing the accumulation of genomic instability 
(Burnett-Hartman A.N. et al., 2011).   
The role of other factors, such as the consumption of alcohol and sugar is more 
controversial. Alcohol intake seems to be associated more with an increased risk in 
rectal cancer than in colon cancer for which it has a modest effect (Valentini V. et 
al., 2008).  Some non-dietary factors like smoking tobacco, radiation, chronic 
inflammation, increase the risk of colorectal cancer (Wang J. et al., 2012).  For both 
incidence and mortality, the association was stronger for rectal cancer than colon 
cancer.  Cigarette smoking, both active and passive, has been identified as risk 
factors for rectal cancer in case-control and cohort studies. Recent smokers and 
those that have smoked many packs/years of cigarettes have been estimated to have 
from a 50% increment to a doubling of risk of rectal cancer compared to non-
smokers (Hooker C.M. et al., 2008). The association between cigarette smoking and 
rectal cancer may be impacted by the ability to detoxify polycyclic aromatic 
hydrocarbons (PAH) generated from cigarette smoking (Curtin K. et al., 2009).  
Increasing evidence suggests that diabetes mellitus is associated with an elevated 
risk of CRC. One possible explanation linking diabetes to CRC is hyperinsulinemia, 
because insulin is an important growth factor for colonic mucosal cells and 
stimulates colonic tumour cells (Larsson SC et al., 2005). 
1.1.2 Protective factors 
A large number of factors have been reported by at least some studies to be 
associated with a decreased risk of CRC. These include regular physical activity, a 
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variety of dietary factors, the regular use of aspirin or non-steroidal anti-
inflammatory drugs (NSAIDs), and hormone replacement therapy in 
postmenopausal women. Evidences suggest that aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs) protect against the development of colonic adenomas 
and cancer. Regular use of aspirin and other NSAIDs are associated with a 20 to 40 
percent reduction in the risk of colonic adenomas and colorectal cancer in 
individuals at average risk. How the aspirin produce this protective factor is not well 
understood yet. Proposed explanations include the increased apoptosis and 
impairment of tumour cell growth by inhibition of cyclooxygenase-2 (Wang J. et al., 
2012).  
 
1.2 RECTAL ANATOMY 
The large bowel is divided into two anatomical regions: proximal “right” region and 
distal “left” region. The rectum is part of the distal region that includes: splenic 
flexure, descending colon, sigmoid colon and rectum. This division is supported by 
the distinct embryonic ontogenesis. The proximal large intestine develops from the 
embryonic midgut and it is supplied by the superior mesenteric artery; the distal 
large intestine forms from the embryonic hindgut and it is supplied by the inferior 
mesenteric artery. Interestingly, rectum originates from the cloaca. The rectum 
presents three lateral curvatures: the upper and the lower are convex to the right, the 
middle convex to the left (Figure 1). The adult rectum is 15-20 cm in length and is 
divided into equal thirds: the upper third, which is mobile and has a peritoneal coat; 
the middle third which is the widest part of the rectum and where the peritoneum 
covers only the anterior and part of the lateral surfaces; and the lowest third, which 
lies within the muscular floor of the pelvis and has important relations to fascial 
layers. These fascial layers are surgically important, as they are a barrier to 
malignant penetration and valuable guides to operation. The artery supplies are 
divided in superior, middle and inferior rectal arteries. The arteries and their 
accompanying lymphatic are kept to the back of the rectum by dense connective 
tissue (mesorectum) that decreases up to disappear in the lowest third. The venous 
drainage includes the superior haemorrhoidal veins draining the upper half of the 
anal canal above the dentate line pass upwards to become the rectal veins. It forms 
part of the portal venous system and ultimately drains into the splenic vein. The 
rectum presents more abundant diffuse lymphatic tissue and lymph nodules. Rectum 
lymphatic drainage occurs in the mesorectum, to the inferior mesenteric artery, 
lateral to the internal iliac artery and down to the inguinal area. 
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Figure 1. Rectum anatomy 
 
The rectum is composed of an innermost layer of mucosa that lies over the 
submucosa, and two continuous sheaths of muscle, the inner circular and outer 
longitudinal layer. Rectum histology resembles that of the colon, but it is 
distinguished by transverse rectal folds in its submucosa and the absence of tenia 
coli in its muscularis externa. The mucosa of the rectum largely resembles the colon, 
with a simple columnar epithelium shaped into straight tubular crypts.  Rectum 
presents crypts that are longer than the crypts in small intestine. The crypts are more 
widely spaced and a higher proportion of goblet cells are interspersed among the 
adsorptive cells. Neutral mucopolysaccharide is predominant in the ascending colon, 
whereas in the rectum acidic mucin is predominant or exclusive. The mucus 
facilitates the passage of the increasingly solid colonic contents, and covers bacteria 
and particulate matter. Rectum shows an unusually high concentration of endocrine 
cells, compared with the other segments (Bailey & Love's Short Practice of Surgery, 
25th edition, 2012).  
 
1.3 COLORECTAL CANCER PROGRESSION 
The development of rectal cancer is common, for many aspects, to that of the colon 
cancer. Morphological data, consolidated with clinical, epidemiological and 
molecular observations, suggested the hypothesis that its occurrence is the result of a 
long series of events leading to the definition of the “adenoma-carcinoma sequence” 
as model of cancer progression (Figure 2). This transformation occurs slowly and 
gradually in about 10-15 years and progresses through both histological changes and 
genetic alterations, highlighting a multistep progression at both molecular and 
pathophysiological level (Vogelstein B. et al., 2000; Fodde R, 2001). 
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Figure 2. Colorectal cancer morphological progression 
 
Intestinal epithelium shows numerous invaginations called crypts, each of which 
contains several thousands of differentiated cells and a small number of active stem 
cells located at the bottom of the crypts (Kauh J. et al., 2004). Cells constantly 
migrate from the basal level to the intestinal lumen in a process 3-6 days long. 
During the migration the cells grow up and differentiate, losing their ability to 
divide. In the intestinal lumen they are eliminated by exfoliation that involves 
apoptotic mechanism of death. In this way, there is a complete and continuous 
renewal of the mucosa epithelium, while death and growth cell rates are equivalent 
(Fodde R., 2001). It has been shown that in tumours, there exist a subset of stem cell 
or cancer stem cells that drive tumour growth and possess similar characteristics of 
proliferation, self-renewal, clonogenicity and multi-potentiality as stem cells show 
in normal organs (Buczacki S. et al., 2011). One hypothesis is that colorectal cancer 
stem cells could originate from gastrointestinal stem cells, which represent the 
natural target of tumourigenic mutations due to their long life and their capacity for 
self-renewal (Ricci-Vitiani L. et al., 2008). Alternatively, differentiated cells could 
re-acquire stem-like characteristics. These two possibilities are not mutually 
exclusive, and it is not certain in which tumours or specific circumstances either 
occur (Buczacki S. et al., 2011).  
The first recognizable histological neoplastic lesion consists in the so-called 
“aberrant crypt foci” (ACF) that is caused by hyperproliferation of epithelial cells. 
ACFs are characterized by impaired luminary opening and thickened epithelium. 
The clonal expansion could lead to the formation of a benign tumour, known as 
“adenoma” or “polyp” that are limited and enclosed in a fibrotic membrane. 
Adenoma epithelium is characterized by abnormal morphology including alteration 
of cell differentiation, presence of hyper-chromatic nuclei and loss of cell polarity. 
The rectum, along with the sigmoid colon, is the most frequent site of polyps in the 
gastrointestinal tracts.  The rectum shares substantially the same spectrum of polyps 
as the colon. They can be either single or multiple. Adenoma could be classified 
according to different histopathological features like the dimension, the histological 
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type, and the degree of dysplasia. Colon adenomas can be subdivided in a large 
group of non-progressive lesions (∼95%), and a small group of progressive lesions 
(∼5%). It is not well understood which and how many adenomas might evolve in 
adeno-carcinoma but its features could favour the progression. The progression is 
marked by a gradual increase in dimension and in aggressiveness. In the first phase 
adeno-carcinoma is limited to the epithelium (carcinoma in situ); as it evolves, it 
acquires the ability to invade the tissue underneath the basement membrane 
(invasive carcinoma). The cancer may eventually acquire the ability to spread in the 
blood and lymph vessels and lymph node regions and reach distant organs 
(metastasis) (Kinzler K.W. et al., 1996; Fearon E.R. et al., 2011).  
For colon cancers, the progression pattern is typically characterized by distal 
metastasis, usually at liver site whereas rectal cancers usually have a pattern of local 
recurrence.  This is potentially explained by the fact that superior mesenteric vein 
drains the right colon whereas neither left colon nor rectal vasculature directly drains 
to liver.  Local spread occurs circumferentially rather than in a longitudinal 
direction. Around 2 years is required for complete encirclement. After the muscular 
coat has been penetrated, the growth spreads into the surrounding mesorectum. If 
penetration occurs anteriorly the sex organs are invaded (prostate, seminal vesicles, 
bladder in male, uterus and vagina in female). Spread via the venous system occurs 
late. The principal sites for blood-borne metastases are liver, lungs, adrenals (Bailey 
& Love's Short Practice of Surgery, 25th edition, 2012). 
 
1.3.1 Molecular pathways involved in cancer progression  
Cancer progression requires the accumulation of genetic and epigenetic alterations 
that affect signalling pathways that regulate hallmark behaviours of cancer and 
create clonal growth advantage.  CRC phenotypically appear to be a homogeneous 
disease while it is a heterogeneous disease at the molecular level, suggesting the 
existence of multiple CRC subtypes with distinct biological and clinical properties. 
Three are the most pathways involved in tumorigenesis (Worthley D.L. et al., 2007; 
Beggs A.D, et al., 2008). In more than 50% of the cases, CRCs are consequences of 
events that cause chromosome instability (CIN), associated with amplifications and 
deletions of chromosomal regions. Chromosome instability occurs mostly through 
the accumulation of numerical or structural chromosomal abnormalities, aneuploidy, 
and allelic deletions. In about 15% of sporadic colon cancers and tumours from 
patients with hereditary non-polyposis colorectal cancer (HNPCC), has been 
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observed nucleotide instability (MIN). MIN occurs by inactivation of genes 
involved in Mismatch Repair System (MMR) that has the function of repairing 
DNA replication errors. These events lead to insertions, deletions or substitutions of 
a few nucleotides in DNA strands.  CpG island methylator phenotype (CIMP) 
contributes to up to 20% of sporadic CRCs. CpG island methylation phenotype, is 
characterized by the hypermethylation of genes that play a role in carcinogenesis. 
Aberrant methylation of CpG-rich regions (CpG islands) at the promotor region or 
at the 5’ region of genes, leads to transcriptional silencing and therefore, inactivation 
of the gene (Jass J.R., 2007). Most sporadic microsatellite unstable colon tumours 
are CIMP positive, whereas CIMP is uncommon in HNPCC syndrome-associated 
cancer that exhibits MIN. CIMP is significantly more frequent in tumours of the 
proximal colon (30-40 %) than in distal colon or rectal cancers (3-12%). 
Rectal cancer is mainly associated with chromosomal instability that frequently 
exhibits a temporal genetic alteration sequence correlates with the histological 
cancer progression. Development of the normal gut and subsequently maintenance 
of colon tissue homeostasis is regulated by the balance between several key signal 
transduction pathways, in particular the Wnt, Notch, Hedgehog, and BMP pathways. 
Of these, the Wnt signal transduction pathway is most relevant to maintain the stem 
cell population. Constitutive activation of Wnt signalling stimulates proliferation 
and is a common and early event in colon tumour development, occurring in about 
80% of colon adenomas (Jimenez C. et al., 2010). The initial event, which is first 
observed in dysplastic cells present in the foci of aberrant crypts, is more frequently 
represented by the biallelic inactivation of the APC gene (Adenomatous Polyposis 
Coli). It has been considered that APC inactivation shows the highest malignant 
potential in cancer progression, as it is altered in 70-80% of cases of sporadic 
adenomas and carcinomas. APC is a tumour suppressor gene on chromosome 5q and 
it has a broad spectrum of functions, ranging from control of the Wnt signal 
transduction pathway, to cell adhesion, migration, signal transduction, apoptosis, 
microtubule assembly and chromosomal segregation at mitosis. APC usually lead to 
the degradation of citoplasmatic β-catenin, inhibiting the activation of Wnt pathway 
that is usually activated during embryogenesis and for the maintenance of tissue 
specific compartments of stem cells. APC inactivation interferes with the inhibition 
of Wnt pathway, increasing β-catenin accumulation and translocation to the nucleus 
where it promotes proliferation through expression of oncogenes like Myc and 
Ciclin D1 (Fearon E.R., 2011). 
The loss of function of APC may also interfere with the normal regulation of 
mitosis, contributing to chromosomal instability (Worthley D.L. et Al., 2007). 
	   13	  
Alterations in APC and Wnt pathway may represent a convenient mechanism in the 
progression of early lesions in the later stages as adenomas. Mutations or 
chromosomal deletions that determine the loss of other genes such as DCC, SMAD2 
and especially KRAS and SMAD4 contribute to the adenoma growth and its 
progression to neoplasia. KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog) encodes for a GTP-binding protein. Its alteration determines the loss of its 
GTPase activity and thus constitutive signalling through the downstream, (MAPK) 
pathway. At the molecular level, KRAS alteration induces genomic instability and/or 
by affecting G1 and G2/M cell-cycle transit times and apoptosis. Activating KRAS 
mutations are found in 35-42% of CRCs and in a similar percentage of advanced 
adenomas. DCC (Deleted in Colorectal Carcinoma), SMAD2 and SMAD4 (mothers 
against DPP homolog 2 and 4) are all located at 18q21.1 and allelic loss at this site 
is found in up to 60% of CRCs.  DCC encode a netrin-1 receptor it can induce 
apoptosis of epithelial cells when netrin-1 ligand is not bound. Furthermore, DCC is 
a caspase substrate, and mutation of the site at which caspase-3 cleaves DCC, 
completely suppresses the pro-apoptotic effect of DCC (Ren X.R. et al. , 2004). 
SMAD proteins are signal transducers and transcriptional modulators that mediate 
multiple signalling pathways. These proteins mediate the signal of the Transforming 
growth factor (TGF-β), and thus regulate multiple cellular processes, such as cell 
proliferation, apoptosis, and differentiation.    
As described above, although colon and rectal cancer are classified as a single entity 
of study, morphological and clinical-pathological differences exist between these 
two types of tumour.  On the basis of these evidences, studies have been made to 
highlight if there were molecular differences that could explain the different 
behaviour. So far the multistep model of rectal progression was confirmed but there 
are evidences that there may be alternative genetic events during tumour 
progression, events that occur at different frequency or at different temporal time. In 
a study of Kapitejan et al (Kapitejan E. et al., 2001) a greater presence of β-catenin 
in the nucleus of cells of rectal tumours than those of the colon has been highlighted; 
Frattini et al (Frattini, M. et al., 2004) showed a broader range of mutation types in 
APC in the colon than in the rectum. Mutations in APC have been found in 60% of 
colon tumours, compared to 80% for rectal cancer (Worthley D.L. et al., 2007). On 
the contrary, there is a higher prevalence of KRAS-dependent pathway alteration in 
colon cancer compared to the rectum tumour. Pamplona et al (Pamplona R.S. et al., 
2011) revealed only small gene expression differences between tumours arising in 
the colon or rectum, that are largely driven by the HOX family of genes. However 
other studies (Li J.N. et al., 2012) found different gene expression profiling and 
different protein expression, indicating that the situation could be more complex. 
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1.4 TNM CLASSIFICATION 
Prognosis of rectal tumours is closely correlated to the degree of tumour extension 
and the accurate preoperative staging is therefore essential to determine the most 
appropriate treatment protocol. Current protocols use the Tumor-Node-Metastasis 
(TNM) classification system that allows the physician to establish the grade of 
tumour progression by studying three parameters: 
• T: the size of the primary tumour 
• N: involvement of regional lymph nodes; this parameter depends on the 
number of affected lymph nodes and on the distance of lymph nodes affected 
from the primary site of the tumour 
• M: presence of distant metastases or disseminated tumour cells in organs 
other than the site of tumour origin.  
TNM classification is a dual system that includes a clinical classification (pre-
treatment) and a pathological (post-operative). The distinction between the two is 
crucial, as they are based on different types of examinations and they fulfil different 
purposes. In general, the classification of the clinical stage cTNM is used to evaluate 
the extent of the disease prior to the treatment, and it provides information for 
choosing the most appropriate treatment protocol. Modern imaging techniques 
(trans-rectal and endoscopic ultrasound and pelvic-rectal MRI), in addition to 
standard investigations (digital exploration, endoscopy, proctoscopy, trans-rectal 
scan and surgical exploration), allow physicians to more precisely determine tumour 
characteristics and prognostic factors in the preoperative setting. This knowledge 
has been used to improve cancer stage specific treatments.  After the surgery, post-
surgical pTNM staging help for prognostic evaluation and it is based on the 
integration of the data collected prior to treatment with those highlighted with 
pathological examination and surgical (Rodel C. et al., 2012) (Figure 3). 
 
Figure 3. The colon cancer progression staging and the correspondent TNM classification. 
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1.5 RECTAL CANCER THERAPY: SURGERY AND CHEMO-
RADIO THERAPY 
Treatment decisions are mainly based on TNM classification and on the 
Circumferential Resection Margin (CRM) at time of diagnosis. Based on their TNM 
stage, rectal cancers can be treated with a different therapeutic approach (Zampino 
M.G. et al., 2009).  Standardized surgical techniques, specifically Total Mesorectal 
Excision (TME), introduced in the mid-1900s, have reduced local recurrence rates in 
rectal cancer from 39% to 10% and increased 5-year-survival rates to 71%. TME is 
one of the most influential factors in rectal cancer outcomes and is now considered 
the standard of care for clinical practice. T1 or T2, lymph node–negative rectal 
cancers have very low local recurrence rates and high cure rates after TME surgery 
(Julien L.A. et al., 2010). Although the surgical resection is, for the majority of the 
cases, curative the recurrence risk and the mortality increase when the tumour 
locally spread the tissue (TNM II) or the local lymph nodes (TNM III). The 
prognosis of rectal cancer is clearly related to the degree of penetration of the 
tumour through the bowel wall, the presence of nodal involvement. Additional 
relevant parameters are the grading, the angio- or venous invasion and the perineural 
invasion.  In these cases, it has been observed that neo-adjuvant therapy for rectal 
cancer, implemented as a combination of chemotherapy and radiation therapy, has a 
beneficial effect on local control. 
1.5.1 Neo-adjuvant chemo-radio therapy  
Neo-adjuvant chemo-radio therapy has been accepted as a standard care in the 
treatment of patients with locally advanced rectal cancer.  The advantages of neo-
adjuvant therapy utilizing radiation are due to improve responsiveness of tissue that 
is not hypoxic by previous surgery. Theoretically, ionizing radiation is more 
effective in irradiation of virgin tissue due to the increased oxygen tension in this 
tissue. Accordingly, preoperative radiation and chemotherapy are more effective in 
producing tumour cell kill in the non-disturbed pre-surgical tumour bed compared to 
the hypoxic postsurgical bed. Several other advantages with neo-adjuvant therapy 
include less radiation-induced small bowel injury in the pelvis, which has not been 
fixed by previous surgery, and the ability to excise the irradiated rectal segment and 
perform an anastomosis to healthy, non-irradiated colon, resulting in improved post-
operative function. In addition, studies have shown that chemo-radiation therapy, in 
the preoperative setting, decreased of acute toxic effects and long-term toxic effects 
compared to giving it post-operatively (Sauer R. et al., 2004). Modern regimens, 
including improved imaging, better chemotherapy, and more accurate and focused 
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radiation, have resulted in an increased frequency of tumour down-staging (refers to 
the change in stage between pre-therapy clinical evaluation and post-therapy clinical 
or pathologic evaluation), a higher likelihood of complete clinical and pathologic 
responses, and a decreased local recurrence rates in stage II and III rectal cancer. In 
addition, the utilization of neo-adjuvant therapy in the management of stage IV 
disease has shown potential for prolonged survival. The combination of the 
treatments has been established to improve tumour down-staging tumour down-
sizing, survival and in some cases, sphincter preservation (Julien L.A. et al., 2010). 
The major local effects of chemoradiotherapy, that cause cell damage, are elicited by 
irradiation, whereas the chemotherapy enhances these effect as a radiosensitizer, 
most often with a small direct effect on tumour cells damage. Ionizing radiation can 
have multiple effects on cells by disrupting chemical bonds in all the basic 
components of cells such as membranes, lipids, proteins and most importantly, in 
the genetic compartment of the cell, the DNA. The most well-studied target of 
radiation is DNA. Although all components can theoretically damaged by radiation, 
studies demonstrated that the main target is the nucleus. Radiation damage can cause 
base damage, DNA-protein crosslink, single-strand or double strand breaks, which 
occurs directly through ionization or indirectly through the action of chemical 
radicals that are produced during irradiation. Classic radiobiology classifies 
radiation cell interaction into 5 categories: repair, redistribution, reoxygenation, 
repopulation, and molecular regulation (Harrington K et al., 2007).  Multiple 
pathways are involved mediating the cellular response to ionizing radiation and they 
culminate in either cell checkpoint arrest, which allow DNA damages to repair, or 
the activation of cell death pathways through necrosis or apoptosis. These cells 
accumulate in G2/M to be repaired. DNA damage starts to be repair within minutes 
by error-free processes (base excision repair, nucleotide excision repair, homologous 
recombination) and error-prone processes (nonhomologous end joining). Single 
strand breaks are generally repaired by nucleotide excision repair whereas double 
strand breaks are repaired by 2 mechanisms: nonhomologous end joining and 
homologous recombination. Cells in G2/M are more sensitive to radiation as double 
strand break will likely lead to aberrant chromosome formation during mitosis 
causing cell death. This sensitivity is used to improve the cell death through delivery 
of radiation in multiple fractions. The interval from one radiation fraction to another 
allows the resistant cells, not killed in response to the first fraction, to progress to 
G2/M before the next fraction. This process is called redistribution of cells into the 
cell-cycle phases and it is due to the synchronization and accumulation of cells in 
the G2/M phase that have to be repaired (Selzer E. et al., 2012). Sensitivity in this 
cell-cycle phase is due to the condensed chromatin that enhances the probability for 
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the photon to passes through more DNA and causes irreparable double-strand 
breaks. Fractionation of treatment also improve tumour cell killing through 
reoxygenation of cell that were hypoxic and therefore resistant before the radiation. 
Reoxygenation of cells improves the sensitivity to radiation because oxygen makes 
permanent the damage caused by free radicals (Woodward W.A. et al., 2008). In 
addition to the DNA damage some studies emphasizes the role of multisystem tissue 
interaction in radiation response (Barcellos-Hoff M.H. et al., 2006). 
Chemotherapeutic agents are used in combination with the radiotherapy because it 
has been noticed an increment of the cell sensitivity to the radiotherapy. The 
chemotherapeutic drug commonly used in rectal cancer treatment is 5-fluorouracil 
(5-FU), which induces the arrest of DNA synthesis with a consequent interruption of 
the duplication of the cell. The 5-FU action is directed to the transcriptional 
inhibition of the gene coding for Thymidylate Synthetase (TS): an enzyme that 
catalyzes the transfer of a methyl group to deoxyuridine monophosphate (dUMP) 
with the formation of thymidine monophosphate, a key metabolite in DNA 
synthesis. 5-FU is an analogue of uracil with a fluorine atom at the C-5 position in 
place of hydrogen. It rapidly enters the cell using the facilitated transport mechanism 
of uracil. Into the cell, 5-FU is converted to several active metabolites: 
fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate 
(FdUTP) and fluorouridine triphosphate (FUTP) (Figure 4). These active 
metabolites disrupt RNA synthesis and the action of TS. 5-FU is inactivated by an 
enzyme to dihydrofluorouracil (DHFU). More than 80% of administered 5-FU is 
normally catabolized primarily in the liver (Longley D.B. et al., 2003). 
 
 
Figure	   4.	   Fluorouracil	   metabolism.	   5-­‐Fluorouracil	   (5-­‐FU	   is	   converted	   to	   three	  main	  active	   metabolites:	   fluorodeoxyuridine	  monophosphate	   (FdUMP),	   fluorodeoxyuridine	  triphosphate	   (FdUTP)	   and	   fluoro	   uridine	  triphosphate	   (FUTP)	   by	   a	   series	   of	   enzyme	  conversions	   and	   phosphorilations.	   The	   active	  metabolites	  can	  damage	  RNA	  molecules	  or	  can	  inhibit	   the	   Thymidylate	   synthetase	   (TS),	  inhibiting	   the	   DNA	   synthesis.	  	  Dihydropyrimidine	   dehydrogenase	   (DPD)-­‐mediated	   conversion	   of	   5-­‐FU	   to	  dihydrofluorouracil	  (DHFU)	  is	  the	  rate-­‐limiting	  step	  of	  5-­‐FU	  catabolism	  in	  normal	  and	  tumour	  cells.	   Up	   to	   80%	   of	   administered	   5-­‐FU	   is	  broken	  down	  by	  DPD	  in	  the	  liver	  (Figure	  from 
Longley D.B. et al., 2003).	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Current standard of treatment includes administration of ionizing radiation for 45-
50.4 Gy in 25-28 fractions associated with chemotherapy (5-FU) administrated 
during radiation treatment. 
Although there are numerous positive evidence, the application of the same protocol 
to tumours with similar characteristics in terms of TNM classification, has shown a 
broad histopathological response from one patient to another, ranging from complete 
regression to complete resistance highlighting the individual variability between the 
patients: in literature, the pathological complete response (pCR) are described with a 
variability ranging from 5 to 35% of cases (Reerink O. et al., 2004).  
1.5.2 Tumour regression grade (TRG) 
Tumour response to neo-adjuvant therapy appears to be an important prognostic 
factor and it is evaluated by determining the degree of tumour regression: Tumour 
Regression Grade (TRG). Tumour regression stratifies the response on the basis of 
the biological effect of radiation and chemotherapy to the tumour piece. The 
classification is based on the observation, made by the pathologist, of the presence 
of tumour cells directly on the piece of surgical resection. Tumour response to CRT 
is usually scored following the criteria proposed by Mandard AM et al.: TRG-1, 
pathological complete response (pCR); TRG-2, presence of residual cancer cells; 
TRG-3, fibrosis outgrowing residual cancer cells; TRG-4, residual cancer cells 
outgrowing fibrosis; and TRG-5, absence of response. The classification is 
represented graphically in Figure 5: 
 
Figure 5. Mandard Tumour Regression Grade used to classify the histopathological response in this 
study (took from Smith F.M. et al, 2007). 
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1.6 TUMOUR RESPONSE VARIABILITY TO THE NEO-
ADJUVANT CHEMO-RADIO THERAPY 
Different TRG values show a high variability in the biological response that is 
unrelated to the change of the tumour stage (T) after therapy. 
In order to increase the response rates to preoperative chemo-radio therapy, agents 
such as oxaliplatin and antibody-based regimens have been incorporated into 
multimodal treatment concepts, and these strategies are currently under extensive 
evaluation. However, at the same time, the inclusion of more toxic agents has 
increased the acute toxicity and long-term side effects of these treatments. In some 
cases, acute organ toxicity necessitates a dose reduction or even termination of 
therapy (Cunningham D., 2010). Furthermore, any higher grade of acute toxicity 
impairs the quality of life of the individual patient. The variability treatment-
associated tumour regression and toxicity from one patient to another are the major 
clinical problems, thus attention to the possibility to individualize rectal cancer 
treatment has increased (Grade M. et al., 2012).  The ability to predict tumour 
response before or in the early stage of the treatment may significantly impact the 
selection of patients for pre-operative combined therapy, establishing a more 
effective and personalized therapy. The benefits also include the avoiding of 
unnecessary toxic treatments and the reduction of time, costs and side effects in the 
patients with resistant tumours (Smith F.M. et al., 2007). The main interest of the 
scientific community is to customize the treatment so that the majority of 
individuals might have a targeted therapeutic benefit depending on the 
characteristics of the tumour. There are many factors that can contribute to the 
variability in the biological response to the treatment: the size of the tumour, the 
type and dose of radiation therapy and chemotherapy administered, the time elapsed 
between the end of treatment and surgery, histomorphological parameters 
(differentiation, inflammatory response, etc).  However, it is a well-recognized fact 
that individual sensitivity to chemo-radiation therapy is influenced by the genetic 
background and contributes to the toxicity of treatment effects (Lindsay KJ. et al., 
2007). Molecular information, which includes genomic, trascriptomic and proteomic 
effectors, modulate tumour and stromal cells response causing different sensitivity 
to the treatment.  This involves complex signalling processes that differ by cell type, 
cell contest, cell differentiation. Understanding the genetic background and the 
different molecular events related to the different tumour response could provide 
relevant clinical advantage on the ability to predict the chemo-radio resistance. 
Furthermore, information on the molecular pathways and the mechanisms 
underlying the tumour transformation might be used for the development of new 
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therapeutic agents more effective and less toxic to the body.  To this end, extensive 
investigations have been performed to identify molecular biomarkers differentiating 
responsive and resistant tumours.  
 
1.7 MOLECULAR TUMOUR BIOMARKERS 
Molecular tumour biomarkers are molecules produced by tumour itself or by other 
tissue in response to the presence of tumour or other associated conditions. While 
clinical exams show the presence of the tumour, molecular markers indirectly detect 
the tumour. Ideally a molecular marker should be peculiar only of the tumour and it 
should be easily and consistently identified. However, tumour often shows 
characteristics similar to the normal tissue and none of the known tumour markers is 
specific only for tumour cells. A number of different kinds of molecules can be 
biomarkers: DNA, RNA, proteins, metabolites. 
- These molecules could have different functions:  they can be part of 
apoptosis or proliferation process, they can be hormones, enzyme, oncofetal 
antigens or receptors;  
- These molecules could have different location: they can be nuclear, 
cytoplasmatic or extracellular molecules.  
In the last few years active researches has been carried out to find biomarkers with 
the aim of potentially stratify rectal cancer patients.  The majority of the studies 
have focused on tumour-tissue differences. Many groups investigated single or 
multi-biomarkers, focused on specific pathways involved in tumour progression, 
DNA repair systems, cell cycle progression pathway, pathways involved in death 
mechanisms (Kuremsky J.G. et al., 2009; Bertolini F. et al., 2007; Reerink O. et al., 
2004). DNA alterations, gene expression patterns and protein expressions were 
analyzed for detecting reliable biomarkers. However, for most studies, the results 
were conflicting and still remain inconclusive, highlighting the complexity and 
heterogeneity of the molecular mechanism involved in chemo-radio resistance. 
Since complex phenotypes like tumour responsiveness to chemo-radio therapy, do 
not depend on the alteration of a single molecule, high-throughput technologies have 
emerged for investigating multiple genetic events. Gene expression microarray have 
been applied to interrogate complex genetic pathways and networks simultaneously. 
Many groups analyzed the gene expression profile of tumour biopsies collected 
before the chemo-radio therapy. (Kim I.J. et al., 2007; Watanabe T. et al., 2006; 
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Ghadimi B.M. et al., 2005; Kuremsky J.G. et al., 2009; Brettigam-Moore K.H. et al., 
2011). However, gene signatures found by different authors had very limited overlap 
of genes and the results of testing published gene signature on different tumour 
cohort were useless. Several reasons could lead to this result and they range from 
technical to clinical differences. Collection of tumour biopsy before the treatment is 
usually carried out during colonoscopy or rectum exploration and it is often difficult 
to get enough tumour material. Lack of standardized clinical management rules and 
definitions, differences on the collection, storage, processing and quality control of 
biological material, differences in the microarray procedures and in the evaluation of 
results make difficult the comparisons between different works and make difficult 
the definition of reliable biomarkers.  Furthermore, several recent publications have 
provided evidence that tumour microenviroment is essential in modulating the 
tumour response to chemo-radio therapy since neighbour cells can express 
molecular factors that could be involved in different signalling pathways associated 
to tumour resistance (chemotactic molecules, growth factors, death factors) and they 
can regulate the recruitment of immune system cells.  Irradiated cells can induce 
mutagenic response in neighbouring cells, which are not directly traversed by 
particle radiation, via gap junctions (bystander effect) (Pajonk F et al., 2010; 
Mothersill C. et al., 2004). 
All these features highlight the complexity and heterogeneity of the individual 
tumour response and the importance of considering response to treatment in a broad 
contest that can take into account not only the signalling pathway of tumour cells 
but also the microenvironment as a part of a unique system. A potential alternative 
to response prediction tissue-based methods is the development of blood-based 
methods. Blood obtained by venopuncture is the most accessible human specimen, 
the least invasive, and feasible to monitor over long periods of time. The blood is 
like a liquid biopsy that captures different molecules from all organs and tissue in 
health and disease thus reflecting the physio-pathological state of a body. The 
dynamic nature of the circulatory system and its constituents reflects diverse 
physiological or pathological states, and the ease with which the blood can be 
sampled makes it a logical choice for biomarker applications. Blood components 
that provide an indication of cancer status include various cellular elements such as 
circulating tumour cells, cell-free DNA and RNA, proteins, peptides and 
metabolites. These tests are more desirable because they are less dangerous and they 
don’t present the side effects that could have the invasive type of analysis, which 
also must be performed by health care professionals with high level of 
specialization. Furthermore, it is possible to study blood-based markers in patients 
over time, making possible the disease monitoring. This would give many 
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advantages in early diagnosis as well as in monitoring the recurrences or the 
molecular alteration during a treatment, for determining the effectiveness.  
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PROJECT 1. Circulating cell-free DNA (cfDNA) as 
a promising diagnostic, prognostic and predictive 
marker of tumour malignancy 
 
2 cfDNA 
In the course of the search for new biomarkers, circulating cell-free DNA (cfDNA) 
has become a popular target of interest.  
The existence of nucleic acids (DNA and RNA) in human blood has been reported 
for the first time in 1948 by Mandel and Metais (Tsang J.C.H. et al., 2007). This 
attracted little attention in the scientific community until the observation, several 
years later, of a direct correlation between the amount of cfDNA in plasma and 
serum and the tumour disease. Although circulating cfDNA is present in healthy 
individuals, elevated concentrations have been found in cancer patients, reflecting 
the physiological and pathological states.  In support of this evidence many studies 
detected tumour specific alterations, suggesting the application of cfDNA as a 
potential candidate biomarker of diagnosis (Schwarzenbach H. et al., 2011). In the 
1994 mutated RAS gene fragments was detected in blood of cancer patient 
(Sorenson G.D. et al., 1994) and then, during the past decade increasing number of 
scientific groups found different tumour-specific alterations such as microsatellite 
instability, loss of heterozygosity, mutations, polymorphisms, methylation. Different 
groups tried to exploit the detection of genetic alteration in cfDNA for several 
clinical purposes such as early diagnosis, prognosis, and prediction of recurrences. 
However, cfDNA assays, which target specific mutations, require that the mutations 
in the tumour occur frequently at a specific genomic site. A major drawback of 
cfDNA assays is the low frequency of some mutations that occur in tumours 
resulting in observation of a lower percentage of patients that present tumour 
specific cfDNA compare with the real situation. The mutational background of 
cancer is enormously complex and this makes it quite difficult to find cancer 
specific mutations. Furthermore detection of a specific genetic alteration is 
complicated by the presence of cfDNA originated from normal cells that increase 
the background noise making the analysis difficult (Kohler C. et al., 2011). Tumours 
are usually a mixture of different cancer cell clones (which account for different the 
genomic and epigenomic alterations causing by the tumour heterogeneity) and other 
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normal cell types, such as stromal and haematopoietic cells (Schwarzenbach H. et 
al., 2011). Thus, during tumour progression and turnover, both tumour-derived and 
wild-type (normal) cfDNA can be released into the blood. The proportion of cfDNA 
that originates from tumour cells varies owing to the state and the size of the 
tumour. Furthermore, cfDNA is variably fragmented and the usual molecular tools 
of investigation that exploit the DNA replication strategy such as PCR, qPCR, 
sequencing, could fail the mutation detection. These problems are relevant in the 
prospective of use specific cfDNA biomarker for early detection of cancer or 
prognosis of the disease. Quantitative alteration of cfDNA has been observed to 
correlate with the tumour disease because elevated levels of cfDNA in serum and 
plasma have been detected in many cancer types. However the percentage of cfDNA 
that originates from the tumour are variable from patient to patient and sometimes 
different studies found discordant results. Concentrations of overall cfDNA vary 
considerably in plasma or serum of both patient and healthy groups. The causes may 
be biological (histology, the size, the stadium, the origin of the tumour), or they can 
be technical such as differences in the processing, in the recovery of cfDNA or in 
methods of genomic alteration detection. Furthermore, the origin and the mechanism 
of cfDNA release could be different in relation to different physiological condition 
and in relation with the presence of tumour.  
 
2.2 ORIGIN OF cfDNA 
To date, the physiological event that lead to the release of cfDNA during cancer 
development and progression are still not well understood.  Among the various 
hypotheses, it is thought the release of nucleic acids into the blood could be related 
to the apoptosis and necrosis of cancer cells in the tumour microenvironment. 
Secretion has also been suggested as a potential source of cfDNA as well as mitotic 
catastrophe and autophagy (Gormally E. et al., 2007).  
In a physiological state, fate of cells are constantly regulated by a fine balance 
between survival and death signals that are activated in response to internal or 
external environmental stimuli, regulating the cell homeostasis.  In physiological 
situations the usually exploited process of death is apoptosis, a regulated mechanism 
in which transcriptional and translational machines are intensively employed to 
ensure the controlled elimination of dying cells, preventing the involvement of 
inflammatory response. During apoptosis, genomic DNA is cleaved into DNA 
fragments of around 180bp in length. This is the result of cutting internucleosome 
fragments by endonucleases. This mechanism represents a real barrier to tumour 
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formation, because it is involved in the elimination of cells that undergo alterations 
to the genetic material exceeding the capacity of cellular repair. Indeed, inactivation 
of programmed death pathway is one of the important events in the development, 
progression and aggressiveness in cancer. In this situation the main events of cell 
death are non-apoptotic, such as tumour necrosis and mitotic catastrophy. In 
particular, necrosis is a pathological cell death that involves the enzymatic digestion 
of the cell, which fails to maintain the cell membrane integrity, causing the release 
of its content outside. This mechanism generates a spectrum of DNA fragments with 
variable and longer dimensions, made by incomplete and non-organized enzymatic 
cleavage (Kumar V. et al., 2009). Therefore, the increased length (integrity) of 
circulating cfDNA in cancer patients has been postulated to be a consequence of 
pathologic processes other than apoptosis that could be peculiar of tumour cells. 
Indeed, the degree of alterations in circulating cfDNA integrity has been shown to 
reflect the extent of cancer involvement. Different cell death mechanisms seem to be 
also involved in the response to neo-adjuvant treatment. Chemo-Radio therapy 
(CRT) exploits cell damages and in particular DNA damage to eliminate cancer cells 
(Lindsay KJ et al., 2007; Selzer E. et al., 2012; Woodward W.A. et al., 2008). Some 
studies found a correlation between observations of a high intrinsic apoptotic cell 
tumour index and the positive tumour regression (Smith F.M. et al., 2006). 
Therefore, the analysis of the integrity of cfDNA could provide an indication of the 
contribution of the various processes of death in the release of cfDNA. (Wang B.G. 
et al., 2003; Umetani N. et al., 2006). 
 
2.3 THE ROLE OF CFDNA AS PREDICTING TOOL OF 
HISTOPATHOLOGICAL RESPONSE: THE FIRST APPROACH 
 
A wider project started before my PhD program, has involved the evaluation of the 
cfDNA quantity and cfDNA integrity as markers in different cancer diseases, with 
diagnostic and prognostic purposes. The project has also included analysis of 
cfDNA concentration and cfDNA integrity fluctuation in rectal cancer, in relation to 
the tumour response to CRT. The obtained results, which have been recently 
published in a paper cited at the end of this thesis, are briefly described below. 
In this study we measured the cfDNA concentration and the cfDNA integrity in a 
retrospective study of 67 patients with locally advanced rectal cancer and we 
evaluated their association with tumour response to preoperative chemo-radio 
therapy. To maximize the sensitivity of the cfDNA quantification, we performed 
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quantitative real time PCR (qPCR) assays on the Alu repeat sequences. These 
sequence elements are part of SINE family (Short Interdispersed nuclear Elements) 
and they are non-coding, and highly repeated in the genome. The Alu sequence is a 
genomic region that extends for about 280 bp and it is composed by two tandem 
repeats of approximately 120 bp.  
cfDNA integrity was assessed as a ratio of the concentration of a fragment longer 
than 180 bp over the concentration of fragment smaller than 180bp. In brief we first 
demonstrated the significant increment of plasma cfDNA concentration and cfDNA 
integrity (AUC=0.90) in rectal cancer patients in comparison to healthy subjects 
with negative colonoscopy. This finding suggested the differential origin of cfDNA 
according with the pathological status. Moreover, after the CRT, cfDNA integrity 
was found to be associated with tumour response. During the treatment we observed 
a significant decrement of cfDNA integrity in Good responders (p-value=0,0048) 
caused by a decreasing of the longer cfDNA fragments that was not observed in 
Poor responders (p-value=0,0005).  
 
2.4 CRITICAL POINTS 
In this study cfDNA concentration and cfDNA integrity were evaluated with two 
sets of primers, Alu115 and Alu247, as reported by Umetani (Umetani N. et al., 
2006) where Alu115 amplified both the shorter and longer fragments and Alu247 
amplified only the longer DNA fragments. cfDNA quantification was obtained using 
the Alu115 primers represents the total plasma cfDNA, while quantification of the 
Alu247 primers reflected the amount of cfDNA released mainly from non-apoptotic 
cells.  qPCR were performed by using SYBR Green non-specific chemistry. SYBR 
Green is an asymmetrical cyanine dye used as a nucleic acid stain. It binds in non-
specific way to DNA molecules. Therefore, we performed a careful standardization 
of the method for gaining confidence that the correct fragment lengths were 
amplified. However, even if SYBR Green preferentially binds to double-stranded 
DNA, it will also stain single-stranded DNA and RNA with low performance. 
Moreover, SYBR Green exhibits a very strong fluorescent signal, but it has been 
shown to inhibit the PCR reaction if it is used at concentration sufficient to saturate 
the double stranded molecules generated during the amplification. Therefore, it must 
be used at low non-saturating concentrations to prevent reaction inhibition, but in 
this condition the signal could be less reproducible, because of the variability of the 
dye molecules number that can bind DNA amplicons. In addition, melt curve 
analysis using SYBR Green is complicated by its preferential binding to specific 
DNA fragments containing higher GC%, and by the dye redistribution due to the 
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non-saturated condition that occurs during the melting analysis altering the detection 
of low quantity of aspecific products or primer pairing with the melting curve 
(Gudnason H. et al., 2007; Eischeid A.C. et al., 2011). Limits of the technique used 
to detect the cfDNA and the limited control of the variables that influence the 
measurement, affect the quality and the reliability of the data. This problem can 
become important in a study where the quantitative information of fragments, with 
different lengths, have to be correlated in a ratio index.  
In association with Euroclone S.p.A. and in agreement with the aim of my Ph.D. 
project, we designed and standardized more specific and easy to use qPCR assays in 
view of a potential development of a scientific kit.  We exploited the Taqman 
chemistry involving the use of a fluorogenic probe that emits fluorescence only if 
DNA polymerase amplifies the right amplicon, increasing the specificity. A 
comparison between SYBR green non-specific chemistry and Taqman specific 
chemistry was performed for evaluating the possible differences in quantification 
and in sensitivity. We measured cfDNA of the same cases with the qPCR chemistry 
in parallel. 
Then we investigated the cfDNA concentration and cfDNA integrity in a 
prospective study of locally advanced rectal cancer patients to evaluate the 
association of these markers with the histological response to the chemo-radio 
therapy.  Accordingly with the previous study, we mainly focused our attention on 
the kinetics of the size distribution of cfDNA along the chemo-radio therapy. For 
this purpose we introduced a time point analysis after two weeks from the initiation 
of the CRT.  
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3 MATERIAL AND METHODS 
3.1 PATIENTS AND TREATMENT CHARACTERISTICS 
The prospective study included 49 rectal cancer patients who received neo-adjuvant 
chemo-radio therapy and underwent a surgical resection at the 2nd surgical section of 
Department of surgical, oncological and gastroenterological sciences (University of 
Padova). The pre-treatment evaluation of a rectal cancer patients that will undergo to 
a neo-adjuvant treatment, included a complete clinical history and physical 
examination, colonoscopy, complete blood cell count, transrectal ultrasound, pelvic 
computed tomography scan or magnetic resonance imaging, abdominal/chest 
computed tomography and carcino-embryonic antigen test. The inclusion criteria for 
CRT were as follows: a) biopsy-proven adenocarcinoma of the mid-low rectum (< 
11 cm from the anal verge); b) clinical stage T3-4 and/or node-positive; and c) 
Eastern Cooperative Oncology Group performance status 0-2. These patients were 
treated with external beam radiotherapy using high-energy photons (> 6 MV), with 
conventional fractionation (≥ 50 Gy in 28 fractions, 1.8 Gy/day, 5 sessions per 
week), and 5-fluorouracil (5-FU)-based chemotherapy administered by bolus or 
continuous venous infusion. A standard total mesorectal excision was performed 4 
to 8 weeks after the completion of CRT. Blood samples were collected before the 
CRT and before the surgical resection. Another draw blood was collected after 2 
weeks from initiation of the CRT. After the surgery, rectal resections were analyzed 
by a pathologist that observed the presence of tumour cells. The tumour response to 
CRT was defined using the Tumour Regression Grade (TRG) and was scored 
following the criteria proposed by Mandard et al. We defined patients with TRG 1 
and 2 as Good responders and patients with TRG 3, 4 or 5 as Poor responders. The 
study protocol was reviewed and approved by the local ethics committee (protocol 
number 740 P), and each patient provided written informed consent. 
 
3.2 cfDNA EXTRACTION 
Ten mL of peripheral blood was collected into a purple-top blood collection tube 
(containing EDTA additive) before physical examination or biopsy. Plasma samples 
were obtained by centrifugation of peripheral blood at 3,000g for 10 minutes. 
Plasma samples were carefully collected from the upper portion of the supernatant 
and stored in aliquots at −80°C. The DNA was extracted from 500µl of plasma with 
a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). The procedure involves 
cellular degradation and protein denaturation by adding Lysis buffer solution (AL 
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buffer) and proteinase K to the plasma sample in proportion 1:1 and 1:10 for buffer 
and proteinase K respectively.  The extraction method exploits the tendency of DNA 
molecules to adsorb to a silica column in the presence of high concentration of salts, 
ethanol and guanidine isothiocyanate. We introduced a carrier RNA poly-dA 
(Qiagen, Hilden, Germany) in the initial sample solution for increasing the binding 
efficiency of DNA fragments to the column. Purification of the DNA was performed 
by using Washing Buffer 1 and 2 (AW1 and AW2), which ensure the complete 
removal of any residual contaminants without affecting DNA binding. We increased 
the number of washing step with Washing Buffer 2 to eliminate all the organic 
residues. Elution of the nucleic acid from the columns was performed with the 
Eluition Buffer (AE), an ethanol-free solution with low concentration of salts. 
 
3.3 QUANTITATIVE PCR OF PLASMA cfDNA FRAGMENTS: 
PRIMER-PROBE SPECIFIC Alu ASSAYS 
On the basis of the Alu repeat consensus sequence, we designed two Taqman PCR 
assays. We used Primer Express V 3.0 (Applied Biosystem, Milan) to design several 
primer-probe sets. Primer-probe sets were evaluated in silico to minimize primer 
and probe complementarities; we used OligoAnalyzer 3.1 (Integrated DNA 
technologies, IDT) software to evaluate the different primer-probe for hairpins, self-
dimers and hetero-dimers. We selected two primer-probe assays of 83 bp (Alu83) 
and 244bp (Alu244) in length.  Alu83 assay was designed within the longer 
amplicon and thus it amplified both the short and the longer fragments, whereas the 
second primer set (Alu244) amplified only the long DNA fragments. cfDNA 
quantification obtained using the Alu83 assay represents the total cfDNA, while 
quantification of the Alu244 primers reflects the amount of cfDNA released mainly 
from non-apoptotic cells. We estimated the cfDNA integrity for each sample as the 
ratio of the long over the short fragments (Alu244/Alu83). The two assays shared the 
same probe: 5’-6FAM-CCTGGCCAACATGGTGAAACCCC-TAMRA-3’. Primers 
for the Alu83 assay were: primer forward 5’-CTGAGGTCAGGAGTTCGAGACC-
3’; primer reverse 5’-CCACGCCCGGCTAATTTT-3’ and primers for the Alu244 
were: primer forward 5’-GCGGTGGCTCACGCCTGTAA-3’; primer reverse 5’-
GGAGTGCAGTGGCGCGATCT-3’. Amplicon sizes and specificity were 
confirmed in gel electrophoresis. Real-time PCR amplification was performed with 
10ul of FluoCycle probe master mix (Euroclone, Milan) in a 20ul total. We 
performed the optimization assays by varying the primer and probe concentrations. 
We evaluated primer concentration ranging from 50nM to 900nM. Alu244 was 
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amplified using 900nM and 900nM of primer forward and reverse respectively, 
while Alu83 was amplified using 300nM and 900nM of primer forward and reverse 
respectively. Alu probe concentration was set to 250nM. The reaction was 
performed using 7300 Real-Time PCR System (Applied Biosystem, Milan) with 
hold 95°C for 5 minutes, followed by 35 cycles of 95°C for 15s and 62°C for 60s. 
The absolute amount of cfDNA in each sample was determined by a standard curve 
using 10-fold dilutions (from 10 ng to 0,1 pg) of genomic DNA derived from 
peripheral lymphocytes of clean-colon healthy subjects. A negative control (water 
template) and a positive control (cfDNA from a volunteer) were performed in each 
plate.  
3.3.1 Primer-probe specific Alu assays: a comparison with previous 
SYBR green based assays 
A comparison between SYBR green non-specific chemistry and Taqman specific 
chemistry was performed for evaluating if the two chemistry methods showed 
differences in quantification and in sensitivity. The setting of the two SYBR green 
assays are described as follow: Alu115 primers were as follows: forward, 5'- 
CCTGAGGTCAGGAGTTCGAG-3' and reverse, 5'-
CCCGAGTAGCTGGGATTACA- 3'; Alu247 primers were as follows: forward, 5'- 
GTGGCTCACGCCTGTTAATC- 3' and reverse, 5'-CAGGCTGGAGTGCAGTGG-
3' (PRIMM, Milan). Real-time PCR amplification was performed with 10ul of 
SYBR Green master mix (Applied Biosystem, Milan) in a 20ul total. Alu247 was 
amplified using 200nM and 600nM of primer forward and reverse respectively, 
while Alu115 was amplified using 500nM and 800nM of primer forward and 
reverse respectively. The reaction was performed using 7300 Real-Time PCR 
System (Applied Biosystem, Milan) with hold 95°C for 10 minutes, followed by 35 
cycles of 95°C for 30s and 64°C for 30s, followed by melt curve analysis. We 
quantified the cfDNA concentration and we assessed the cfDNA integrity using both 
the Taqman and SYBR green assays. For this purpose we analyzed a cohort of 90 
patients with colon cancer and 46 healthy subjects with the two sets of assays in 
parallel. 
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3.4 STATISTICAL ANALYSIS  
Descriptive results are expressed as median and 25%-75% percentiles (Q1-Q3). We 
performed Mann-Whitney U test to compare plasma concentrations of short, long 
cfDNA and median cfDNA integrity ratio between histopathologic Good responders 
and Poor responders for each defined time between groups: before the CRT (T0), 
after the CRT (T2) and after two weeks from initiation of CRT (T1).  
A P-value of < 0.05 was considered statistically significant. 
The variation in the levels of cfDNA was studied comparing cfDNA levels of Good 
responder and of Poor responder patients at different time point draw-blood. The 
Wilcoxon signed-rank test was performed to assess the significance of changes 
within each histopathological response group. Results were considered significant at 
p <0.05 (two-tailed). The statistical analyses were performed using the SAS 
statistical package (SA, release 9.1.3, Cary, NC, USA) and with GraphPad Prism 
version 5.0 
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4 RESULTS 
 
4.1 PRIMER-PROBE SPECIFIC ALU ASSAYS: A COMPARISON 
WITH PREVIOUS SYBR GREEN BASED ASSAYS 
We compared the cfDNA quantification results using two different sets of qPCR 
assays that exploited SYBR green and Taqman chemistry. For this purpose we 
standardized and optimized the qPCR procedure of the Taqman primer sets that we 
designed. Figure 1 shows the optimal efficiency and comparability of the two 
Taqman assays. It is noticed that although we used low range of DNA quantity, the 
curves of amplification crossed the threshold line soon in the PCR reaction.  
	  Figure	  1.	  Standard	  curve	  of	  Alu83	  (green)	  and	  Alu244	  (purple)	  made	  with	  serial	  dilution	  1:10	  from	  10	  ng/ul	   to	  1pg/ul.	  A)	  Amplification	  curves;	  B)	   standard	  curve	  graph	   that	   shows	   the	  Ct	  number	  in	  relation	  to	  the	  log	  of	  the	  DNA	  concentration.	  	  
We analyzed cfDNA from plasma of a same study, including 136 subjects between 
patients and controls, with Taqman and SYBR chemistry assays as described in the 
material and methods. Briefly, we carried out a standard curve for each qPCR assay 
and we quantified the concentration of cfDNA on plasma (ng/ml). Observing the 
SYBR green assay results we noticed that the cases that showed cfDNA 
concentration up to 3ng/ml, measured by Alu115, usually showed high cfDNA 
integrity value regardless to the physiopathology status of the subject. Therefore we 
performed two separately comparison analyses on the basis of the total cfDNA 
quantified by Alu115 using a cut-off of 3ng/ml. Figure 2A shows box plot of cfDNA 
concentration measured with the two different chemistry assay (Taqman assays: 
Alu83 and Alu244; SYBR green assays: Alu115, Alu247) for those samples that 
presented Alu115 cfDNA concentrations lower than 3ng/ml. As said before, samples 
that presented low values of total cfDNA quantified by Alu115, showed also similar 
quantities for the longer fragments (Alu247 SYBR green assay), producing a high 
range of cfDNA integrity that exceed the unit (Figure 2B). However, on the basis of 
the assays design, it is unlikely that the cfDNA integrity is often above the unit. The 
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analysis of the same plasma samples performed by Taqman assays revealed an 
increment of the cfDNA concentration detected with both the Alu244 and Alu83 
Taqman assay (Figure 2A). The total cfDNA concentration (short fragment), 
quantified by Alu83 Taqman assay, was eight times higher compared with that 
quantified by Alu115 SYBR green assay and the long fragment concentration, 
evaluated by Alu244 Taqman assay, is two times higher compare to the Alu247 
SYBR green assay concentration. According to the increment of the two fragments 
concentrations, the Taqman cfDNA integrity was considerably reduced in the 
analyzed cases (Figure 2B). These results indicated a better ability of Taqman assays 
to detect low quantities of cfDNA fragments, improving the sensitivity of the 
analysis. However, SYBR green and Taqman assays detected similar cfDNA 
fragments quantities for the cases where total cfDNA, quantified by Alu115 SYBR 
green assay, ranged from 3ng/ml to 100ng/ml (Figure 2C). The cfDNA integrity 
ratios assessed by SYBR green assays and by Taqman assays are comparable in this 
range of cfDNA concentrations indicating the reliability of both the two chemistry 
assays. 
 
 
Figure 2. Quantification of cfDNA fragments made by Taqman assays (Alu83 and Alu244) and by 
SYBR green assays (Alu115 and Alu247) in a same cases study. A) Selection of samples that showed 
total cfDNA concentrations, detected by SYBR Alu115, up to 3ng/ml of plasma. B) cfDNA integrity 
related to those samples with total cfDNA up to 3ng/ml of plasma. C) Selection of samples that 
showed total cfDNA concentrations, detected by SYBR Alu115, ranged from 3ng/ml to 100ng/ml of 
plasma. D) cfDNA integrity related to those samples with total cfDNA concentration range from 
3ng/ml to 100ng/ml of plasma. 
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4.2 EVALUATION OF cfDNA CONCENTRATION AND SIZE 
DISTRIBUTION IN A PROSPECTIVE STUDY OF LOCALLY 
ADVANCED RECTAL CANCER PATIENTS      
 
We tested the cfDNA primer-probe specific Taqman assays on a set of 49 plasma 
samples from prospective patients with locally advance rectal cancer treated with 
neo-adjuvant CRT. 
On the basis of TRG, 23 rectal patients were considered Good responders (TRG 1 
n=10, TRG 2 n=13) and 26 were considered Poor responders (TRG 3 n=18, TRG 4 
n=7, and TRG 5 n=1). Complete details of the patients, tumour, and treatment 
characteristics are summarized in Table 1. 
 
Table 1. Patients, tumour and treatment characteristics of the 49 patients included in the study. 
 
 
n° %
Age Median (range) yrs 67 (48-80)
Male 36 73,5
female 13 26,5
 ! 7 cm 18 36,7
> 7 cm 31 63,3
Continuos infusion 7 14,3
Bolus 38 77,6
Not available 4 8,2
 5-Fluorouracile alone 20 40,8
Oxaliplatin 20 40,8
Not available 9 18,4
0 11 22,4
I 14 28,6
II 12 24,5
III 7 14,3
IV 1 2,0
not available 4 8,2
yes 36 73,5
no 2 4,1
not available 11 22,4
0 2 4,1
1 16 32,7
2 18 36,7
3 6 12,2
4 1 2,0
not available 6 12,2
1 10 20,4
2 13 26,5
3 18 36,7
4 7 14,3
5 1 2,0
Good responders (TRG 1-2) 23 46,9
Poor responders (TRG 3-4-5) 26 53,1
TRG
Acute toxicity
pTNM
Patient characteristics
5-Fluorouracil administration
Tumor distance from the anal verge
Sex 
Other drugs
Radical surgery
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4.2.1 Relation of cfDNA levels and tumour response to CRT: cfDNA 
levels in plasma pre-CRT and post-CRT 
We first evaluated the cfDNA quantity and cfDNA integrity in plasma of Good and 
Poor responders collected before the CRT. 
As we noticed in the published paper, before the CRT, cfDNA levels and cfDNA 
integrity were not able to classify rectal patients on the basis of tumour response to 
treatment (Table 2). 
In particular, the cfDNA integrity range, showed by Good responders, overlapped 
the range of cfDNA integrity found in Poor responders, indicating that the 
mechanism of cfDNA release from apoptotic and necrotic processes might not 
predict the response of the tumour to the treatment before it is applied.  
 
Table 2. Pre-CRT plasma levels of cfDNA in patients divided by the tumour regression response to 
CRT. (Good= Good responders; Poor= Poor responders; Q1-Q3= Range from first to third quartile) 
(*=ng/ml) 
 
After the CRT we noticed that, in Good responders, the median value of cfDNA 
integrity decreased comparing with the median value before the CRT while in Poor 
responders it remained stable. The median value of cfDNA integrity in Good 
responders decreased about 50% and the same behaviour was noticed in the 
previously published paper. However, cfDNA integrity between Good and Poor 
responders did not reach the statistical significance as in the pilot study. Although 
the median values difference between Poor and Good responders was considerable, 
the range of cfDNA integrity values of Good responders was wide and it included 
the Poor responder integrity value range (Table 3). 
 
Marker Response N Median Q1-Q3 p-value
Good 23 17.36* 9.44 ;82.52
Poor 26 19.23* 7.44 ;57.79
Good 23 44.59* 19.83 ;74.20
Poor 26 22.49* 9.5;74.18
Good 23 0.88 0.32;1.19
Poor 26 0.73 0.47;1.18
0.3464
0.2793
0.9202
Alu244 pre-CRT
Alu83 pre-CRT
cfDNA integrity 
pre-CRT
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Table 3. Post-CRT plasma levels of cfDNA and cfDNA integrity in Good responders and in Poor 
responders. (Good= Good responders; Poor= Poor responders; Q1-Q3= Range from first to third 
quartile) (*=ng/ml) 
 
4.2.2 Monitoring the tumour response to CRT: variation of cfDNA 
in plasma pre- and post-CRT 
Although the post-CRT cfDNA concentrations of short and long fragments were not 
showed a statistical difference according with the response to CRT, the variations of 
cfDNA concentration and cfDNA integrity before and after the CRT were similar to 
those found in the published paper. Differences of cfDNA concentrations and of 
cfDNA integrity between pre-CRT and post-CRT did not show any significant 
tendency in Poor responders. Conversely, in Good responders group the 
concentration of the longer fragment (Alu244) significantly decreased after the CRT 
(p-value=0.0024) while shorter fragments did not show a precise variation tendency. 
These different tendencies of shorter and longer cfDNA caused a significant 
decrement in cfDNA integrity (p-value=0.012) (Table 4). 
Table 4. Variation of the cfDNA levels and cfDNA integrity between pre- and post-CRT in Good 
responders and Poor responders. (Good= Good responders; Poor= Poor responders; Q1-Q3= Range 
from first to third quartile; S=signed rank) (*=ng/ml) 
 
Good 23 20.12* 7.43;36.62
Poor 26 18.81* 6.38 ;46.47
Good 23 44.95* 16.06;76.55
Poor 26 31.16* 19.39;49.66
Good 23 0.44 0.19;1.19
Poor 26 0.71 0.42;0.89
Alu244 post-
CRT
Alu83 post-CRT
cfDNA integrity 
post-CRT 0.3165
0.6165
0.7035
Marker Response N Median Q1-Q3 p-value
Response Marker variation N Median Q1-Q3 S p-value
Alu244 post-pre 23 -5.65* -39.2;1.4 -93 0.0024
Alu83 post-pre 23 -1.09* -36.5;8.7 -25 0.4593
cfDNA integrity post-pre 23 -0.2 -0.5;0.0 -79 0.0126
Alu244 post-pre 26 -3.6* -29.1;8.2 -32.5 0.4198
Alu83 post-pre 26 -0.53* -26.4;20.4 -0.5 0.9902
cfDNA integrity post-pre 26 0.01 -0.57;0.25 -26.5 0.5116
Good
Poor
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These data confirmed the published paper results in which we showed a different 
kinetic of distribution of the fragments potentially associated with non-apoptotic 
death mechanism of release, only in the Good responders group. Poor responders 
did not show evident change tendencies in the cfDNA integrity between pre- and 
post- treatment confirming the different behaviour between these two groups. 
However, differences between the two response groups are still not well-defined and 
marked; patients within the groups showed high variability in the quantity of shorter 
and longer cfDNA making the assessment of a cut-off for clinical purposes difficult. 
 
4.2.3 Monitoring the tumour response to CRT: variation of cfDNA 
in plasma after two weeks from the initiation of the therapy 
T1 time draw blood was carried out after two weeks from starting the CRT, meaning 
in the middle of the neo-adjuvant treatment. We performed the analysis of cfDNA 
concentration and cfDNA integrity to evaluate if the initial perturbation of the 
biologic system could give meaningful evidences according to the different tumour 
response. 
The draw blood at this time point is difficult to obtain because multiple variables 
could influence: patient availability, patient physiologic state, and the different 
medical hospitals where the patient does the therapy. Therefore we were able to 
collect only 12/23 T1 time point plasma of Good responders and 13/26 T1 time 
point plasma of Poor responders. 
Table 5. Variation of the cfDNA levels and cfDNA integrity between pre-CRT (T0) and T1 time 
point in Good responders and Poor responders (Good= Good responders; Poor= Poor responders; Q1-
Q3= Range from first to third quartile; S=signed rank)  (*=ng/ml) 
 
Analyzing the variation of cfDNA markers before the CRT and after two weeks 
from the initiation of the therapy we noticed that both the concentration of short and 
long cfDNA fragment were very variable and this situation is evident in the 
Response Marker variation N Median Q1-Q3 S p-value
ALU 244 (T1-T0) 12 -2.8* -43.1;9.5 -10 0.4697
ALU 83 (T1-T0) 12 -5.85* -19.3;22.9 -1 0.9697
cfDNA integrity (T1-T0) 12 -0.14 -0.4;-0.01 -26 0.0425
ALU 244 (T1-T0) 13 -14.4* -19.3;2.2 -27.5 0.0574
ALU 83 (T1-T0) 13 1.32* -18.3;17.4 -0.5 10.000
cfDNA integrity (T1-T0) 13 -0.16 -0.37;0.16 -15.5 0.3054
Good
Poor
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evaluation of the variation of the cfDNA concentration compared with the basal 
level of cfDNA before the CRT (T0). Observing the variation of cfDNA integrity a 
significant decrease of this marker is showed in Good responder patients whereas 
Poor responder did not show a defined variation tendency (Table 5). This data gave 
somehow proof of the difference in size distribution of the cfDNA in association 
with the histopathology response. However, the number of patients is too small to 
give confidence of the results. The variation of cfDNA between T1 and T2 time 
point for this subset of patients did not give any significant tendency in both Good 
and Poor responders  
 
4.3 PORTABILITY OF THE CFDNA ANALYSIS STRATEGY 
In parallel with this study we evaluated the cfDNA markers in other tumour types 
and for different clinical purposes. 
4.3.1 Colon cancer  
We investigated cfDNA markers in colon cancer in order to evaluate their diagnostic 
and prognostic values. In particular we analyzed a cohort of healthy subjects, 
adenoma patients, and early and late colon tumour patients. We evaluated cfDNA 
level (Alu83) and cfDNA integrity (Alu244/alu83) in association with 
hypermethylation analysis of promoter region of two genes involved in colon 
tumour progression (SFRP1 and OSMR). A significant increment of cfDNA 
integrity in colon cancer patients compared to healthy subjects was revealed. 
Interestingly, early stage of colon cancer revealed a significant difference in cfDNA 
integrity compared to the controls indicating the potential role in early diagnosis. 
The frequency of cfDNA hypermethylation events and the quantity of 
hypermethylated genes found in cfDNA increased in association with the tumour 
progression. A correlation between the cfDNA integrity and the frequency of 
methylation event was observed, indicating the relation between the tumour cfDNA 
and the portion of longer cfDNA fragment.  cfDNA methylation was associated 
specifically with the tumour disease but we detected cfDNA methylation in only 
65% of the patient with tumour-tissue methylation. These results demonstrated that 
cfDNA markers showed potential benefit in the colon tumour diagnosis and 
prognosis in association with the other clinical diagnostic screening procedures. 
(Paper in preparation) 
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4.3.2 Thyroids malignancies 
cfDNA levels and cfDNA integrity were analyzed in thyroids malignancies with the 
aim of developing a non-invasive tool for the diagnosis and prognosis. In this study 
we coupled the analysis of these markers with the cfDNA hypermethylation of 
specific genes associated with thyroid cancer (SLC5A8 and SLC26A4) and with the 
evaluation of an approved clinical marker (BRAFV600E). cfDNA quantification 
showed a high ability to discriminate healthy individuals from tumour patients. 
Furthermore an increment of total cfDNA was observed with the progression of 
papillary thyroid tumours and correlations between long cfDNA fragment levels and 
histological types of thyroid tumours were found. Correlations between positive 
methylation events and the increase concentration of total cfDNA and of long 
cfDNA fragment were observed as well as the correlation between BRAF mutation 
with the increment of cfDNA integrity. These results highlighted the amount of 
information that cfDNA could providefor identification, diagnosis and prognosis of 
thyroids cancer, in association with marker already in clinical diagnostic. 
(Publication under submission) 
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5 DISCUSSION 
In recent years, blood-based tests and in particular circulating cfDNA has become a 
popular target of interest as potential biomarker candidate for tumour detection or 
prognosis because it can easily be isolated from human plasma, serum and other 
body fluids. Besides its non-invasive nature that allows the clinician for an easy 
access to the specimen, at the same time, its use reduces the physical and 
psychological stress to the patient. Numerous studies reported both qualitative and 
quantitative alterations in tumour patients indicating its correlation with the 
proliferative disease (Schwarzenbach H. et al., 2011). In this study, we focused our 
attention on the evaluation of the cfDNA as a potential marker to predict tumour 
response in patients with rectal cancer who received neo-adjuvant CRT. Many 
clinical, pathological and molecular tissue-based markers have been investigated 
according to the response after neo-adjuvant CRT, but, to date, the results has been 
contradicting and highly variable. Considering the lack of solid molecular 
information associated with the resistance to the chemo-radio therapy and the lack 
of differences regarding the clinical characteristics of tumour of patients included in 
the cases study, we focused our attention on the different pattern of cfDNA 
fragments length produced by cell death mechanisms. Although many different 
mechanisms can contribute to the cfDNA release, the nature of cell death, and in 
particular apoptotic and non-apoptotic mechanisms, has appeared to be of relevance. 
These different death strategies influence the pattern and size distribution of 
circulating fragments: while apoptotic death mechanism releases mainly DNA 
fragments shorter than 200bp into circulation, non-apoptotic death mechanism, and 
in particular tumour necrosis, is characterized by the presence of different size 
fragments that are more likely greater than 200bp. Macrophages or other scavenger 
cells might phagocyte necrotic and apoptotic cells and macrophages that engulf 
necrotic cells can release digested DNA into the tissue environment (Choi J. J. et 
al., 2005). Physiological alteration of the cellular environment due to the presence of 
tumour could be caused alteration on the cell death mechanisms and different sizes 
of fragment could be found in different blood samples. Recently, several studies 
have showed the diagnostic potential of cfDNA integrity index in comparison to 
healthy controls (Holdenrieder S. et al., 2008; Jahr S. et al., 2001; Giacona M.B. et 
al., 1998). cfDNA integrity was found higher in breast tumours (Umetani N. et al., 
2006; Deligezer U. et al., 2008; Agostini M. et al., 2012) and prostate tumours,  
plasma of head and neck tumours (Jiang W. W. et al., 2006), lung malignancies 
(Sriram K.B. et al., 2012), and naso-pharyngeal carcinoma (Chan K.C.A. et al., 
2008). 
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In association with Euroclone S.p.A. and in agreement with the aim of my Ph.D. 
project, we designed and standardized more specific and easy to use qPCR assays in 
view of providing an easy, reproducible and non-invasive method of investigation. 
With this improved method we found significant data that highlighted the diagnostic 
and prognostic significance of cfDNA quantity and cfDNA integrity in different 
cancer types such as colon cancer and thyroid cancer, as reported in our published 
and submitted papers.  
The aim of neo-adjuvant chemo-radio therapy in locally advanced rectal cancer is 
the death of tumour cells, for reducing the tumour mass. The different sensitivity of 
tumour to the chemo-radio therapy causes a different proportion of tumour cell to be 
able to survive. In addition cell death might occur also for the cells in the tumour 
microenvironment, for normal cells and for immune system cells, in different 
proportion and with different death strategies. cfDNA integrity index, indicated as 
the ratio of fragment longer than 200bp over the total cfDNA, could give 
information regarding the proportion of different mechanisms involved in cfDNA 
release.  
In the current study we investigated the cfDNA levels and cfDNA integrity in 
association with therapy monitoring during the treatment of rectal cancer patients 
undergoing preoperative chemo-radiation. At the time of diagnosis (before CRT; 
T0), we did not detect significant differences in cfDNA concentration and in cfDNA 
integrity between Good and Poor responders. Accordingly with our previously 
published paper these results suggest that, before the therapy, cfDNA mechanism of 
release is similar between Poor and Good responders, or the cfDNA markers could 
not differentiate the histopathological response. In particular we observed a high 
variability of the cfDNA quantities and cfDNA integrity in both Good and Poor 
responders, leading to a conclusion that the cfDNA release could be affected by 
numerous different factors. Non-significant differences were also found in the 
evaluation of the cfDNA concentration and cfDNA integrity after the end of the 
CRT, although a substantial decrement of cfDNA integrity was observed in Good 
responders. Despite these results, some scientific groups suggested that the analysis 
of the kinetics of the plasma cfDNA concentration in cancer patients, could lead to 
more essential information, in particular during the course of treatment 
(Fleischhacker M. et al., 2007).  We therefore focused on the kinetics of short and 
long cfDNA fragments to assess whether differences along the treatment have the 
potential to discriminate between Good responders and Poor responders. The 
kinetics of cell death and cfDNA release into circulation could be altered during the 
neo-adjuvant therapy period. For this reason we evaluated the variation of the 
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cfDNA concentration and cfDNA integrity until two weeks from the initiation of the 
CRT. The analysis, made in a subset of patients, found a statistical significant 
decrement of cfDNA integrity only for the group of Good responders. However 
cfDNA concentrations and cfDNA integrity showed high variability in both the 
response groups. This variability could due to the low number of patients analyzed 
but it could be due to the latency effect of chemo-radio therapy. Cell death, which is 
mainly due to radiation therapy, is not showed immediately after the CRT dose. For 
this reason the treatment is usually fractionated in more doses. Furthermore 
mechanisms of repopulation, DNA repair, and cellular redistribution could be 
variably activated in the irradiated tumour cells, increasing the individual disparity. 
Although comparison of short and long cfDNA fragment concentrations between 
Good responders and Poor responders revealed comparable plasma cfDNA levels 
before (T0) and after (T2) the chemo-radio therapy, the variation of cfDNA from T0 
to T2 showed a statistically significant difference in long cfDNA fragment 
concentration and cfDNA integrity, for Good responders. Indeed, Good responder 
patients showed a significant decrement of long cfDNA fragment concentration (p-
value=0.0024) and of cfDNA integrity (p-value= 0.0126) that the Poor responders 
did not show. The current study confirmed the results of our previous study by 
detecting a difference in the kinetics of long cfDNA fragments and cfDNA integrity 
in Good responders, enhancing the idea that the proportion of cfDNA fragment size 
might be potentially reversible after curative treatment. Decrement of cfDNA 
integrity in association with the positive response to CRT and therefore with the 
tumour mass reduction could be due to a differential process of cfDNA release and 
therefore to a shift of the cell death mechanism. Instead, the persistence of plasma 
cfDNA integrity level after the CRT may also be associated with many undefined 
factors including, maybe, the incomplete eradication of the tumour.  
Other studies found a correlation between the level of cfDNA in patients with 
different cancer types and response to a given therapy. Chan K.C. et al. highlighted 
that the persistence of DNA integrity aberrations after curative radiotherapy in 
nasopharyngeal carcinoma patients was associated with an increased probability of 
disease recurrence (Chan K.C. et al., 2008). 
5.1 Current Limitations 
Although we confirmed the significant decrement of cfDNA integrity and the long 
cfDNA fragment concentration in Good responders, the high variability within the 
group decrease the accuracy and the overlapping range of data observed in Good 
and Poor responders make the selection of a cut-off difficult, limiting the clinical 
potential of these markers. The high variability is subjective to the individual plasma 
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sample analyzed. Numerous factors could influence the detection of the DNA 
circulating in blood and they might be of technical nature as well as of biological 
nature. A major technical issue that hampers consistency in all the cfDNA assays is 
the efficacy of the extraction procedures, because usually only small amounts of 
DNA is obtained from plasma and serum. As we seen when we performed the 
optimization of cfDNA extraction procedures, Fleischhacker et al. found that 
significantly different amounts of absolute DNA values were obtained from plasma 
using different DNA isolation methods. Because of the small quantity and highly 
fragmented nature of cell-free DNA in plasma and serum, a fast, efficient, and 
reliable isolation method is still a problem and so far there is no agreement on a 
standardized method. Improvement is ongoing in these aspects for cfDNA analysis 
to be more robust, consistent, comparative and informative. (Fleischhacker M. et al., 
2011) To overcome this problem we has begun a collaboration with a group of 
INESC Microsistemas e Nanotecnologias (INESC MN), Lisbon, Portugal, for the 
development of a hybridization detection system based on magnetoresistive (MR) 
sensors associated to the use of superparamagnetic micro- and nano-particles as 
reporter systems to detect cfDNA directly from the body fluids (Freitas P.P. et al., 
2011). To date this approach is to the first step of fabrication but we hope for 
implementing the system soon. 
On the other hand, the biological factors that could be involved in the variability of 
cfDNA markers between subjects are numerous and different; the proportion of 
cfDNA that originates from tumour cells or that might be related to the presence of 
tumour, could be influenced by clearance, degradation and other physiological 
filtering events of the blood and lymphatic circulation. The influence of non-tumour 
cells on DNA fragments is currently not known and will also need to be evaluated. 
In order to better resolve the complex heterogeneity of tumour progression and 
histopatological response to chemo-radio therapy, we focused our attention on the 
circulating proteome because of its composition fluctuates and changes depending 
on a combination of numerous intracellular and environmental stimuli.  
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PROJECT 2. Circulating Low Molecular Weight 
peptidome for cancer biomarkers discovery 
 
 
6 CANCER BIOMARKERS AND CLINICAL PROTEOMICS  
 
The proteome is the entire set of proteins produced by an organism at certain time or 
under defined conditions. It comprises much more information than the genome, 
because it is a high dynamic system which composition fluctuates and changes 
depending on a combination of numerous environmental factors. In this contest, the 
proteome could better reflect the complexity of molecular processes involved in 
cancer since its expression dynamically fluctuate in response to different 
intracellular and extracellular stimuli. For this reason, one of the most interesting 
fields of molecular oncology has become the clinical proteomics, the division of 
proteomics that focused on the analysis of proteins expression changes during the 
development of a disease or during the progress of a therapy. Identification, 
characterization of unique patterns of protein expression, or biomarkers, associated 
with specific diseases is one of the most promising areas of clinical proteomics 
(Pietrowska M. et al., 2012). A lot of effort has been put to the determination of 
biomarkers whose measurement would be clinically valuable for diagnostic 
prognostic or predictive purposes and readily obtainable from the patients. In this 
regard, commonly used blood-based biomarkers include prostate-specific antigen 
(PSA) for prostate cancer, Carcino-embrionic antingen (CEA) for monitoring 
colorectal cancer, and estrogen receptor for estrogen-dependent mammary cancer. 
However, most of these single biomarkers do not reached the level of sensitivity and 
specificity that it is required for clinical purpose. 
Sensitivity problem arise when biomarker is not present in all the patients or if the 
level is too low to detect it. This is due to the molecular heterogeneity of tumours 
from patient to patient. Cancer is a complex disease in which alterations of specific 
physiologic mechanisms that regulate the cell life could occur through modification 
of signalling pathways at different levels (Push W. et al., 2003).  
The emergence of new powerful and high-throughput analytical technology has 
facilitated numerous attempts for cancer biomarker discovery, increasing the 
sensitivity of detecting trace amount of molecules and increasing the amount of data 
available. The advances of proteomic technologies have allowed analysis of many 
proteins simultaneously enabling the systematic interrogation of complex proteomes 
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and the identification of differentially expressed proteins in cells, tissues and body 
fluids. Depending on the type of analyte, various techniques of ionization and 
separation of ions in the analyzer are used in the field.  Among proteomic 
technologies, Matrix-assisted laser desorption/ionization mass spectrometer 
(MALDI-MS) is one of the most widely used proteomic technologies because it has 
allowed rapid progress in cancer biology investigation. It has become the major tool 
for proteins, peptides and other biomolecules (oligonucleotides, carbohydrates, 
lipids) analysis in relatively complex samples because of its valuable and useful 
features, including high sensitivity, mass accuracy, minimal sample preparation, 
ease of use and heightened throughput. MALDI-MS is capable of performing 
parallel rather than serial analyses, and of analyzing changes in global protein 
expression pattern or specific sub-proteome. These characteristics allow for multiple 
biomarker screening analyzing, promoting the understanding of pathogenesis of 
cancer, and might improving early detection, prognosis as well as therapeutic 
monitoring (Aebersold R. et al., 2003; Bateson H. et al., 2011). MALDI-MS was 
developed in the late 1980s by Hillenkamp and Karas (Karas M. et al., 1988) and it 
exploits the efficient and directed energy transfer during a matrix-assisted laser –
induced desorption event that ionizes the peptide residues and allows for the 
measurement of compounds with high accuracy and sensitivity. MALDI-MS 
instruments are usually coupled with time of flight ion analyzer (MALDI-TOF MS) 
in which ions separation occurs in a vacuum and the arrival time at the detector is 
dependent upon the mass to charge ratio, since the kinetic energy of the ions is equal 
for each ion. Intrinsic properties of the technique include: low sample consumption; 
high-resolution spectra of peaks by using the reflectron mode and the delay time; 
tolerance toward moderate amount of salt and buffer allowing proteins to be 
characterized directly without further purification that can be very difficult and time 
consuming. Another advantage of this technique is the minimal fragmentation 
because MALDI-TOF MS is a ‘soft’ ionization technique, the vaporization and the 
ionization are mild and it does not break down the analyte. Furthermore it almost 
exclusively creates singly charged ions, which mean that the m/z value becomes a 
very real measurement of the actual mass of the particles. Single laser pulse 
produces a quantity of ions that are detected in a millisecond timescale, allowing the 
acquisition of data from multiple laser pulses in a short time, allowing for detection 
of multiple peptides and proteins in the same analysis (protein profiling). MALDI-
TOF-MS is used for analysis of proteins and peptides with molecular weight ranging 
from 500Da to as much as several thousand Da but peptides analysis are more 
efficient compared with larger proteins, which are difficult to ionize (Lewis J.K. et 
al., 2000; Hortin G.L. et al., 2006, Aebersold R. et al., 2003). 
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6.1 RELEVANCE OF LOW MOLECULAR WEIGHT PEPTIDOME 
PROFILING 
 
Accordingly with technologies progress, increasing interest has been arisen for the 
dynamic nature of sub-proteomes presented in blood, as it constantly perfuses tissue 
and it thus reflects diverse physiological or pathological states (Taguchi A. et al., 
2013). In particular, circulating low molecular weight (LMW) peptidome seems to 
be a source of disease-specific biomarkers. Until recently, the peptidome was 
considered by the scientific community simply a pool of the protein fragments result 
by degradation or proteolytical activity of active proteases, with an informational 
content equivalent to biological ‘trash’ or ‘noise’ (Petricoin E.F et al., 2007). 
However, during the past five years, a novel concept has come into sight, suggesting 
that the peptidome could instead contain useful disease-specific information. While 
full-length tissue proteins are usually too large to passively diffuse into the 
circulatory system and only secreted proteins are detectable, peptides and fragments 
of proteins of different cellular localization can shed from all cell types still 
representing the parent proteins. Peptides show better permeability between tissue 
and cell membranes than the corresponding full-lenght proteins. Furthermore, the 
protein fragment itself can have a powerful diagnostic capability because its origin 
can be due to a tumour specific event. Proteases are proteins that cleave amino acid 
sequences at precise locations and they participate in basically every physiological 
as well as tumour specific process. Tumour specific proteolytic cascades within the 
tissue can generate fragments that diffuse into the circulatory system. Genomic 
sequence alteration can cause an atypical protein expression or secretion patterns. 
Over-expression of proteases and its secretion can increase the circulating level of 
extracellular domain peptides. Another mechanism of biomarker elevation in 
biological fluid is the increase of signal peptide secretion and shedding of 
membrane-bound protein with an extracellular domain (Kulasingam V. et al., 2008). 
However, tumour specific peptides are derived not only from a cancer population of 
cells that has a small volume compared to the totality of the tissues but they are also 
derived from the microenvironment tissue surrounding the tumour cells. The 
interaction with tissue microenvironment is essential for cancer progression and 
various molecules such as cytokines, growth factors, extracellular matrix molecules 
mediate this type of communication. Also normal cellular processes can generate 
peptide fragments. However, the tumour microenvironment, through the aberrant 
processes of cell growth, cellular invasion, altered immune system function, and 
angiogenesis can produce an unbalance amount of peptides or it can generate a 
unique cascade of events that lead to a specific fragmentation. In addition, tissue 
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invasion by the tumour might permit direct release of molecules into the interstitial 
fluid and, through the lymphatic circulation, into the blood. The irregular and leaky 
nature of the new tumour microcirculation and the different hydrostatic pressure 
increase the peptides shedding. LMW blood peptides could be derived from all cells 
and tissue types, or they are cleavage products of resident blood proteins. It was also 
proposed that some LMW information might not come from tissue but might be 
generated in the blood sample by degradative proteinases that are already present in 
the blood. (Petricoin E.F. et al., 2007) 
It has recently indicated that peptides could accumulate on the high-concentration 
resident proteins such as albumin, and then acquire its longer half-life. Blood 
resident proteins can thereby protect the bound species from kidney clearance. 
(Tirumalai R.S. et a.l, 2003)   
 
  
Figure 1. Different ways of peptide generation and elevation into the circulatory system. Circulating 
peptides could be shed and generate from all cell types present in the tissue microenvironment. 
(Petricoin E.F. et al, 2007) 
 
 
 
6.2 LIMITS OF THE DETECTION OF LOW MOLECULAR 
WEIGHT PEPTIDES  
 
One of the major challenges of MS-based serum/plasma proteomics is the high 
dynamic range of known plasma proteins that spans nine orders of magnitude. This 
wide range limits the detection of tumour-tissue-derived proteins in the circulation 
that are present in trace amounts (present at ng/ml to pg/ml) within a large 
background of abundant and non-relevant proteins. It is known that the 20 most 
abundant proteins represent over 99% of the total protein amount whereas the low 
molecular weight low-abundant peptides comprise less than 1% (Lee H.J. et al., 
2006).  Blood protein content is dominated by proteins such as albumin, 
transferring, haptaglobulins, immunoglobulins, and lipoproteins. This large dynamic 
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range exceeds the analytical capabilities of traditional proteomic method, making 
the detection of lower abundance peptides extremely challenging. Components of 
highest molar abundance, in complex mixtures, generally dominate the MALDI-
TOF MS spectrum and tend to suppress the detection of lower abundance proteins 
(Hortin G.L. et al, 2006). The presence of albumin, representing around 60% of all 
blood proteins, is the major factor changing the yield of ionization and affecting the 
ability to register low abundance serum components.  In this situation, sample 
fractionation is a crucial step to generate reproducible and high quality mass spectra 
enabling the analysis of the peptidome (Savino R. et al., 2012). 
Several methods have been proposed to reduce the complexity of the biological 
material on study. Different strategy focused on the depletion of albumin from the 
serum/plasma specimen prior MS analysis. Among them, several methods have been 
used such as immunoaffinity depletion, ion exchange chromatography, 
isoelettrofocusing, and organic solvent extraction. However, even if depletion of the 
most abundant proteins increased the peptides signal, it is well known that albumin 
can act as carrier proteins and bind a vast assortment of peptides and protein 
fragments prolonging their half-life in blood (Karpova M.A. et al, 2010). Several 
methods coupled with denaturating condition have been proposed to reduce the 
problem (ultrafiltration, continuous elution under denaturation condition). However, 
these strategies require complex and time-consuming procedures of protein 
depletion prior to MS analysis, limiting throughput and introducing other concerns 
about experimental variability, reproducibility, sample handling procedures, and 
protein stability during sample processing (Findeisen P. et al., 2005).  The 
development of nanomaterials, with controllable physicochemical properties, has 
widely improved the use of nanotechnology in biomedical applications, and among 
these, in biomarker discovery.  
 
 
6.3 NANOMATERIAL-ASSISTED PROFILING STRATEGIES IN 
CLINICAL PROTEOMICS 
 
Nanomaterials have been considerably explored in biology due to the matching of 
their chemical, physical, structural, and topographical properties with those of the 
molecules and building blocks of most biological systems. The ability to develop 
objects and structures at the nanoscale and the possibility to precisely control their 
interactions with cells, organelles, enzymes, proteins, and nucleic acids (DNA or 
RNAs) permitted the emergence of nanomaterials in the biomedical field with a 
wide range of applications (Ferrari M. et al., 2005; Riehemann K. et al., 2009) such 
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as pharmaceutical, therapeutics, medical imaging, and diagnostics (Ferrari M., 
2005; Hu y. et al., 2011, Godin B. et al., 2011). Among those materials, mesoporous 
silica has received growing interest because of its unique physicochemical 
properties. The discovery of mesostructured materials was made in the 1990s; the 
scientists of Mobil Oil Corporation discovered MCM-41 material in 1992. Due to 
the very ordered and adjustable pore diameters, uniform pore size distributions, 
large surface areas, confined pore volumes, and well-defined porous structures, 
mesoporous silica has been extensively applied to the adsorption, separation, 
immobilization, storage and identification of biomolecules. Mesoporous silica can 
be synthesized and assembled in different structures, shapes and dimensions 
(nanoparticles, nanowires, nanotubes, nanorods and thin films) (Sakamoto J.H. et 
al., 2010).  Recently, properties of nanomaterials have been increasingly exploited 
for reducing the complexity of the complex sample (such as blood) and for isolating 
the low-abundance peptides without losing its clinical value. One of the first studies 
reported peptides and protein fractionation using zeolite nanocrystals establishing 
the proof-of-concept of the MS profiling assisted by nanomaterial. As a 
consequence, different mesoporous silica materials were tested for this purpose 
showing its suitable features and opening the possibility to extend the detection of 
LMW species beyond the limit of conventional diagnostic methods (Zhang, Y. et al., 
2005; Terracciano R. et al., 2006; Savino R. et al., 2012). 
In this scientific contest the Nanomedicine Department of the Methodist Hospital 
Research Institute (Houston, Texas) developed a size-exclusion strategy based on a 
Mesoporous Silica Chip (MSC).  
This tool has variable pore dimensions, structures and surface chemistries that allow 
the efficient depletion of large proteins and the selective isolation of the circulating 
LMW proteome from body fluids samples (Hu Y. et al, 2010). This device is 
structured as a platform in which a small amount of sample is spotted on the 
mesoporous silica surface. In this way, many samples can be processed at the same 
time allowing high throughput processing. In combination with the consistency in 
the properties, the ease of manufacturing and the fast sample handling procedures it 
resulted in the development of a reliable, quick and powerful exploratory screening 
approach for biomarker discovery (Figure 2). In previous studies the Nanomedicine 
group optimized the synthesis of the MSC presenting various pore structures, 
chemico-physical characteristics of the porous surfaces and demonstrated the 
significant enrichment of the peptides and small proteins after using the MSC, 
confirming the depletion of the majority of the large molecules (Bouamrani A. et al, 
2010; Hu Y. et al, 2010). 
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Figure 2. Principle of peptide fractionation using MSC. The rapid 3-step fractionation procedure 
consist of an incubation step, in which sample was incubated on the surface of the chip LMW 
proteins and peptides are trapped into the pores; a washing step in which the large proteins, excluded 
from the pores, were eliminated and an elution step for recovering the peptides subsequently 
analyzed by MALDI-TOF-MS (modified by Bouamrani A. et al, 2010). 
In this study we performed a characterization of the mechanism of interaction 
between specific peptides and MSCs by varying the critical parameters involved in 
the process. We studied the influence of the peptide features, such as mass and 
charge, in relation with the physical and chemical properties of MSC, in order to 
evaluate the specific role of each of these features in the overall process of protein 
absorption, retention, and fractionation.  
We then applied the optimized peptide fractionation procedure, in combination with 
MALDI-TOF MS, to investigate the circulating low molecular weight peptidome of 
locally advanced rectal cancer patients treated with neo-adjuvant chemo-radio 
therapy. Peptidome exploration was carried out at different time points along the 
neo-adjuvant treatment with the aim of identifying peptide expression patterns that 
could be able to predict the histopathological response to therapy.  
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7 MATERIAL AND METHODS 
 
7.1 MSC FABRICATION AND CHARACTERIZATION 
 
Mesoporous silica chip has been produced by the Nanomedicine Department at The 
Methodist Hospital Research Institute, Houston (Texas, USA). 
The principal methodology for the synthesis of mesoporous silica is focused on the 
evaporation induced self-assembly procedure. Hydro-alcoholic solution of a soluble 
silicate and a structure-directing polymer are mixed and after dip or spin coating, the 
evaporation of the solvent drives silica/copolymer self-assembly into a uniform thin 
film. In particular, tetraethyl orthosilicate (TEOS; Sigma-Aldrich, St. Louis, MO, 
USA) is dissolved in a mixture of ethanol, distilled water and HCl. Separately 
Pluronic surfactant copolymer (BASF Co.) is dissolved in ethanol by stirring at 
room temperature. The silicate is mixed with the triblock copolymer solution 
followed by stirring of the resulting solution for 2h at room temperature. The pH of 
precursor solution is controlled at 1.5 to prevent the precipitation of mesoporous 
silicate and balance the procedure between the silicate hydrolysis and condensation 
of hydrolyzed silicate to polymer micelle. The coating solution is deposited on a Si 
(100) wafer by spin-coating at the spin rate of 2000 r.p.m. for 20 s. To increase the 
degree of polymerization of the silica framework in the films and to further improve 
their thermal stability, the films are heated at 80◦C for 12h. They are then calcinated 
at 425◦C to remove the organic surfactant. The temperature is raised at a rate of 1◦C 
min−1, and the furnace is heated at 425◦C for 5h. The thickness of the thin film could 
be controlled by adjusting the concentration of polymer in the precursor solution, 
while the porosity is related to the ratio between copolymer and tetraethyl 
orthosilicate in the starting material. Oxygen plasma treatment is applied to ensure 
the hydrophilicity.  
 
Figure 3. Scheme of chemical formation of the 
mesoporous silica film during the production of 
MSC for proteomic applications: A) Fresh 
coating solution; B) formation of micelles; C) 
evaporation-induced self-assembly during spin-
coating process; D) view of a pore after aging at 
elevated temperature (Figure modified from 
Bouamrani A. et al, 2010). 	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The characterization techniques used to study the mesoporous silica include 
variable-angle spectroscopic ellipsometer (J. A. Woollam Co., M-2000DI) offering 
the thickness of the thin films and their porosities, transmission electron microscopy 
(TEM) used to acquire micrographs of the plane view of mesoporous silica thin 
films with an FEI Technai (FEI Co.) at a high tension of 200kV, N2 
adsorption/desorption applied to measure the adsorption/desorption isotherm and the 
pore size distribution. The hydrophilicity of the films is evaluated through contact 
angle measurement. 
 
 
7.2 MSC EXPERIMENTAL PROCEDURE 
 
For each experiment 5ul of standard protein solution or plasma was spotted onto the 
porous layer of the chip.  Plasma was diluted in solution with acetonitrile (final v/v 
concentration of 5%) because, affecting the protein/protein interactions, it helped to 
release the low-molecular weight peptides associated with albumin or other carrier 
proteins that are removed using the MSCs. Then the solutions were removed and the 
wells were washed several times with 10ul of deionized water to remove surface 
bound material. Desorption of peptides was carried out by pipetting up and down for 
20 times with 5ul of elution buffer made by a 1:1 (v/v) mixture of Acetonitrile 
(ACN, Sigma) and 0,1% of Trifluoroacetic acid (TFA, Sigma). 
 
 
7.3 EVALUATION OF PROTEIN REMOVAL FROM THE 
SURFACE OF THE MSC 
 
7.3.1 Protein concentration measurement 
 
Protein concentration was measured using a microBCA assay (Pierce, Rockford, IL) 
and read with the absorbance at 562nm on a UV/Vis Spectrophotometer (Spectra 
Max M2, Molecular Devices). In order to determine protein recovery from the MCS, 
absorbance values were converted into protein amounts using the formula calculated 
through a standardization curve.  For every experiment performed, results were 
internally standardized using known amounts of Albumin (0.5µg/ml to 30µg/ml) 
according to the instruction of the microBCA kit. 
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7.3.2 Surface characterization 
 
7.3.2.1 Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) 
 
Fourier Transform InfraRed (FT-IR) is a method of infrared spectroscopy in which 
IR radiation is passed through a sample. Some of the infrared radiation is absorbed 
by the sample and some of it is passed through (transmitted). The result is a 
spectrum of peaks that correspond to the frequencies of vibrations between the 
bonds of the atoms making up the material. Because each different material is a 
unique combination of atoms, no two unique molecular structures produce the same 
infrared spectrum. Therefore, infrared spectroscopy can result in a positive 
identification (qualitative analysis) of every different kind of material. In addition, 
the size of the peaks in the spectrum is a direct indication of the amount of material 
present.  
Surface adsorption was investigated through Attenuated Total Reflectance Fourier 
Transform Infrared (ATR-FTIR) spectroscopy. ATR-FTIR is a sampling technique 
that enables samples to be examined directly in the solid or liquid state without 
further preparation. A beam of infrared light is passed through the ATR crystal in 
such way that it reflects at least once off the internal surface in contact with the 
sample. This reflection forms the evanescent wave that extends into the sample.  
Because the evanescent wave into the solid sample is improved with a more intimate 
contact, solid samples are usually firmly clamped against the ATR crystal, so that 
trapped air is not the medium through which the evanescent wave travels, as that 
would distort the results. The measured signal is digitized and sent to the computer 
where the Fourier transformation takes place. Before the sample is analyzed, it is 
necessary to measure a background spectrum that is normally a measurement with 
no sample in the beam. Thus, all spectral features, which are present, are strictly due 
to the sample.  
In this study pieces of MSCs with different pore size were incubated with plasma 
and they were analyzed after removal of the flow through, after 2 washes and after 5 
washes. Spectra were collected by placing the crystal on the surface of chips. 
Spectra were recorded using a Nicolet 6700 spectrometer (Thermo Scientific, 
Waltham, MA) with a Smart iTR diamond ATR attachment. Typically, 64 scans 
were performed in the wave number range of 4000–600/cm with a spectral 
resolution of 4 cm-1. Clean chips were used as negative control. (Introduction to 
Fourier Transform Infrared Spectrometry, 2001)  
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7.3.2.2 X-ray photoelectron spectroscopy (XPS) 
X-ray photoelectron spectroscopy is a quantitative spectroscopic technique that 
measures the elemental composition, the chemical state, and electronic state of the 
elements that exist within a material.XPS is a surface chemical analysis technique 
that can be used to analyse the surface chemistry of a material in its state and after 
some treatments. XPS spectra are obtained by irradiating a material with a beam of 
X-rays while simultaneously measuring the kinetic energy and number of electrons 
that escape from the top 1 to 10 nm of the material being analyzed. XPS requires 
ultra-high vacuum conditions. 
A typical XPS spectrum is a plot of the number of electron detected versus the 
binding energy of the electron detected. Each element produces a characteristic set 
of XPS peaks at characteristic binding energy values that directly identify each 
element existing in or on the surface of the material being analyzed. These 
characteristic peaks correspond to the electron configuration of the electrons within 
the atoms. The number of detected electrons in each of the characteristic peaks is 
directly related to the amount of element within the area irradiated.  
7.3.2.2.1 XPS surface spectra:  
The surface adsorption of the chips was monitored by XPS surface spectra using a 
PHI Quantera XPS with monochromatic Al Kα X-ray (1486.7 eV) source. The 40W, 
15kV and 200µm diameter X-rays were shot on the sample. The vacuum pressure 
during the analysis was always lower than 5.0E-8 Tor. The XPS survey scan spectra 
in the 1100.0 eV binding energy range were recorded in 0.5eV steps with a pass 
energy of 140eV. High-resolution scan spectra of C1s were recorded in 0.1eV steps 
with pass energy of 26 eV. Low energy electrons and Ar+ ions were conducted for 
specimen neutralization in each measurement. The spectral lines were referenced 
against the C1s signal at 284.50 eV. Like to the ATR-FT-IR study, we incubated 
pieces of different MSCs with plasma and protein solution and we analyzed them by 
XPS after removal of the flow through, after 2 washes and after 5 washes. The 
photoelectron peaks considered were C1s, Ni2, Si 2p. Clean chips were used as 
negative control.  
7.3.2.2.2 XPS depth profiling: 
In order to investigate the protein enrichment at different depths along the chip 
thickness, XPS depth profiling was carried out after Ar ion etching of the chips 
using a rapid etching ion gun (XP-HSIG, JEOL). Ar sputtering was performed over 
a 2 mm square area. Ar ion bombardment angle was 90°, while current and voltage 
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was 19 mA and 800 V. XPS spectra were measured after Ar bombardment each 
time. The sputter rate was determined at different sputtering times by measuring the 
pit depth after the experiment and dividing by the etching time. The pit depth was 
measured using a Veeco Dektak Series 3 Stylus Profiler System. To minimize 
effects of charging at the insulating films, a low-energy electron gun was used for 
charge neutralization.  The photoelectron peaks considered were C1s, Ni2, Si 2p and 
the depth profiling was carried out in a range from 0 to 630 nm. The depth profiling 
was performed after each protocol steps: after incubation of the plasma, after the 
washing procedure and after elution step. The depth profiling of a clean chip was 
used as a negative control. 
 
7.4 FACTORS THAT INFLUENCE PEPTIDE ADSORPTION 
PROCESS 
7.4.1 Evaluation of the effect of time of incubation and of 
temperature on the adsorption kinetic equilibrium 
Human serum and plasma from a healthy donor were bought from Sigma. For each 
experiment 5ul of protein solution or plasma/serum, added with ACN (final v/v 
concentration of 5%), were spotted onto the porous layer of the chip. Adsorption 
kinetic was investigated by incubating samples on a mesoporous silica chips (MSC) 
for 5, 15, 30 and 60 minutes.   The effect of temperature on the amount of peptides 
retained in the pore was studied by processing the samples at 4°C, 25°C, and 37°C. 
The protein content of the elution was assessed by microBCA protein quantification 
method as described above and by MALDI-TOF-MS.   
7.4.2 Study of adsorption of specific standard peptides on different 
pore size MSCs 
Adsorption of Angiotensin II, ACTH (CLIP18-37), and Aprotinin on MSC was 
carried out following the procedure described in “MSC experimental procedure”. 
Effect of pH on peptide adsorption was evaluated after adjusting the single peptide 
solutions to pH 4, 7, or 10 by using different concentrations of TFA and ammonium 
hydroxide (NH3OH).  Adsorption kinetic of peptides on MSC was performed with 4 
serial 1:5 dilutions to obtain concentrations ranging from 1.6 to 400pmol/ul.   
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To study the effect of increased protein complexity on the specific adsorption of 
peptides in solutions we investigated the recovery of each of the three peptides I) 
alone in solution, II) in a simple mixture of peptides (equal combination of 
Angiotensin II, ACTH (CLIP18-37), and Aprotinin), III) in a complex mixture of 
proteins with a higher range of molecular weight, and IV) spiked in a biological 
sample (plasma) that was checked for the absence of the specific peptide peak to 
avoid misinterpretation of the results. Each peptide elution and each peptide 
concentration was analyzed directly on MALDI-TOF-MS. One well was spotted 
only with the matrix as negative control, for observing matrix-specific peaks.   The 
peptide adsorption study was performed using MSCs with different pore size and 
structure as described in the result section. 
 
 
7.5 ANALYSIS OF CIRCULATING LMW PEPTIDE PROFILE OF 
HUMAN PLASMA SAMPLES 
 
We performed the LMW fractionation of plasma from colorectal cancer patients 
collected during operatively or endoscopic treatment in the Second Surgery Clinic of 
The Department of Surgical, Oncological and Gastroenterological Sciences 
(University of Padova). Informed consent was obtained from all patients and the 
study was approved by the Medical Ethics Committee. 
 
7.5.1 Peptide adsorption study of human plasma 
 
We first investigate plasma samples of three controls (subjects healthy with clean 
colon by endoscopically check), and three colon-rectal cancer patients 
(histologically confirmed). We evaluated the peptide profiling of samples by 
changing the pH of sample incubation and by using different pore size MSC. In 
particular each sample was incubated at native pH (usually around 7-7.5) and at pH 
5 by adding 1ul of 0.5% TFA (Thermo Fisher Scientific, Waltham MA, USA). 
Then, each sample was fractionated by using 4nm and 6nm pore size MSCs. We 
incubated the samples one hour onto the MSC and we washed the surface five times. 
We performed the analyses in triplicate, for each sample. Peptides samples were 
eluted from the pores by using 5ul of a 1:1 mixture of ACN:TFA (50%:0,1%).  The 
elution samples were stored at -80°C. Elution analysis was performed by using 
MALDI-TOF-MS. 
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7.5.2 Analysis of LMW peptide profile of locally advanced rectal 
cancer patients treated with neo-adjuvant chemo-radio therapy 
(pCRT) 
 
7.5.2.1 Patient characteristics 
Between 2008 and 2010 a total of 69 patients with primary adenocarcinoma of the 
rectum underwent pCRT followed by surgery.  The pre-treatment evaluation of the 
patients included a complete clinical history and physical examination, colonoscopy, 
complete blood cell count, transrectal ultrasound, pelvic computed tomography scan 
or magnetic resonance imaging, abdominal/ chest computed tomography, and 
carcinoembryonic antigen test. The inclusion criteria for pCRT were as follows: 
biopsy-proven adenocarcinoma of the mid–low rectum (<11 cm from the anal 
verge); clinical stage T3–4 and/or node-positive disease; and Eastern Cooperative 
Oncology Group performance status score of 0–2. 40 patients were included in the 
study group because they underwent surgery at our institution and they had at least 
pre- and post CRT plasma.  
These patients were provided preoperative external-beam radiotherapy with high-
energy photons (>6 MV) with conventional fractionation (>50 Gy in 28 fractions, 
1.8 Gy per day, 5 sessions per week), and 5-fluorouracil (5-FU)-based 
chemotherapy administered by bolus or continuous venous infusion. A standard total 
mesorectal excision was performed 4 to 8 weeks after the completion of 
preoperative CRT. We also analyzed the peptidome profile spectra from plasma of 
43 subjects with negative colonoscopy.  
 
7.5.2.2 LMW peptidome profiling 
We performed the LMW peptide profile fractionation from plasma of rectal cancer 
patients that was collected at different timing: before the pCRT (T0), two weeks 
after the initiation of pCRT (T1) and after the conclusion of pCRT, before the 
surgery (T2). For this study 5ul of plasma with 5%ACN and pH set around 5 was 
spotted onto the surface of 6nm pore size MSC. We incubated triplicates of each 
sample for one hour and we washed the MSC surface five times. Peptides samples 
were eluted from the pores by using 5ul of a 1:1 mixture of ACN:TFA (50%:0,1%).  
On each MSC we spotted and fractionated commercial plasma bought from Sigma-
Aldrich, in triplicate. The elution samples were stored at -80°C. 
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7.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION 
TIME OF FLIGHT MASS SPECTROMETRY (MALDI-TOF-MS)  
MALDI-TOF-MS provides for sensitive detection of low molecular weight proteins, 
whereas other traditional methods of analysis are employed for detecting larger 
proteins. This characteristic yields the MALDI-TOF-MS ideal for providing new 
insights into small peptides and protein components. 
Typically a small amount of analyte is co-crystallized on a specific plate with a large 
molar excess of matrix molecule, a UV-absorbing weak organic acid. Matrix is a 
low molecular weight organic compound comprising of an aromatic ring and 
carboxylic acid that provides the chromaphore for absorbing laser energy at the 
correct wavelength and creating an acidic environment for protonating the analyte, 
respectively. The matrix is usually present in 1000- to 10000-fold excess of the 
analyte to protect it from laser ablation decay. A nanosecond-duration laser radiation 
pointed on this mixture causes both the sample and the matrix to be vaporized and 
released (desorbed) from the surface. The matrix enhances indirectly the analyte 
vaporization by strongly absorbing laser light energy. Furthermore the matrix is 
used as a proton donor and receptor allowing the ionization of the analyte in both 
positive and negative ionization modes, respectively. The ionization depends on the 
matrix-analyte combination, but it is not dependent only on the number of acidic or 
basic group of analyte. The mass analyzer typically used with the MALDI ionization 
source is a linear-time-of-flight  (TOF) or a TOF reflectron. The linear TOF is the 
simplest devices and the analysis is based on accelerating a set of ions to a detector 
where the ions have the same energy. The separation occurs in a vacuum and the 
arrival time at the detector is dependent upon the mass to charge ratio, since the 
kinetic energy of the ions is equal for each ion. Ion species with low mass/charge 
(m/z) ratios are accelerated to higher velocities and reach the detector before the 
ions with higher ratio.  When the ion reaches the detector, this produces a single 
electric impulse that is converted to digital signal. Single laser pulse produces a 
quantity of ions that are detected in a millisecond timescale, allowing the acquisition 
of data from multiple laser pulses in a short time. The resolution of this instrument is 
enhanced by the introduction of an electrostatic analyzer, the reflectron that extend 
the ion way, increasing the amount of time that the ions need to reach the detector. 
The accuracy and the resolving power is increased by the delay extraction function 
that “cools” the ions immediately after the MALDI ionization. This cooling period 
reduce the temporal spread of ions once they enter to the TOF analyzer. This 
technique detect a relative low mass range, typically <10000 m/z and it provides 
optimal performance for m/z up to 4000. Furthermore fast ions, with low m/ z, 
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produce stronger detector responses than slow ions (Hortin G.L. et al, 2006; Lewis 
J.K. et al, 2000). 
7.6.1 Analysis of proteins and peptides by MALDI-TOF MS 
During desorption/ionization of proteins by laser pulses, both positive and negative 
molecular ions are formed, usually single charged. The yield of positive ions is 
greater for most proteins and peptides and for this reason they are usually analyzed 
in the positive ion mode. The ionization efficiency of the peptides is highly variable, 
with preferential ionization of peptides containing Arginine. Multiple ionic forms, 
doubly charged ions or ions coupled with sodium, matrix or other ions, complicate 
the profile and they depend on variables of sample composition, sample preparation 
and type of matrix used. There is competition among different proteins and salts in a 
specimen for ionization and this causes the phenomenon termed ion suppression, 
which reduces the sensitivity of detection and the yield of specific ions.  
Analysis of low molecular weight peptides was performed using α-cyano-4-
hydroxycinnamic acid (CHCA,Sigma-Aldrich, St. Louis, MO, USA). A matrix 
saturated solution of CHCA in 100% ACN and 0.1% TFA in ratio 1:1 (v/v) was 
used for peptide detection.  We spotted four or three elution replicates of each 
sample (of the different study analyses performed) onto the MALDI plate. We used 
0,5ul of sample elution that was let it dry and then we spotted 0,5ul of matrix 
solution onto the sample. MALDI-TOF MS experiments were performed on a 4700 
MALDI-TOF/TOF Analyzer (Applied Biosystems Inc., Framingham, MA, USA) 
operating in linear and reflectron positive ion mode using a 337 nm nitrogen laser.  
In linear mode samples were evaluated at the range of 800-10000 m/z with focus 
mass at 4000 m/z. Settings were optimized at a laser intensity of 4000.  In reflectron 
mode, samples were evaluated in the range of 600-4000 m/z with focus mass at 
2000 m/z Before any analysis the plate’s calibration settings were update through 
external mass-calibration (m/z) based on the monoisotopic values of [M + H]+ of 
Bradykinin (1-7), Angiotensin II, P14R, ACTH clip (18–39), Insulin oxidized B 
chain at m/z of 757.3997, 1046.5423, 1533.8582, 2465.1989, 3494.6513 
respectively (ProteoMass peptide MALDI-MS calibration kit, Sigma-Aldrich). The 
single spotted sample was analyzed automatically. Each mass spectrum was 
averaged with three thousand laser shots across the spot. In each MALDI plate we 
spotted a negative control, made by spotting CHCA alone and triplicates of a 
commercial plasma sample elution (Sigma-Aldrich). 
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7.6.2 Peptide identification: MALDI-TOF/TOF analysis of plasma 
samples 
 
MSC elutions of plasma rectal cancer patients collecting at different timing were 
used for identifying different peptides. Spectra have been obtained in the range 500-
3500Da with a Bruker Ultraflex II TOF/TOF instrument equipped with a nitrogen 
laser (λ=337 nm) and operating in reflectron positive ion mode. A peptide 
calibration standard mixture (calibration range 700-3200 Da) has been used for the 
instrumental calibration before analysis. For each spectrum, at least 2500 laser shots 
were collected. Once the most interesting peptides were selected, their fragmentation 
spectra were acquired in the laser-induced dissociations (LID) mode (LIFT® 
technology, Bruker Daltonics). 
- Compounds and sample preparation: 
We prepared the matrix by dissolving the α-cyano hydroxyl cinnamic acid (CHCA) 
in a 0.1% TFA/acetonitrile 50/50 solution. Peptide identification of elution sample 
was performed without using any enzymatic digestion. 
We mixed 5µL of MSC elution sample with 5µL of a saturated solution of CHCA. 1 
µL of mixed solution was placed near the calibrants onto the MALDI plate and left 
to crystallize before analysis.   
- Proteins and peptides identification procedure: 
Before the identification procedure, all spectra have been manually processed in 
order to eliminate peaks originating from the HCCA matrix. A direct comparison of 
samples with a blank solution (HCCA alone) was used. As shown in Figure 4, we 
identified several matrix adducts in the mass range 500-900Da (e.g., at m/z 568, 
656, 666, 672 and 877).  
 
 
Figure 4: HCCA alone spectrum (upper panel) compared to a sample spectrum (lower panel). 
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After the matrix peaks removal, MS/MS analysis has been performed in order to 
obtain the fragmentation spectra. The fragmentation was performed directly on the 
peptides presented on the total MS spectra; each m/z of interest (precursor ion) was 
selected and its fragments (product ions) were simultaneously detected. Fragment 
ions cannot be observed in linear mode because they have the same velocity as the 
precursor ion. However in a reflectron TOF mass analyzer these fragments penetrate 
the reflectron at different depths and they arrive at different flight times at the 
reflector detector. These fragments are represented in the mass spectrum and provide 
structural information. The obtained peptide mass fingerprints, as well as the 
precursor ion’s molecular weight are used to search a database.  
Fragmentation spectra have been processed using flexAnalysis (version 3.3) software 
and, after baseline subtraction, a peaks list has been generated using Snap as peak 
detecting algorithm. 
The peptide identification was performed by correlating the peaks list produced 
through the experimental MS/MS spectra with a peaks list from theoretical spectra 
predicted for each peptide and contained in a protein sequence database.  
The peaks list has been used for peptides/proteins identification via on-line search 
engines such as: Mascot (http://www.matrixscience.com) and MS-Tag 
(http://prospector.ucsf.edu). The search has been performed using large and 
comprehensive protein databases (such as NCBInr) when possible.  
A summary of the most important parameters used it for the on-line search is 
reported: 
 
 
 
 
 
 
 
 
 
In both the search engines that we used, MS/MS data were matched against 
sequence tags predicted for all proteins in the selected database.  This means that all 
searches are based on comparisons between the experimentally observed 
fragmentation pattern and the predicted fragments for all hypothetical peptides 
having the same molecular mass. A series of hits is obtained, ranked by a MOWSE 
(Molecular Weight Search) based scoring.  
Database
NCBInr or
UniProtKB
Enzyme No enzyme
Taxonomy Homo SapiensFixed 
modification NoneVariable 
modifications Oxidation (HMW)Parent 
tolerance 1.2 DaFragment 
tolerance 0.6 Da
Instrument MALDI-TOF/TOF
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In the case of Mascot search engine, a typical results report consists of a protein 
score graphically represented (Figure 5) and of a peptide view window in which it is 
possible to check the fragment matching. This ions score is calculated as -10xLog 
(P), where P is the probability that the peptide match is due to a random event.   
 
 
 
For several peptides, for which a correspondence in a search engines were not find, 
the peptide sequence was obtained directly from the spectra, without referring to 
sequence database help. The primary sequences were identified using protein 
BLAST (Basic Local Alignment Search Tool), a tool that calculate sequence 
similarity that aligns the peptide sequence with a BLAST databases of protein 
sequences available from NCBI. The program compares protein sequences to 
sequence database and calculates the statistical significance of matches. 
 
 
7.7 DATA PROCESSING AND STATISTICAL ANALYSIS 
 
Before conducting the statistical analysis, the raw t2d MALDI-TOF-MS files were 
converted to text files using ConvertPeakList software. Then they were imported 
into SpecAlign software version 1.22 for the pre-processing procedure: all spectra 
were aligned using the PAFFT correlation method and intensity was normalized to 
TIC. The baseline was corrected and the negative values were removed prior to the 
analysis. 
7.7.1 Study of adsorption of specific standard peptides on different 
pore size MSCs 
Absolute intensity of four replicates of each peptide was evaluated by calculating 
the mean, standard deviation and the standard error. Then the mean values were 
used for subsequent analysis. We performed kinetic analysis of MALDI-TOF MS 
Figure 5. Graphical protein 
score in which proteins are 
represented by the red bars. 
The proteins labelled with 
the blue arrow are under 
the significant threshold. 	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signal intensity in relation to the different peptide concentrations and the different 
factors that potential affect the fractionation procedure: time of incubation, 
temperature of incubation. Kinetic analysis was performed for each peptide, 
incubated in solution at different pH and fractionated with different pore size MSCs. 
Statistical analysis among the different conditions tested were performed by using 
Mann-Whitney non-parametric test or ANOVA test followed by student’s t-test for 
unpaired data, and a significant difference was assumed for p-value<0.05. Bars plot, 
kinetic curves and statistical analysis were performed with GraphPad Prism version 
5.0 
7.7.2 Analysis of circulating LMW peptide profile of human plasma 
samples  
Absolute intensity of triplicates of each peptide was evaluated by calculating the 
mean, standard deviation and the standard error. Then the mean values were used for 
subsequent analysis.  
We used classification techniques, such as cluster analysis (CA) and principal 
component analysis (PCA), as useful statistical tools able to discover structures in 
the experimental data. These techniques have the advantage to reduce the 
dimensionality of the data, and to allow independent classification of cases. 
 
7.7.2.1 Principal component analysis (PCA) 
 
PCA is a mathematical procedure that transforms a number of possibly correlated 
variables into a smaller number of uncorrelated variables. The data are represented 
in a dimensional space of n variables, which are reduced to a few principal 
components that are linear combinations of the original variables, indicating the 
maximum variation within the data. PCA is a method of data visualization useful in 
identifying new meaningful underlying variables, and it can detect the presence of 
clusters within multivariate data.  
Sample analysis was performed using MarkerView™ Software v1.1 (AB Sciex, 
Concord, Canada) on the matrix of m/z values for all patients and controls. The 
software provides for supervised (PCA-DA) and unsupervised (PCA) analysis. 
Unsupervised methods allow the structure within the data to be determined and 
visualized. PCA processing was carried out unsupervised mode with a Pareto 
scaling method.  The loading plot provides valuable insight into variables that lead 
to sample clustering illustrating which variables are up- or down-regulated. 
Supervised methods use prior knowledge of the sample groups to determine the 
variables that distinguish the groups. For this purpose, MarkerView software 
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performs a combination between PCA and the supervised technique, the 
Discriminant Analysis (DA).  This software also allows t-test analysis to be 
performed, useful for determining which variables lead to the significant differences 
between groups, through the calculation of the probability for each m/z variable to 
distinguish two different groups. We also analyzed each variable with Mann-
Whitney non-parametric test to enhance differences of median values. We 
performed multivariate analysis between control subjects and rectal cancer patient 
plasma collected before the pCRT, for identifying a peptide profiling peculiar of the 
rectal cancer disease. Then we examined the peptide profiling of rectal cancer 
patient in relation to the histopathological response to the treatment. In this contest, 
we compared plasma peptides relative abundances of Good and Poor responders 
collected in different time point: before the pCRT (T0), during the pCRT (T1), and 
after the pCRT (T2). We also performed analysis in relation to the time-points of the 
treatment, to monitoring the potential fluctuation of peptide abundances over the 
time of treatment in a individual group of response. 
7.7.2.2 Cluster analysis 
Another classification method is Cluster analysis. Hierarchical clustering was 
performed using Cluster software and visualized with TreeView Software. The 
MALDI-data were log-transformed, normalized and median centered. Pearson 
correlation was used to calculate the distance between the samples and complete 
linkage clustering was performed.  
 
For each analysis that was performed, a pattern of several significant peptides were 
identified. Each peptide was individually analyzed to observe its discriminative 
power according with the specific analysis. We carried out Mann-Whitney non-
parametric test and receiver-operating characteristic curves (ROC-Curve) to 
compare the ability of the different ionic species to discriminate between the 
different groups of patients. Sensitivity and specificity, statistical measures of the 
performance of a diagnostic test, were calculated on the basis of ROC-Curves. 
Sensitivity is defined as the probability of a positive test among patients with disease 
(true positive) whereas specificity is the probability of a negative test among 
patients without disease (true negative). The area (AUC) under the ROC curve 
indicates the ability of the test to discriminate between patients. 
Box plots and Roc curves, kinetic curves were performed with GraphPad Prism 
version 5.0 
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7.7.2.3 Multiple Logistic regression analysis 
The specific panels of m/z ionic species found at T0 and T2 time point, in relation 
with the histopathological response, were also analyzed by multiple logistic 
regression analysis in order to investigate the adjusted association of the selected 
m/z ionic species. The m/z ionic species associated with the probability of 
histopathological non-responsive event (Poor responders with TRG: 3-5) were 
determined by univariate analyses using the logistic regression model. Variables 
with p-value<0.3, in univariate logistic regression analysis, were included in the 
multiple regression. The best subset of predictor variables was determined using the 
stepwise selection method according to a selection entry and stay criterion of 0.1. 
The goodness of fit for the final logistic regression model in interpolating the 
observed data was evaluated using the Hosmer-Lemeshow test. The test assesses 
whether or not the observed event rates match the expected event rates in subgroups 
of the model population. It is similar to a Chi Square test, and indicates the extent to 
which the model provides better fit than a null model with no predictors, or, in a 
different interpretation, how well the model fits the data, as in log-linear modeling. 
The Hosmer and Lemeshow's goodness of fit test divides subjects into deciles based 
on predicted probabilities, and then it computes a chi-square from observed and 
expected frequencies. If chi-square goodness of fit is not significant, then the model 
has adequate fit the data. The area under the ROC-Curve was used to quantify the 
predictive performance of the fitted model. An AUC-ROC equal to 1 denotes perfect 
discrimination between distinct groups of patients, while a value equal to 0.5 
denotes the lack of discrimination. It was computed with 95% confidence intervals. 
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8 RESULTS 
 
8.1 MESOPOROUS SILICA CHIP (MSC) FABRICATION AND 
CHARACTERIZATION 
 
The MSC were produced by the evaporation-induced self-assembly procedure under 
acidic conditions using Pluronic triblock copolymers as structural templates. 
Different nanostructures and pore configurations can be produced by varying the 
molecular weight of the block copolymer, the ratio of the hydrophilic (PEO) to 
hydrophobic (PPO) block volume in the amphiphilic polymer, and the proportion of 
the polymer in the starting material. We used two typical triblock copolymers with 
different molecular weight and composition:  
PEO5 -PPO70 -PEO5 (Pluronic L121), PEO106 -PPO70 –PEO10 (Pluronic F127).  
Furthermore, by adding a swelling agent to the precursor solution, it is possible to 
enlarge the MSC pore size. In table 1 and in figure 6 are shown the characteristics of 
MSC that we used in this study.  
 
Table 1. Characteristics of Mesoporous Silica Chips used for protein adsorption study  
 
 
   
 
 
 
 
Figure 6. Chip characterization: Pore distribution graphs of 4nm, 6nm and 7nm MSC, TEM images 
of the MSC surface structure.  
 
Sample label Surfactant Pore structure
Average pore  
size (nm) Porosity (%) Contact angle
4nm F127 Cage-like 3.7 56.0 18.0
6nm L121 Random 6.0 55.0 7.4
7nm L11+PPG Radom 6.7 57.0 10.4
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8.2 EVALUATION OF PROTEIN REMOVAL FROM THE 
SURFACE OF THE MSC 
 
In order to investigate the adsorption of specific peptides into the MSC pores, a 
verification of complete removal of proteins stuck on the chip surface was needed. 
We spotted commercial serum and plasma on the MSC and we performed different 
numbers of serial washing steps.  After each washing step, we measured the protein 
content with microBCA kit and we performed a MALDI analysis on both the washed 
and eluted samples. The amount of proteins removed during the washing procedure 
decreased increasing the number of the washing steps (Figure 7A). After five 
washes, proteins were almost absent on the MSC surface and the amount of proteins 
recovered from the chip with the elution step was significantly higher than the 
amount of proteins measured in the last 2 washing steps.  
Moreover, we characterized the surface of the chip before and after the washing 
steps by using FTIR and XPS (Figure 7B). As shown in the FTIR spectra, the clean 
chip (control chip) displayed peaks at 1059.29 cm-1 , which originated from the Si-O 
bond of the silica surface (Roy S. et al, 2010). In contrast, the spectra produced with 
the chip after protein incubation showed weaker peak for Si-O moieties, which is 
due to the immobilization of proteins on the chip shielding the silica surface. The 
spectra also presents bands at 3000 and at 2800 cm-1 assigned to C-H stretching 
modes of CH2 and CH3 groups of protein and bands at 1474, 1460 and 1398 cm-1 
attributed to C-H asymmetric deformation modes of the alkyl groups. Moreover, two 
strong peaks at 1645 and 1525 cm-1 on the spectra corresponded to amide I and 
amide II modes that link amino acids of the protein adsorbed on the silica surface. 
The amide I band primarily represents the C=O stretching vibrations of the peptide 
bond groups while the amide II band is caused by C-N stretch coupled with N-H 
bending mode (Kulikova G.A. et al, 2010). However, as shown in the IR spectra, 
these peaks decreased significantly after two washes and almost disappeared after 
five washes. Conversely, increasing the washing steps, the peak originating from the 
Si-O bond of silica surface became significantly sharpened, as well as the peak 
shown in the spectra of control chip. 
Figure 7B (on the right) displays XPS survey peaks attributing to relative amount of 
C, N and Si atoms of protein adsorbed on the chip surface before and after the 
washes. The chip before washing procedure exhibited a significant amount of N and 
C atoms which originated from the coated protein molecules while the chip after the 
washing steps showed diminishing peaks of these atoms and increasing peak of Si 
atoms. On the basis of these considerations, we concluded that a number of five 
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washes were optimal to remove proteins from the chip surface and we performed all 
the experiments described in the paper accordingly.  
 
 
 
Figure 7. A) Protein concentration recovery from each washing step and from the elution step using 
4nm (pink) 6nm (purple) and 7nm (blue) MSC . B) ATR-FTIR spectra (on the left) and XPS 
characterization (on the right) of MSC surface after sample loading and sequential washing compared 
with a clean MSC. The graphs show the presence of protein stuck on the surface when the sample is 
loaded and in the first two washing steps. After 5 washing the presence of proteins are almost absent. 
 
 
8.3 XPS DEPTH PROFILING  
 
In order to quantify the amount of peptides penetrated into the MSC and to 
determine the depth at which the peptides can reach within the chips, XPS depth 
profile analyses were performed. This study allowed the possibility to quantify the 
capture and reclaim of peptides from the MSC as a function of depth, with 
nanometric resolution. By means of surface XRD analysis, coupled with sequential 
removal of superficial MSC layers through Ar sputtering, we performed a depth 
profile of the nitrogen and carbon, typical protein components, and of Si, the 
component of MSC. The intensity of the scanned elements was recorded after each 
etching and plotted versus the depth (nm) from the surface. At first, we carried out a 
series of depth profiles on a clean MSC film. We then spotted plasma sample and 
we carried out the profiling of nitrogen, carbon, and silicon atoms in depth both 
before and after the washing procedure.  A clean chip showed the presence of silica 
component along the depth of the chip (data not shown). Carbon environmental 
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contamination is found mainly in the proximity of the surface, but the presence is 
still tracked deeper into the film, while environmental nitrogen was absent. On the 
basis of these preliminary results we exploited the presence of nitrogen in amino 
acids to study the penetration of peptides into the porous MSC. After the sample 
spotting, a thick protein layer was present on the MSC (Figure 8A) that prevent the 
depth profiling analysis. Figure 8B shows the XPS depth profile after the washing 
procedure. The signals of silica and nitrogen showed an opposite behaviour. Initial 
Si 2p signal increased with increasing the depth of etching and after 150 nm the 
signal was stabilized. The presence of a low Si 2p signal is due to the fact that XPS 
does not only read the top surface, but actually penetrated the surface for some nm 
in depth.  On the opposite side, N signal decreased with the depth: after 50nm the 
signal decreased by about 75% compare to the signal found near the surface, while 
after 100nm the signal stabilized. This indicated that the higher amount of peptides 
is recovered in the first 50nm in depth from the surface. After the elution (Figure 
8C), nitrogen signal decreased indicating that the elution was effective along the 
depth in which there is the higher quantity of peptides. 
 
 
  
Figure 8. A) TEM of a MSC cross section after plasma spotting and XPS spectra of N1s and of Si 2p 
both at the plasma surface and at 2um in depth from the surface. B) XPS spectra of a MSC at 0 nm, 
45nm, and 630nm depth of nitrogen and silica after 5 washing. The protein density within the chip 
varies in depth. C) XPS depth profile spectra of a MSC at 0nm, 45nm, and 630nm of Nitrogen after 
elution with the buffer and graph of the protein recovery rate after elution. The protein recovery 
within the chip is effective in the first 45nm in depth from the surface.     
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8.4 FACTORS THAT INFLUENCE PEPTIDE ADSORPTION 
PROCESS 
8.4.1 Effect of time of incubation 
Commercial plasma was incubated for different time (5, 15, 30, and 60 min) on the 
MSCs and, after five washings, elutions were performed and measurement of 
protein concentration was made with microBCA kit. The adsorption kinetic of the 
peptides on the MSC pores as a function of contact time is shown in Figure 9. The 
Langmuir isotherm model, the most widely used protein adsorption model, 
adequately reproduces our experimental data and the parameters are summarized in 
Figure 9A. Langmuir adsorption isotherm is characterized by binding site saturation 
over the time. A possible explanation refers to the time to reach the equilibrium in 
which the available pore surface is completely filled with adsorbed molecules. As 
predicted by the model, the adsorption rate is fast, with half of binding sites 
occupied in less than 6 min and the equilibrium capacity is reached after 30 min.  No 
major differences were found in the adsorption kinetic for the three different chips in 
the present study.  The fast equilibrium coverage of the adsorbent constitutes an 
essential parameter for a rapid and efficient enrichment procedure.  
 
Figure 9. Kinetic of proteins adsorption as function of incubation time. A) Kinetic of the recovery 
after fractionation of protein sample, at different incubation time. The kinetic fit with Langmuir 
isotherm model. B) Histogram of the number of peaks recovered at different protein sample 
incubation time. C) MALDI-TOF MS spectra of proteins recovered after elution at different 
incubation time. Mean values and standard deviations of 3 independent experiments are shown. 
On the basis of these results, we performed the subsequent experiments with a 
sample incubation of 60 minutes to reach the equilibrium capacity. 
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8.4.2 Effect of temperature 
 
Adsorption protein behavior was studied under three different temperature 
conditions 4°C, 25°C, and 37 °C, respectively (Figure 10). In Figure 10A we 
reported the protein content for both the washing steps and for the elution. The 
amount of proteins removed through the washing steps was low at 4°C, compared to 
25 °C and 37°C which gave comparable results. Similar results were observed for 
protein recovery in the elution, indicating a lower protein harvesting at 4°C. The 
difference in protein recovery could be explained by the mechanism of protein 
diffusion into the pores. Increased adsorption rates can be expected due to an 
accelerated diffusivity of proteins towards the adsorbent surface.  
At low temperatures, molecules have a lower kinetic energy to enter the pores. 
Higher temperatures increase the kinetic energy of molecules enhancing the rate of 
diffusion as well as the probability of interaction between the proteins and the silica 
surface chip.  Although the amount of proteins was analogous at 37°C and 25°C, the 
MALDI-TOF MS spectra showed better results in terms of number of detected 
peaks (Figure 10B) and peaks intensity (Figure 10C) when the procedure has been 
done at 25°C. Protein recovery at 37°C can be affected by degradation processes 
(proteolytic and enzymatic process accelerated the degradation of peptides). 
 
Figure 10. Effect of temperature on the amount of protein retained in the MSC. A) Histogram of the 
amount of proteins washed out from the surface for each washing step in relation to the amount of 
proteins recovered from the pore after elution, at different temperature: 4°C, 25°C, and 37°C 
respectively. B) Histogram with the number of peaks obtained by a MALDI analysis of elution at 
different temperature. C) MALDI spectra profile of the elutions at different temperature. Mean values 
and standard deviation of three independent experiments are shown.   
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8.4.3 Study of adsorption of specific standard peptides in different 
pore size MSC 
 
Adsorption behavior of three peptides with molecular weight ranging from 1000Da 
to 6500Da and with different isoelectric points was specifically studied at different 
pH, with increasing environmental complexity, on both the three different MSCs. 
The physicochemical properties of the peptides are described in Table 2 and the 
structures are shown in Figure 11. 
 
Figure 11. Conformation of the three peptides used in the adsorption study: Angiotensin II, 
ACTH(CLIP), and Aprotinin.  
 
Table 2. Physicochemical characteristics of the three peptides analyzed
 
 
In Figure 12, adsorption isotherms of the three proteins are shown for 4, 6, and 7nm 
MSC pore size. Concentrations ranging from 1,6pmol/ul to 400pmol/ul for each 
peptide were incubated on the different MSCs and were processed according with 
the optimized procedure. We run the elution products on MALDI-TOF and then we 
plotted the absolute intensities of each peptide as a function of the initial 
concentrations. Each graph presents the specific peptide adsorption curve for the 
different MSC. 
 
	   76	  
 
Figure 12. Adsorption kinetic isotherm of a specific peptide incubated at a pH of 7 on a MSC 
synthesized with pore average of 4nm, 6nm, and 7nm. The x-axis indicated the peptide concentration, 
the y-axis indicate the absolute intensity of peptide signal at MALDI-TOF. (A) Angiotensin II, (B) 
ACTH(CLIP 18-37), (C) Aprotinin. Error bars correspond to standard deviation of 4 replicates.  
 
The Langmuir isotherm model seems to reproduce adequately the experimental data 
for all the peptides tested. The sharp initial rise of the curves suggested a high 
affinity between the protein and the adsorbent surface. Increasing the concentration 
of the peptide the isotherms reached a plateau because of the saturation of the pores.  
As in the kinetic equilibrium, the Langmuir equation is expressed as:   
 
where C is the peptide concentration, Q max represents the maximum adsorption 
amount (the pore saturation uptake) and Kd is the adsorption constant. The uptake 
rate of the peptide on MSC is expected to depend strongly on the pore size structure 
of the sieve material as well as on the molecule dimensions. However, the graphs 
showed a higher uptake capacity with 4nm pore size MSC irrespectively to the 
dimension of the peptide. The data can be explained considering that each peptide 
can fit in all the tested pore sizes but the 4nm MSC possesses a higher number of 
pore entrances compared to the MSC with larger pores and that increases the 
available surface improving the capacity rate. 
 
8.4.3.1 Effect of pH on protein adsorption capacity 
 
The protein adsorption efficiency and stability on MSC is strongly affected by the 
pH of the solution.  The driving forces for the peptide uptake on the silica surface 
include different kind of interactions between proteins and between silanol groups 
and proteins.  pH of the solution determines the electrostatic state of  proteins 
causing differences in surface charge and surface charge density.  
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Electrical charges of the proteins results from the ionization of carboxylic, tyrosyl, 
amine, and imidazole groups of amino acid side chains that can drive intermolecular 
attraction and repulsion between amino acids residues, while hydrophobic and 
electrostatic interaction can be performed between amino acid residues and silanol 
groups on the surface of the silica pore. 
 We investigated the absorption recovery of the three peptides at three different pH: 
4, 7, and 10 respectively. The silica surface is mainly negatively charged at pH>2, 
so the important factor is the isoeletric point (pI) of the peptide and the amino acid 
residues that can be electrically charged. 
 
 
Figure 13. Effect of pH on peptide adsorption capacity. Histograms of absolute intensity recovered 
with MALDI-TOF MS (x-axis) after peptide incubation on MSC with different pore size (y-axis). 
Peptides were incubated in solution with pH4, 7, and 10. A) Angiotensin II; B) ACTH; C) Aprotinin. 
Error bars correspond to standard deviation of 4 replicates.  
 
In Figure 13 three histograms related to the three specific peptides are shown. 
MALDI-TOF signal intensity that correlates with the recovery of peptide is plotted 
in relation to the pH and the different MSC. The graph 13A shows the adsorption 
recovery of the smaller peptide, Angiotensin II. In contrast with what we expected, 
the uptake rate is not significantly affected by the pH. The isoelectric point of 
Angiotensin II is around 7, hence, the peptide is positively charged at pH below its 
pI and negatively charged when the pH is higher. However, Angiotensin II is 
composed by eight amino acids with only two amino acids chargeable residues. This 
information, according with the experimental data, suggested that the net charge 
variation of the protein at pH4 and pH10 might not be enough to significantly affect 
the interactions involved in the peptide adsorption. Moreover, as described above, 
the small dimension of the peptide improved its entry in the pores.  For 
ACTH(CLIP) and Aprotinin the uptake is clearly a function of pH solution (Figure 
13B and C). A higher amount of protein adsorbed and eluted from all different pore 
size MSCs were obtained when ACTH fragment and Aprotinin were incubated at 
pH close to the isolectric point (pI) of the peptide, at pH4 and pH10 respectively. 
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When the pH equals the pI of a protein, the number of positive and negative charges 
is in balance resulting in a neutral molecule. In this condition, the lateral Coulombic 
repulsion between the protein molecules due to the patches of amino acids 
sequences with a similar local charge is minimized.  At isoelectric point, the ionic 
forces between the peptide and the silica are small and the molecules and silica 
adsorbent surface can be close enough to promote stabilization through Van deer 
Waals attraction that acts on all molecules irrespectively to the electrical charge.  
Consequently higher packing density on the surface is possible and a smaller surface 
area is required for protein to adsorb, increasing the monolayer capacity. The 
adsorption at pI may greatly depend on the mesoporous surface structure and on its 
relation to the hydrophobic interactions. At a pH higher than the pI the adsorption of 
ACTH fragment is reduced.  
Under these conditions the peptide is negatively charged and the electrostatic 
repulsion between the peptide molecules and silanol groups of silica film decreases 
the amount of adsorption. This is quite evident in the Figure 14B where the 
Langmuir curves of ACTH incubated at different pH solution was spotted and eluted 
from the 3 different chips. The maximum capacity was reached when the peptide 
was incubated in a solution with a pH close to the peptide pI. Moreover at pH=pI the 
experimental data fitted better with the Langmuir model. Increasing the pH, ACTH 
fragment showed a significant and constant uptake reduction, for every kind of chip. 
In particular both the 4nm and the 6nm MSCs showed a decrease of the maximum 
uptake by 27% and by 58% for pH7 and pH10 respectively and the uptake decreased 
by 55% and by 78% for 7nm MSC (Table 3). 
 
Table 3. Langmuir adsorption isotherm parameters (Bmax: maximum uptake recovered in percentage, 
Kd:  adsorption constant, R2: coefficient of correlation) for each specific peptide (Angiotensin II, 
Aprotinin, ACTH(CLIP 17-38) and for each pore size MSC (4nm, 6nm, 7nm). 
Percentage of Bmax was calculated for each peptide and each MSC pore size by setting the highest 
value as the 100%  
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Adsorption performance decreased also when Aprotinin was incubated in solutions 
with pH lower than the pI, although the protein net positive surface charge should 
favor the interaction with silica surface. The involved driving forces could be the 
electrostatic force between the positive charges of ionized proteins and the negative 
charges of the silica film itself, and the repulsive positive force between peptides.  
With decreasing pH, Aprotinin surface charge increases, and repulsive coulombic 
forces between amino acid residues (lateral interaction) become more pronounced, 
reducing the protein adsorption on the silica (Figure 14C).  Table 3 clearly showed 
that uptake (Bmax) diminished by decreasing the pH. 
 
 
 
Figure 14. Adsorbed Angiotensin II (panel A), ACTH (CLIP18-37) (panel B), Aprotinin (panel C) as 
function of protein concentration (adsorption isotherm) for different pH solution and different pore 
size MSCs. Data are fitted with Langmuir isotherm. Error bars correspond to standard deviation of 4 
replicates.  
 
However, looking at the adsorption curves of Aprotinin (Figure 14C) we noticed 
that at the initial protein concentrations the uptake curve of protein at pH equal to 
the pI is similar to the curve for incubation at pH 7.  In solution, proteins rotate 
freely whereas on a surface each protein will adapt a certain orientation, which 
determines the part of the molecules interacting with the surface. It can be assumed 
that adsorbed proteins and peptides initially adapt an orientation to maximize 
favourable surface-peptide interaction. At low concentrations the peptide-peptide 
repulsion is negligible because of the large distance between the molecules. 
Increasing the molecule density on the surface results in a smaller peptide-peptide 
distance.  
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This interaction becoming increasingly dominating and it can trigger orientational 
changes that lead to a decreased peptide-surface interactions.  These considerations 
are proper for pH solutions that are not too far from the peptide pI.  
In a situation in which the charge of the proteins is more pronounced, the lateral 
interaction between molecules is higher and this could reduce the effect of attraction 
with the silica surface also at very low peptide concentrations. However, the pH is 
not the only variable involved in the adsorption process.  The pore size also 
modulated the peptide uptake.  
Figure 14, supported by Table 3, shows that at the iso-electric point the peptide 
uptake is similar, irrespective to the different pore size chip whereas, when the 
specific peptide acquires a net charge, the uptake decreases even if the pore size of 
the MSC increased. A possible simplistic explanation can be provided by thinking at 
the peptides dimension according to the pore size. The ratio between the pore size 
diameter and the rough peptide diameter can give us a simplify idea of the number 
of molecules that can fit into the pore section area. In the Figure 15 is shown a 
schematic model of the pores and the peptides that fit into them. Different number of 
ACTH molecules can fit in the different MSC pore area: roughly 2, 6, or 7 
molecules can fit in the 4nm, 6nm, or 7nm pore size MSC, respectively. For 
Aprotinin, 1 molecule can fit in the 4nm pore while around 2 and 3 molecules can fit 
in the 6nm and 7nm pore size MSC, respectively. As we described before, 
considering the Langmuir kinetic model of monolayer adsorption, when the pH of 
the solutions is close to the pI of the peptide, the repulsive forces are minimal and 
the molecules can be packed into the pore. Therefore, similar recovery uptake of the 
different pore size chips can be due to the higher number of entrance pores that 
increases the available surface of the smaller pore size chip that compensates, on the 
other hand, the higher uptake from the larger pores. 
  
 
Figure 15. Schematic models of the 
specific peptides for the different pore 
size MSC. A) Angiotensin II; B) 
ACTH(CLIP);C) Aprotinin. 
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When the pH differs from the pI of the peptide, the repulsion between molecules is 
more evident with larger pore size that cannot accommodate the same number of 
molecules in a pore section.  In support of this consideration, although the maximum 
uptake recovery of Aprotinin at pH7 was the same than pH10 using the 4nm MSC, it 
decreased when increasing the pore size. On Table 3, at pH7, B max of Aprotinin 
was attested to 85% and 66% for 6nm and 7nm pore sizes respectively. At pH4 the 
uptake of Aprotinin decreased from 82% with 4nm to 57% and 54% for 6nm and 
7nm respectively. Compared to the 4nm pore size MSC, ACTH maximum uptake is 
similar in the 6nm MSC but in the 7nm MSC it was attested around to 60% and to 
50% at pH7 and at pH10, respectively. 
 
8.4.3.2 Effect of increasing complexity of sample solution in peptide recovery 
 
The effects of electrolytes and of increased protein complexity, on the adsorption of 
specific peptides, were studied for each MSC pore size. 
Four experiments in which the specific peptide was incubated in solutions with 
increasing complexity were reported in order to show the selective harvesting 
capability of MSC: 
I. Interaction with one component in solution; 
II.  Interaction of a simple mixture of 3 peptides;  
III. Interaction of a complex mixture of peptides and proteins with a wide 
range of MWs mimicking a biological fluids 
IV. Interaction with crude human plasma; 
The recovery rate of the MSC was calculated using the same amount of peptide used 
in the experiment and directly analyzed with MALDI-TOF MS.  We performed the 
recovery rate for each peptide in each condition and the relative histograms are 
shown in the Figure 16.  
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Figure 16. Relative recovery of specific peptide incubated in solution with increasing complexity. 
Panel A) Angiotensin II, Panel B) ACTH(CLIP 18-37), panel C) Aprotinin. The relative recovery 
varies increasing protein complexity and introducing the effect of electrolytes.  
Figure 16 panel A presents the graphs related to Angiotensin II. As we discussed 
before, the peptide incubated alone on the MSC showed the same relative recovery 
independently from the different chips and the different pH solutions.  
The result was maintained when the Angiotensin II was incubated with a simple 
mixture of 3 proteins, while when it was incubated in a more complex mixture, both 
the pore dimension and the pH affected the peptide recovery.  
In particular, the chip with smaller pore size (4nm) presented a better recovery of the 
specific peptide, compared to the other pore size chips. When increasing the pore 
dimension, Angiotensin II uptake decreased constantly. The pH conditions of crude 
plasma under which the peptide presented a slightly positive charge gave the higher 
uptake irrespectively to the pore size of the MSC. In Figure 16 panel B, ACTH 
fragment relative uptake is presented. The relationship between ACTH fragment 
adsorption and the pH of the solution was maintained in every different conditions 
tested, with a higher recovery at pH solution close to the pI.  However, increasing 
the complexity of the solution, there presented a decrease of the overall uptake 
according to the pore dimension, particularly at the conditions in which the molecule 
was incubated in solution with pH different from the pI. Compared to the relative 
recovery obtained with a simple mixture, ACTH uptake on the 7nm MSC is clearly 
reduced when the mixture complexity is increased. Spiking the peptide in the plasma 
sample showed a reduction of the adsorption even on the 6nm MSC.  Aprotinin 
showed the opposite behavior compared to the other 2 peptides.  
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In a complex mixture or in the crude plasma, the 6nm and 7nm pore size MSC 
revealed a higher uptake, while with the 4nm pore size MSC it was reduced by 
about 40%. Considering the number of molecules that can simply fit in a pore 
section area we observed that in a complex mixture the uptake is improved when the 
pore is large enough to accept two or three molecules.  With an increased 
complexity of the solution, the pH condition that facilitates the uptake remains the 
one close to the pI of the specific peptide. In addition, it has been observed that the 
recovery is also promoted when the peptide has a positive charge.  
 
8.5 PEPTIDE ADSORPTION STUDY OF HUMAN PLASMA 
PATIENTS 
We evaluated the ability of the MSC to fractionate and capture LMW peptides and 
proteins from human plasma according to different pore sizes and different pH. Four 
different procedures were compared. Plasma samples from three CRC patients and 
three healthy control cases were incubated either at pH 5 or at native pH (around pH 
7-7,5) on both 4nm and on 6nm MSC pore size. Before the sample spotting on the 
MSC, we added ACN (5% v/v) to the sample in order to partially denature abundant 
protein allowing the release of the peptides that were bound to albumin or to other 
proteins (Tirumalai R.S. et al 2003). We analyzed each sample in triplicate. 
 
8.5.1 Data pre-processing 
Identification of disease specific proteins could provide biological information as 
well as potential diagnostic markers or drug targets. However there is little to no 
agreement in determining which ions are the most significant for classifying the 
samples. Protein mass spectra analysis raises a number of technical challenges 
highlighting the limitations of existing analysis method. Mass spectra mining 
involve a high risk of finding pattern in spectra noise. Elimination of confounding 
factors that are introduced by the analytical method applied is very important. For 
this reason each MALDI-TOF spectrum was manually inspected for the presence of 
peaks and for the presence of repetitive noise and matrix peaks.  Matrix can generate 
peaks in the low molecular range of MALDI-TOF spectrum. Matrix peak intensities 
fluctuate in relation to many variables such as sample quality, matrix deposition, 
concentration of sample peptides, distribution of the analytes in the MALDI-TOF 
well and formation of good crystal of sample and matrix. Blank control was used to 
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generate a spectrum of potential matrix peaks. Spectrum of matrix was compared 
with sample spectra and peaks with the same m/z as the matrix peaks were not used 
for subsequent analysis. Moreover, raw MALDI spectra are not amenable to any 
type of quantitative analysis by direct comparison. For this reason, prior to data 
analysis, mass spectra data require more meticulous and customized quality control, 
cleaning, and transformation than most other type of data. Multiple factors govern 
data production such as sample collection, handling and instrumentation. Therefore 
we carried out a pre-processing analysis of the raw spectra to reduce experimental 
variance within the data set for obtaining subsequent reliable statistical analysis of 
data. Pre-processing involves a complex analysis of digital signal processing, data 
exploration, and data engineering techniques. (Norris J.L. et al, 2007; Hilario M. et 
al, 2006) No standard method has been established so far regarding the pre-
processing steps, including the order in which the steps might be performed. 
However, pre-processing analysis includes several processes: 
• Filtering or denoising. This function helps to remove high-frequency 
interfering signal caused by sources unrelated to the bio-chemical nature of 
the sample (electrical interference, random ion motions, statistical 
fluctuation in the detector gain or chemical impurities). 
• Baseline subtraction. Profile spectra typically exhibit an intense and a 
variable chemical noise background that must be quantified and eliminate 
before accurate measures of ion intensities can be determined. There are a 
number of algorithms that have been reported for estimating the baseline, but 
the difficult in developing such algorithm is the lack of any quantitative 
evaluation criteria.  
• Normalization is the process that corrects for systematic variation between 
spectra minimizing the spectrum-to-spectrum differences in ion intensity to 
facilitate direct comparison of spectra. These differences are derived from a 
number of source including instrument variation, sample variability, 
differences in sample preparation. Several normalization processes are 
described in the literature and they can be divided in collective and 
individual normalization process as well as global and local normalization. 
In this study we used the Total Ion Current (TIC) that is one of the global 
normalization procedures and makes the total amount of detected ions (the 
sum of all intensity values) equal in all spectra.  
• Alignment of the spectra is often required when the spectra are generated 
over a long period of time. Misalignment must be corrected to ensure that the 
same protein intensities are correctly identified in a sample (Wong J.W. et 
al., 2005). There are different alignment methods but usually there must be 
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references across the entire spectra: an approach consists to identify peaks 
common to most or all the spectra and spanning the entire mass range of 
interest. The alignment can be performed before the peak identification, 
using different algorithms. in this study we used the Peak Alignment by Fast 
Fourier Transform algorithm (PAFFT) that is not dependent on picking 
peaks but it works by dividing a spectrum into segments before the 
evaluation of the best shift FFT cross-correlation (Wong J.W.H et al., 2005) .  
• Format of data analysis. The desorption/ionization step in MALDI-TOF MS 
is a complex process involving optical and mechanical phenomena, as well 
as thermodynamic and physicochemical processes of phase transition and 
ionization, which are not well understood. Also the matrix (co)crystallization 
has been derived empirically. Different matrix molecules crystallize in 
different shapes and dimensions, proteins tend to accumulate in a non-
homogeneous way in the MALDI well, and the composition of the matrix 
solution and the rate of crystal growth influence the spectral output. These 
phenomena produce shot-to-shot variation, which is related to sampling 
different parts of the target surface and progressive sample ablation with 
repeated sampling (Albrethsen J., 2007). Repeated measurements may, 
therefore, result in largely different absolute intensities. Furthermore, 
spectrum peaks absolute intensities can vary significantly between 
measurements especially if the abundances of the peptides are low. For these 
reasons we decided to primarily analyzed the relative abundances of the 
peaks instead to use the absolute intensities. However, analyses using 
absolute intensities were also performed to verify that results between the 
different approaches did not vary significantly. 
Pre-processing analysis were performed using Specalign software that allows for a 
good interaction from the user. We smoothed the signal; we normalized the ion 
intensities to minimize spectrum-to-spectrum differences in peak intensity. We used 
the Total Ion Current (TIC) that makes the total intensity amount of detected ions 
equal in all spectra. The baseline was subtracted and spectra were binned to a size of 
a unit of m/z to reduce the complexity of the spectra and to obviate any 
amplification of differences from species that might be very close to one another. 
We realigned spectra using PAFFT method to ensure the correct comparison of the 
same ions across a number of samples. We then picked peaks on the basis of the 
average spectrum and we exported the relative intensities of each spectrum. 
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 8.5.2 Reproducibility 
The semiquantitative nature of the peak intensity and the high-throughput capability 
of MALDI-TOF MS permit its use in preclinical explorative research of biomarkers.  
However, the reproducibility of peak intensities is of high importance when we use 
MALDI-TOF MS protein profiling for biomarker research because it is based on the 
comparison of peak intensities between two different conditions (Albrethsen J., 
2007).  If the system is not reproducible, the analysis could lead to significant 
alterations of the proteomic profiling and the generation of artifacts. Bouamrani et 
al, at the Nanomedicine department, already performed an intra-experiment 
variability reproducing the same experiment in six replicates highlighted the 
stability and reproducibility of the methods. Furthermore we evaluated the inter-
experiment reproducibility incubating a commercial plasma, in triplicates, on the 
five MSC that we used for the biomarker analysis. We assessed the consistency of 
the system evaluating the presence of the peaks in every spectrum. The variability of 
the peaks signal, measured by the average CV, was estimated at 13%. 
 
8.5.3 Evaluation of selective peptide fractionation patterns 
To evaluate the influence of different sample pH in combination with different pore 
size MSC we used exploratory techniques such as hierarchical clustering and PCA 
analyses. Unsupervised hierarchical clustering was performed on the complete 
MALDI-TOF MS spectra profiles using the Euclidean distance metrics. The 
distribution of ionic species in all 4 procedures is shown in Figure 17. Irrespective to 
the group of subjects, cluster analysis showed a clear division of the samples 
according to the pH, while, within the pH groups, the separation of the different pore 
sizes is not defined. 
 
Figure 17. LMW proteins 
fractionated with the 4 different 
procedures: A) Clustering 
Analysis of MALDI-TOF 
dataset of the four procedures 
tested: samples incubated at pH 
5 (green) and pH7,5 (purple) 
and fractionate with 4nm MSC 
(red) and with 6nm MSC (blue). 	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Data exploration was further carried out with unsupervised and supervised PCA. 
Figure 18A showed the unsupervised 2D plot of the two first principal components 
(PC) for the different pH of incubation. The score plot is shown on the left of the 
graph and it presents the spatial separation of samples in relation to the selected m/z 
variables that are showed in the loading plot (on the right of the graph). We selected 
the subset of m/z variables that showed a higher discriminatory power among the 
groups. The m/z variables were selected after we performed a t-test analysis of each 
individual m/z variable. T-test determines if the mean of an individual m/z variable 
was significantly different between the two groups, given the standard deviation and 
the number of samples. A clear separation between the two different conditions is 
spatially showed along the Principal Component 1 (PC1) confirming the result 
presented in the hierarchical cluster. Moreover, looking at the loading graph we 
noticed that there were more variables expressed in the group of samples incubated 
at pH5 than those peculiar of the groups of samples incubated at pH7.5. We could 
assume that at pH5 more peptides have slightly positive charge, confirming the 
results presented in the section above, with standard peptides incubated in complex 
samples. In addition variables that contributed more to the group of samples 
incubated at pH7.5 showed higher m/z compared to the group of sample incubated 
at pH5. We analyzed the samples separation in relation to the MSC pore size. The 
unsupervised PCA score plot in figure 18B showed a less clear separation between 
samples fractionated with 4nm or 6nm pore size MSC.  We noticed, as well as the 
pH, a major contribution of variables with higher m/z, for samples fractionated on 
the 6nm pore size MSC.  However, looking at supervised PCA of all the four 
experimental procedures (Figure 18C) we observed a less separation between MSC 
of 4nm and 6nm when the samples were incubated at pH5. m/z variables that 
contributed to those groups were spatially close and they were more numerous than 
those peculiar of the samples incubated at pH7.5. Furthermore the classification of 
control and CRC samples was spatially close for those two groups.  On the basis of 
these experiments we observed that some harvested species are peculiar of the 
different operative procedures. However the major contribution to the different 
fractionation is determined by the pH. All the procedures allowed the healthy and 
the pathological samples to be differentiated, although more consistent results were 
obtained with pH 5, with both pore sizes. These observations demonstrate that the 
MSC selective harvesting and fractionation of peptides and proteins in complex 
biological samples like plasma, is principally due to their charge more than the pore 
sizes. 
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Figure 18. Unsupervised and supervised PCA-DA of LMW proteins fractionated with different 
condition of pH (pH 5 and pH7.5) and pore size MSC (4nm and 6nm pore size). On the left it is 
showed the score plot with the spatial disposition of the sample patients while on the right the loading 
plot showed the different contribution of the single m/z to the separation between the groups. A) 
Sample fractionation with pH5 (green) or pH7.5 (purple) B) PCA of sample fractionation with 4nm 
MSC (red) and 6nm MSC (blue). C) Supervised PCA of sample solutions with pH 5 incubated on 
4nm MSC (full red triangle), of sample solutions with pH 7.5 incubated on 4nm MSC (empty purple 
triangle), of sample solutions with pH 5 incubated on 6nm MSC (full blue square) and of sample 
solutions with pH 7.5 incubated on 4nm MSC (empty green square). 
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8.6 ANALYSIS OF CIRCULATING LOW MOLECULAR WEIGHT 
PROFILE OF RECTAL CANCER PATIENT TREATED WITH 
NEO-ADJUVANT CHEMO-RADIO THERAPY (pCRT) 
 
8.6.1 Patient characteristics 
We performed MALDI-based comparative analysis of the low-molecular-weight 
fraction of plasma proteome of 40 patients with locally advance rectal cancer treated 
with neoadjuvant chemoradio-therapy. 
Rectal cancer TRG was distributed as follow: TRG 1: n=9; TRG 2: n=11; TRG 
3:n=13; TRG 4: n=6; and TRG 5: n=1. On the basis of the TRG distribution, 20 
(50%) patients were considered Good responders (TRG 1 to 2), and 20 (50%) were 
considered Poor responders (TRG 3 to 5). Complete details are shown in Table 4 
 
Table 4. Patients, tumour and treatment characteristics of the 40 patients included in the study 
n° %
Age Median (range) yrs 66 (48-80)
Male 29 72,5
female 11 27,5
 ! 7 cm 25 62,5
> 7 cm 15 37,5
Continuos infusion 3 7,5
Bolus 33 82,5
Not available 4 10,0
 5-Fluorouracile alone 17 42,5
Oxaliplatin 14 35,0
Not available 9 22,5
0 10 25,0
I 11 27,5
II 8 20,0
III 6 15,0
IV 1 2,5
Not evaluable 4 10,0
yes 28 70,0
no 2 5,0
Not available 10 25,0
0 2 5,0
1 13 32,5
2 14 35,0
3 5 12,5
4 1 2,5
Not available 5 12,5
1 9 22,5
2 11 27,5
3 13 32,5
4 6 15,0
5 1 2,5
Good responders (TRG 1-2) 20 50,0
Poor responders (TRG 3-4-5) 20 50,0
TRG
Radical surgery
Acute toxicity
Patient characteristics
Sex 
Tumor distance from the anal verge
5-Fluorouracil administration
Other drugs
pTNM
	   90	  
 
Plasma samples were collected in different time points related to the chemo-radio 
therapy procedure. For each patient, draw samples were collected before the start of 
therapy, after two weeks from the start of the therapy, before the surgery (after 2-4 
weeks from the end of the therapy). Plasma from group of 43 healthy control 
subjects, with negative colonoscopy were analyzed  
 
8.6.2 Analysis of Low Molecular Weight peptide profile 
We performed the LMW peptide analysis and we collected the MALDI-TOF spectra 
for each plasma draw. The MALDI-TOF dataset was aligned and normalized using 
Specalign software and the values were binned to 1 m/z as describe before.  We 
applied the same protocol to all the spectra acquired from different draw blood 
timing and from different patients. We picked peaks on the basis of the average 
spectrum and we exported the peaks absolute and relative intensities of each 
spectrum.   
Looking at the sample MALDI spectra individually, we noticed the presence of few 
peaks with high intensity compare with the other peaks presented; in particular ionic 
species at 1076.6 and 2021.9 showed high intensities and 1060.6 usually showed the 
highest intensities in the majority of the spectra. Therefore, relative abundances 
were calculated on the intensity of m/z at 1060.6. Data from MALDI spectra were 
analyzed in relation to the pathological status, to the response to CRT, and to the 
time point draw samples. The explorative research of biomarkers was performed 
using Principal Component Analysis (PCA) that is considered a useful statistical 
tool able to discover structures in the experimental data. 
 
8.6.3 Control subjects versus not treated rectal cancer patients 
We first analyzed plasma of a group of control subject versus plasma of the rectal 
cancer patients collected before the CRT (T0), irrespectively to the class of 
response, for highlighting the peptidomic differences related to the pathological 
condition.  We carried out the pre-processing data of the raw MALDI spectra for all 
control subjects and rectal patients. By a first visual inspection of the MALDI-TOF 
spectra, differences seem to be present between the overall peak pattern of the 
patients and the healthy controls. Interestingly, spectra of control cases showed a 
lower number of peaks compare to the patient spectra, and of the peaks that the two 
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groups shared, several species showed lower abundances in control spectra (Figure 
19). 
 
 
We performed a PCA multivariate analysis including all the peaks found in rectal 
cancer patient spectra and in healthy control spectra and we confirmed that a good 
discrimination between the two groups was mainly due to the differential presence 
of several peaks, listed below (Figure 20 and Table 5). In figure 20A we used all the 
peaks presented in healthy controls and in patients spectra while in figure 20B we 
performed the multivariate analysis with the subset of peaks that resulted 
preferentially present in one of study groups. The picture shows, on the left, a spatial 
separation of the sample of the two groups and, on the right, the spatial distribution 
of the m/z ionic species that highlight its differential contribution to the separation.  
 
 
Figure 20. A) Unsupervised PCA made with all the peaks found in healthy subjects spectra and in 
rectal cancer patient spectra. B) Unsupervised PCA between group of healthy control and rectal 
cancer patients using the m/z variables differentially expressed in the two groups. Samples spatial 
separation is showed in the score plot on the left, while loading plot is showed on the right. 
 
 
 
Figure 19. A graphic visualization 
of two MALDI-TOF spectra; the 
upper spectrum is related to a rectal 
cancer patient (Blue) while the 
lower spectrum is related to a 
healthy control spectrum (green). 	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Table 5. m/z variables that were present either in rectal cancer patients or in healthy control subjects. 
m/z present only in rectal cancer 
patient spectra 
m/z present only in 
healthy control 
spectra 
1043.4 1934.8 2068.7 
1082.7 2037.2 1985.4 
1103.9 2287.7 2713.6 
1114.1 2484.9  
1120.1 2861.7  
1183.6 2878.1  
1498.9 2933.4  
1516.0    
 
Then we analyzed only the peaks that were in common with both the groups to look 
for potential differences in the intensity levels. We found 20 peaks in common with 
both the groups. We exported the relative intensities and for each triplicate we 
calculated the mean and the standard deviation. We performed an unsupervised PCA 
between the two groups (Figure 21A) but the multivariate analysis was not able to 
separate the groups, maybe because the variance of the m/z variables within the 
groups was large. In order to improve the separation between the two groups we 
tested one m/z variable at the time for its ability to discriminate the pathology using 
t-test analysis. The subsequent unsupervised PCA suggested that although the 
healthy subjects group and the patients group are scattered within the space, a 
separation between the two groups is present. Interestingly, the majority of the 
significant m/z variables are down-regulated in control subjects compare to the 
rectal cancer patients.  m/z at 1865.2 is slightly more abundant while m/z at 1098.0, 
1530.2, 1896.4, and 2365.3 are down-regulated in the control cases (Figure 18B). 
 
Figure 21. Unsupervised PCA of the group of healthy subjects (yellow) and the patients with locally 
advanced rectal cancer (purple). A) Unsupervised PCA with all the m/z variables in common 
between rectal cancer patients and healthy subjects. The picture shows a large overlap of the two 
groups, indicating the inability of the m/z species to classify the groups. B) Unsupervised made with 
the m/z variables that showed higher discriminatory power among the groups, at the t-test analysis. 
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To deepen the analysis we then performed a PCA combined with a Discriminant 
analysis (supervised PCA-DA) dividing the rectal cancer patients on the basis of the 
histopathological response. The software first performs a PCA as usual, which 
reduces the dimensionality of the data by generating the PC’s; then the data are used 
in the Discriminat Analysis (DA) that combined the PC’s with the group 
information to find m/z combinations that maximize the variance between groups 
while minimizing the variance within groups (supervised approach) (Figure 22). The 
separation of the pathological condition (healthy versus cancer) is spatially observed 
along the D1 score plot where the control group shows negative score. The rectal 
cancer groups that defined the tumour response to CRT are separated along the D2 
score plot but the division is less defined. The m/z variables seem to have a lower 
capacity to separate the control group from the group of rectal cancer that respond to 
the therapy.  
 
The comparison of a single class of response with the control group confirmed the 
different capacity for the selected m/z variables to distinguish control cases from 
rectal cases stratified on the basis of the histopathological response. The peptide 
expression trends of individual variables between the healthy subjects, the Good and 
the Poor responders are shown in the box plot in Figure 23. Interestingly box plots 
of some of the selected m/z variables (in particular m/z at 1530.2 and 1880.9) show 
a progressive increased trend from the healthy controls to the Good responders and 
to the Poor responders. This might mean that some peptides increased their 
expression in blood according with the pathology but also according with the 
tumour response to CRT, even before applying the therapy.  Anova statistical 
analyses highlighted significant differences between Poor responders group and 
healthy group for m/z at 2365.3, 1880.9 (p-value < 0.05) and 1530 (p-value < 
0.0001).  Statistical analysis of single m/z variable between two groups at the time 
was performed with non-parametric Mann-Whitney test for unpaired data, and a 
significant difference was assumed for p < 0.05 (two-tailed test). 
Figure 22. Supervised PCA-DA of healthy 
subjects and rectal cancer patients divided on 
the basis of the tumor response. Healthy 
subjects (yellow) are separate from rectal 
cancer patients along the D1. Good responder 
group (blue) highlighted a larger spatial 
overlap with healthy cases compare with 
spatial area of Poor responder group (red). 	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Figure 23. Box plot of the m/z variables selected with the multivariate analyses for the healthy 
(yellow), Good responders (blue) and Poor responders (red) groups. Mann Whitney tests were 
performed for two groups at the time. (*= p-value <0.05; **= p-value < 0.01; ***=p-value<0.001 
(two-tails p-value)). 
8.6.4 Prediction of the histopathological response to the CRT 
Observing MALDI-TOF spectra of the patients we noticed a slightly different 
number of peaks from one patient to another. Usually spectra of T0 and T2 time 
showed more peaks than spectra of the same patient at T1 time.  However the 
additional peaks commonly showed low intensity and they were present in few 
patients. For this reason, we choose to study the peaks that were in common with the 
majority of spectra and that are present through the time points for monitoring its 
variation tendency. 
8.6.4.1 Before the CRT  
Data exploration was carried out on the complete MALDI-TOF spectra profiles of 
rectal cancer patients before the chemo-radio therapy with the aim of identifying a 
differential expression pattern that could be able to predict the histopathological 
response to therapy.  
The unsupervised PCA did not allow a good separation of the patients according to 
the tumour response and we performed a supervised PCA-DA analysis (Figure 24). 
The loading plot of the supervised PCA-DA showed that few m/z ionic species were 
associated to the Good responder spatial classification. These variables mainly had 
m/z lower than 1500. A large number of m/z gave low contribution for 
discriminating the two classes. On the other hand, some m/z ionic species are shown 
to have higher discriminatory power; as already shown in the previous analysis with 
the healthy subjects, m/z at 1530,3 showed a higher positive contribution for Poor 
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responder group. Figure 24 shows negative percentage values for m/z at 1082.7 and 
1498.9 suggesting a higher presence in Good responder group. 
 
Figure 24. PCA-DA of Good responders (blue) and Poor responder (red) groups at T0 time point.  
Therefore we reduced the m/z investigated to enhance the discriminatory capacity of 
the tumour response classes. We performed a t-test of each individual m/z variable 
and we selected the m/z variables based on the probability that t-test showed for 
separating the groups. Ionic species that resulted discriminating the two group at the 
t-test (with a probability higher than 99%) were: m/z at 1530.3, 1934.9, 2154.8, and 
1848.9 that were more abundant in Poor responders and m/z at 1082,7 that was more 
abundant in Good responders. However, the PCA-DA performed with these m/z 
variables showed a slight improvement of the discriminatory capacity (Figure 25). 
 
Figure 25. PCA-DA between Poor responder (red) and Good responder (blue) groups using the m/z 
variables that showed t-test probability >99%. 
 
By combining different information derived from the t-tests, the unsupervised and 
the supervised multivariate analyses, we found a combination of m/z variables that 
improved the discrimination of the groups (Figure 26). 
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Figure 26. PCA analysis between Good (blue) and Poor (red) responders carried out with m/z 
variables selected combining PCA analysis with single variable t-test analysis A) Unsupervised PCA 
shows a discrimination between the 2 groups with a misclassification of four Good responders and 
two Poor responders.  B) Supervised PCA-DA shows the contribution of the selected m/z variables 
(loading plot) on the classification. 
Some Poor responder and Good responder patients are spatially close in the 
unsupervised score plot PCA, lying in the space in which the two groups 
overlapped. This means that the combination of the m/z ionic species may not be 
able to unequivocally classify them. 
The t-test analysis is a good way to test each m/z species for its ability to 
discriminate the condition under investigation and to find the top most significant 
species for developing the subsequent statistical model. However, unsupervised and 
supervised multivariate analyses evaluate the synergy among the species, and 
sometimes variables that could be not significant if they are considered individually, 
could improve the results when used in combination with other variables. Box plot 
of each m/z ionic species in Good and Poor responders are showed in Figure 27. 
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Figure 27. Box plot of the m/z 
variables selected with the t-test 
and the multivariate analyses 
that discriminate between Good 
responders (blue) and Poor 
responders (red) groups. m/z at 
1498.9 did not show high 
differences between Poor and 
Good responders. Mann 
Whitney tests were performed 
for each m/z variable. (*= p-
value <0.05; **= p-value < 
0.01; ***=p-value<0.001 (two-
tails p-value))  	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The ROC-curves for each m/z variable are showed in Table 6. 
Table 6. ROC-Curve features for each m/z variables selected. ROC-Curves were carried out for each 
m/z variable comparing data from Good responder and Poor responder groups . 
Good responder, 
Poor responder 
AUC (95%CI) p-value Cut-off Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
V1082.7 0.73 (0.57-0.86) 0.0056 <0.0785 70 (45.7-88.1) 80 (56.3-94.3) 
V1098.0 0.60 (0.43-0.75) 0.2796 <0.0382 35 (15.4-59.2) 90 (68.3-98.8) 
V1103.9 0.70 (0.53-0.83) 0.0234 <0.0291 55 (31.5-76.9) 85 (62.1-96.8) 
V1530.2 0.75 (0.59-0.87) 0.0020 >0.0923 65 (40.8-84.6) 90 (68.3-98.8) 
V1880.3 0.67 (0.51-0.81) 0.0422 >0.044 60 (36.1-80.9) 75 (50.9-91.3) 
V1934.8 0.73 (0.57-0.86) 0.0048 >0.0488 65 (40.8-84.6) 90 (68.3-98.8) 
V2154.8 0.71 (0.54-0.84) 0.0149 >0.0258 55 (31.5-76.9) 90 (68.3-98.8) 
V2348.1 0.72 (0.56-0.85) 0.0065 >0.0133 90 (68.3-98.8) 50 (27.2-72.8) 
 
An interesting finding is that among the m/z ionic species, three were not found in 
healthy control subjects (1082.7 1103.9, 1934.8) whereas three were found down-
regulated in healthy controls. 
Multivariate logistic regression analysis  
We performed a multivariable logistic regression analysis in order to investigate the 
role of the selected m/z ionic species in predicting the histopathological response. 
We estimated the probability of the non-responsive event (Poor responders with 
TRG:3-5) in function of these variables. For this purpose we performed univariate 
logistic regression analysis for each of the selected m/z ionic species as shown in 
Table 7. 
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Table 7. Univariate logistic regression analysis for each of the previous selected m/z variables 
 
All variables entered the multiple logistic regression model and the stepwise 
selection method identified 5 variables that better predicted the outcome in the final 
model (Table 8). The estimated probability of having a Poor response event (TRG3-
5) increased as the variables m/z 1530.2, 1880.3 and 2348.1 increased, while it 
decreased as the variables m/z 1082.7 and 1098.6 m/z increased. 
Table 8. Logistic regression model carried out with the m/z variables selected through the stepwise 
selection method 
 LOGISTIC MODEL 
 Unit OR 95% CI p-value 
V1082.7 0.01 0.28 0.08-0.92 0.0356 
V1098.6 0.01 0.37 0.13-1.07 0.0667 
V1530.2 0.01 2.94 1.03-8.37 0.0432 
V1880.3 0.01 5.32 0.90-31.4 0.0649 
V2348.1 0.01 16.2 1.01-260 0.0494 
 
N Minimo Massimo Media DS Unit OR 95% CI p-value
Good 20 0.03 0.21 0.10 0.04
Poor 20 0.01 0.13 0.07 0.03
Tot 40 0.01 0.21 0.09 0.04 0.01 0.77 0.63-0.95 0.0151
Good 20 0.02 0.17 0.08 0.05
Poor 20 0.01 0.13 0.06 0.04
Tot 40 0.01 0.17 0.07 0.04 0.01 0.91 0.78-1.06 0.2201
Good 20 0.01 0.09 0.05 0.02
Poor 20 0.00 0.10 0.04 0.02
Tot 40 0.00 0.10 0.04 0.02 0.01 0.76 0.57-1.03 0.0733
Good 20 0.02 0.13 0.06 0.03
Poor 20 0.00 0.29 0.11 0.07
Tot 40 0.00 0.29 0.09 0.06 0.01 1.27 1.04-1.56 0.0179
Good 20 0.01 0.07 0.04 0.02
Poor 20 0.02 0.10 0.05 0.02
Tot 40 0.01 0.10 0.05 0.02 0.01 1.35 0.99-1.84 0.0576
Good 20 0.00 0.14 0.03 0.03
Poor 20 0.01 0.14 0.06 0.04
Tot 40 0.00 0.14 0.05 0.04 0.01 1.28 1.01-1.63 0.0440
Good 20 0.00 0.04 0.02 0.01
Poor 20 0.01 0.06 0.03 0.01
Tot 40 0.00 0.06 0.02 0.01 0.01 2.13 1.13-4.02 0.0190
Good 20 0.01 0.05 0.02 0.01
Poor 20 0.01 0.08 0.03 0.02
Tot 40 0.01 0.08 0.02 0.01 0.01 1.7 0.93-3.10 0.0820
V1880.3
V1934.8
V2154.8
V2348.1
DISTRIBUTION LOGISTIC MODEL
V1082.7
V1098.6
V1103.9
V1530.2
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The Hosmer-lemeshow goodness of fit test is not significant (p=0.8654), suggesting 
that the model adequately fit the data. The ROC-Curve of the logistic model, plotted 
in Figure 28, shows a very high AUC (98%). For the probability of histopathological 
non-response=0.5, the false positive rate is 20% and the false negative rate is 20%. 
The sensitivity and the specificity of the model are both 80%. 
        
 
8.6.4.2	  After	  the	  CRT  
We performed the peptide profiling study on plasma of the rectal cancer patients 
after the CRT. It is noticed that waiting a several of weeks from the end of CRT 
before doing the surgery improves the prognosis. Hence blood samples were usually 
done just before the surgery. 
We followed the same analytical procedure as previously described. We first 
performed an unsupervised PCA and a PCA-DA with m/z variables from the 
complete spectra (Figure 29). 
 
Looking at the loading plot of the m/z variables, in Figure 29, we noticed that a 
higher number of m/z ionic species have negative loadings that are associated to the 
Poor responder spatial classification, as already seen in T0 analysis. However, ionic 
species that are associated to the Good responder group cover the all range of 
Figure 29.  PCA-DA 
of Good responders 
(blue) and Poor 
responder (red) groups 
at T2 time point. 	  
Figure 28. Roc-Curve of the logistic 
regression model, with the five selected m/z 
variables. The Area under the curve is 0.98 
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spectra. We performed student t-test analyses to determine the ability of each m/z 
variable to discriminate the response classes. We found that variables had less 
discriminating power compared to the T0 time point. m/z at 1082,7 showed a t-test 
probability of 99% for Good responders, whereas Poor responders showed higher 
intensity for m/z at 1043.4, 1088.3, and 1934.8 although t-test probability were 
96,7%, 96,7% and 95,8% respectively. Using both the m/z variables with the higher 
t-test scores and the m/z variables that showed higher contributes in PCA-DA we 
were able to define a set of ionic species that is showed in Figure 30. As the T0 time 
point analysis, there are m/z variables that show low value at the t-test but they 
improved the discrimination between groups.  
 
 
Figure 30. PCA analysis between Good (blue) and Poor (red) responders carried out with m/z 
variables selected combining PCA analysis with single variable t-test analysis A) Unsupervised PCA 
shows a discrimination between the 2 groups with a misclassification of three Good responders and 
three Poor responders.  B) Supervised PCA-DA shows the contribution of the selected m/z variables 
(loading plot) on the classification. 
 
The m/z variables that contributed more in Poor responders classification were: 
1043.4, 1183.6, 1530.2, and 1934.8. The m/z which expression was associated to 
Good responders group were: 1082.7 and 1103.9. In Figure 31, a box plot for each 
ionic specie is presented. We noticed that, although m/z at 1530.2 was useful to 
improve the discrimination between Good and Poor responders in multivariate 
analysis, the individual analysis of this ionic species did not show significant 
difference between the two groups, indicating that the combination of the ionic 
species is more powerful than the individual variable.  
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Figure 31. Box plot of the m/z variables selected with the multivariate analyses for Good responders 
and Poor responders groups at the T2 time point. Mann Whitney tests were performed for each m/z 
ionic species two groups. (*= p-value <0.05; **= p-value < 0.01; ***=p-value<0.001 (two-tails p-
value)). 
 
The ROC-Curve of each m/z variable is showed in Table 9. 
Table 9. ROC-Curve features for each m/z variables selected. ROC-Curves were carried out for each 
m/z variable comparing data from Good responder and Poor responder groups . 
Good responder,  
Poor responder 
AUC (95%CI) p-value Cut-off Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
V1043_36 0.67 (0.51-0.81) 0.0489 >0.0603 45 (23.1-68.5) 90 (68.3-98.8) 
V1082_72 0.82 (0.67-0.93) <0.0001 <0.118 100 (83.2-100) 55 (31.5-76.9) 
V1103_9 0.63 (0.46-0.77) 0.1650 <0.0373 55 (31.5-76.9) 80 (56.3-94.3) 
V1183_62 0.72 (0.55-0.85) 0.0099 >0.0555 55 (31.5-76.9) 90 (68.3-98.8) 
V1530_21 0.63 (0.46-0.78) 0.1467 >0.0486 90 (68.3-98.8) 35 (15.4-59.2) 
V1934_8 0.66 (0.50-0.81) 0.0664 >0.039 65 (40.8-84.6) 75 (50.9-91.3) 
 
Multivariate logistic regression analysis  
We performed a univariate logistic regression analysis for each of the selected m/z 
ionic (Table 10).  
Five m/z variables were included in the subsequent multiple regression analysis. By 
applying the stepwise method we selected the best subset of m/z variables and we 
performed a multivariate logistic regression (Table 11). The estimated probability of 
having a Poor response event (TRG3-5) increases increasing the variables at m/z 
1043.4, 1183.8 and 1530.2 while it decreases increasing the variables at m/z 1082.7 
and 1103.9 m/z variables. 
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Table 10. Univariate logistic regression analysis for each of the previous selected m/z variables 
 
Table 11. Logistic regression model carried out with the m/z variables selected through the stepwise 
selection method 
 LOGISTIC MODEL 
 Unit OR 95% CI p-value 
V1043.4 0.01 1.93 0.93-3.99 0.0767 
V1082.7 0.01 0.30 0.13-0.70 0.0055 
V1103.9 0.01 0.28 0.09-0.89 0.0306 
V1183.6 0.01 1.51 0.93-2.44 0.0932 
V1530.2 0.01 1.66 1.03-2.69 0.0374 
 
The Hosmer-lemeshow goodness of fit is not significant (p=0.9713), suggesting that 
the model adequately fit the data. The ROC-Curve of the logistic model plotted in 
figure x shows a very high AUC (97.25%) (Figure 32). For the probability of 
histopathological non-response=0.5, the false positive rate is 15.8% and the false 
negative rate is 19%. The sensitivity and the specificity of the model are 80% and 
85% respectively. 
N Min MaX Mean SD Unit OR 95% CI p-value
Good 20 0.02 0.11 0.04 0.02
Poor 20 0.02 0.13 0.06 0.03
Tot 40 0.02 0.13 0.05 0.03 0.01 1.32 1.01-1.73 0.0458
Good 20 0.04 0.22 0.12 0.04
Poor 20 0.00 0.12 0.08 0.03
Tot 40 0.00 0.22 0.10 0.04 0.01 0.63 0.45-0.87 0.0049
Good 20 0.01 0.08 0.05 0.02
Poor 20 0.01 0.08 0.04 0.02
Tot 40 0.01 0.08 0.04 0.02 0.01 0.82 0.58-1.15 0.2526
Good 20 0.01 0.15 0.04 0.03
Poor 20 0.02 0.15 0.06 0.03
Tot 40 0.01 0.15 0.05 0.03 0.01 1.28 0.97-1.69 0.0750
Good 20 0.02 0.15 0.07 0.04
Poor 20 0.03 0.25 0.10 0.06
Tot 40 0.02 0.25 0.09 0.05 0.01 1.13 0.97-1.31 0.1103
Good 20 0.01 0.10 0.04 0.02
Poor 20 0.00 0.20 0.07 0.06
Tot 40 0.00 0.20 0.05 0.04 0.01 1.21 0.99-1.48 0.0681
V1043.4
V1082.7
V1103.9
V1183.6
V1530.2
V1934.8
DISTRIBUTION LOGISTIC MODEL
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Interestingly R214 and R313, the good responder patients that were misclassified at 
T0 time point, are still misclassified at the T2 time point. We checked the clinical 
parameters available for these patients and we compared the values with those of the 
other patients, but we did not find any explanation for justifying these results.  
 
8.6.4.3 In the middle of the CRT: T1 time point 
T1 time draw blood was carried out after 2 weeks from starting the CRT, meaning in 
the middle of the neo-adjuvant treatment. We performed the peptide profile analysis 
to evaluate if the initial perturbation of the biologic system could give meaningful 
evidences according to the different histopathological response to CRT. The so-
called “induced resistance to therapy” is referred to the mechanisms that cells and 
tissue could activate in response to a stress. These comprise modulation of gene 
expression and protein expression as well as modulation of a number of pathways 
and processes such as cell cycle and cell death. The draw blood at this time point is 
difficult to obtain because multiple variables could influence: patient availability, 
patient physiologic state, and the different medical hospital where the patient does 
the therapy. Therefore we were able to analyze only 12/20 T1 plasma of Good 
responders and 14/20 plasma of Poor responders.  We found that peak intensities at 
this time point were lower than those for T0 and T2 and supervised and 
unsupervised PCAs showed difficult to discriminate the two groups. Combining 
individual t-test analyses and principal component analyses data, we found 5 m/z 
variables that were able to show a kind of separation between Poor and Good 
responders although it was not clear. In particular, unsupervised PCA shows that 
Poor responder samples lie in a big spatial area, overlapping the spatial area of Good 
responders (Figure 33). Box plots in Figure 34 confirmed the difficult of the m/z 
ionic species to distinguish clearly the two groups.  
Figure 32. Roc-Curve of the logistic 
regression model, with the five selected m/z 
variables. The Area under the curve is 0.975 	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Figure 33. PCA analysis between Good (blue) and Poor (red) responders carried out with m/z 
variables selected combining PCA analysis with single variable t-test analysis A) Unsupervised PCA 
shows a high spatial area for Poor responders indicating a variable peptides behaviour of patients 
within the group.  B) Supervised PCA-DA shows the contribution of the selected m/z variables 
(loading plot) on the classification. 
 
Figure 34. Box plot of the m/z variables selected with the multivariate analyses for Good responders 
and Poor responders groups at the T2 time point. Mann Whitney tests were performed for each m/z 
ionic species two groups. (*= p-value <0.05; **= p-value < 0.01; ***=p-value<0.001 (two-tails p-
value)). 
 
Table 12 summarizes the m/z variables that were differentially expressed between 
Good and Poor responders at the individual time points. As it is showed, some m/z 
ionic species were found differentially expressed only in one time-point whereas 
some other were found discriminative in 2 different time points. Interestingly there 
are m/z ionic species that are discriminative before and after the CRT but not during 
the CRT (1103.9, 1530.2, and 1934.8). Three m/z ionic species were in common 
between T0 and T1 time point where four ionic species were in common between 
T0 and T2 time points. Ionic specie at m/ 1082.7 is the only one that showed the 
same behaviour through the time points and it was found more expressed in Good 
responders patients. Another interesting finding is that among the m/z ionic species, 
six were not found in Healthy control subjects (1082.7, 1043.4, 1103.9, 1183.6, 
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1498.9, 1934.8) whereas three were found down-regulated in healthy controls 
(1098.0, 1530.2, 1880.3). 
Table 12. Summary of the m/z variables found differentially expressed between Good responders and 
Poor responders at each time point analyzed (T0, T1, T2). 
 
3.4.2.2.4 Monitoring the CRT: variables tendencies through the time points 
We investigated the m/z variables intensity through the different time points to 
determine if there were tendencies that could be correlated to CRT. We first 
analyzed the relative intensities of all the variables, through the three time points, for 
single response class. Supervised PCA-DA of Good responder and of Poor 
responder groups showed an overlap between the three time points. We were not 
able to find m/z variables which intensities could separate the time-points groups 
(Figure 35A,B) hence we investigated the differences between 2 time-points at the 
time (T0 versus T1, T0 versus T2, and T1 versus T2) for each histopathological 
response class. 
 
 
We applied t-test analysis in combination with supervised PCA-DA and, although 
we found specific set of ionic species that showed a better separation between the 
Figure 35. PCA-DA at the 
three time-points: T0 
(purple), T1 (yellow), and 
T2 (blue) for each 
histopathological response 
class. PCA-DA of Good 
responders (on the left) and 
PCA-DA of Poor 
responders (on the right). 	  
Patients T0 T1 T2
1082,7 1082,7 1082,7
1098.0  1098.0
1103,9 1103,9
1498,9
1530,2 1530,2
1934,8 1934,8
2348,1 2348,1
2154,8
1880,3
1549,5
1865,2
1043,4
1183,6
Good Responders
Poor Responders
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group, the unsupervised analysis with the same ionic species did not confirm the 
classification, suggesting that the PCA-DA forced the separation between groups, 
enhancing little or random differences of intensity. An example is showed in Figure 
36. These differences could be due to the CRT time points but at the current state we 
could not prove it.  
 
Figure 36. Unsupervised PCA (on the left) and supervised PCA-DA (on the right) of Good 
responders between T0 (purple) and T2 (blue) time points. 
 
Then we used a different method to better visualize the possible differences between 
the time points. We used the intensities of each m/z at T0 time as the baseline 
expression before the treatment and we calculated the ratio of the time T1 and T2 
over the T0 time (T1/T0 and T2/T0). Therefore a ratio equal to 1 indicates that the 
expression was equal to the baseline expression, ratio higher than 1 implied an over-
expression and a ratio lower than 1 implied a down-regulation of the specific m/z 
ionic species. Although the differences were not strong, some m/z variables showed 
a different expression tendency compare to the baseline expression.  Looking at the 
graphs in Figure 37 we could notice that, globally in good responders, more m/z 
variables had the median value separate from 1 than those present in Poor 
responders; 36,5% (15/41) and 26,8% (11/41) for Good and Poor responders 
respectively. At T1 time-point many m/z variables showed a decrease of intensity 
compare to T0 time-point, although many of these showed only a slight decrement. 
Observing the T1/T0 ratio, in Good responders 4/15 of m/z variables show a more 
accentuated decreasing tendency of intensity and 1/15 of m/z variables presents 
significant increasing tendency of intensity compared with that observed at the 
baseline time point (graph A in Figure 37, purple box plots with red border). For 
Poor responders 4/11 of m/z ionic species showed decreasing tendency of intensity 
while one m/z variable over 11 showed significant increasing tendency of intensity 
compare with that observed at the baseline time point (graph B in Figure 37, purple 
box plots with red border). Observing the T2/T0 ratio we noticed that the majority of 
m/z ionic species showed an increment after the CRT compare to the baseline levels 
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or the T1 time point, underlined an increment of intensity for the majority of m/z 
variables. For Good responders no variables showed a decreasing tendency of 
intensity whereas 10 m/z had median value of ratio significantly higher than 
1(Figure 37 graph A, blue box plots with red border). For Poor responders one m/z 
showed a decreasing tendency of intensity while 5 m/z ionic species showed median 
value significantly higher than 1 (Figure 37, graph B, blue box plots with red 
border). m/z ionic species that presented a T2/T0 ratio higher than the T1/T0 ratio 
were 8 and 4 for Good and Poor responders respectively. However the T2/T0 ratio 
of these ionic species usually presents highly variable ranges. m/z that showed a 
decrement of T2/T0 ratio compared with T1/T0 ratio were: m/z at 1098.6 for Good 
responders and m/z at 1516.0 and 2037.2 for Poor responders. In particular m/z at 
1098.6 and 2037.2 showed an increase of expression in T1 time-point whereas in T2 
the expression were similar to T0. On the other hand m/z at 1516.0 showed a 
decreased expression in T1 that is emphasize in T2 time point. 
 
Figure 37. Ratio of relative intensity of each peptide at T1 or T2 time point over the intensity of the 
baseline time point (T0): T1/T0 (purple) and T2/T0 (blue) ratio were evaluated for each patient. Box 
plots of T1/T0 ratio (purple) and T2/T0 ratio (blue) of the subset of m/z ionic species that showed 
higher fluctuation in intensity during the CRT in A) Good Responders and B) in Poor responders. 
Ratio higher than 1 indicates increased expression compare to the baseline while ratio lower than 1 
indicates down-regulation of the peptide expression compare to the baseline. Box plots with red 
borders indicate a statistically different tendency compare to the baseline level (equal to 1). 
 
When we compared the box plot pictures of Good and Poor responders we noticed 
that there are some ionic species that are present in both the groups (m/z at 1498.9, 
1847.8, 2861.7). Interestingly these ionic species showed the same tendency over 
the time-points, in both the groups: at the T1 time-point these ionic species the 
intensity do not show significant differences with the T0, while there is a significant 
increment of the ionic species at the T2 time-point. 
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We monitored the tendencies of the peaks that resulted discriminative of the 
histophatological response before and after the therapy in Good and in Poor 
responders as shown in the Figure 38. There are no clear rules or evident trend in 
this subset of ionic species along the therapy. Ionic species did not show big 
difference in the intensity tendencies between Good and Poor responders. Along the 
CRT treatment we could observe that in Good responders the ionic species 1498.9, 
1934.8, and 2154.8 increased after the end of CRT (T2), 1098.6 increased in T1 
while 1043.4, 2348.1 and 1183.6 decrease in T1. Between Good and Poor 
responders many ionic species showed similar tendencies in T1 and T2. The 
majority of m/z variables showed intensities similar to those found at the baseline 
time point for both T1 and T2 time point or they could show a increased tendencies 
in T2, compared with those found in T1. The m/z variables that showed different 
tendencies between Good and Poor responders were m/z at 1098.6, 2154.7, and 
2348.1. 1098.6 increased in T1 and decreased in T2 in Good responders whereas in 
Poor responders it showed expression similar to T0 time point. m/z at 2154.7 
showed an increase in T2 for Good responders that is poorly observe in Poor 
responders and 2348.1 showed a inverse tendencies of T1 and T2 ratio between 
Good and Poor responders. Ionic species that were found differentially expressed in 
both the T0 and T2 analysis (1082.7, 1103.9 and 1530.2) did not show particular 
difference between Good and Poor responders. 
 
Figure 38. Box plots of T1/T0 ratio (purple) and T2/T0 ratio (blue) of the subset of m/z ionic species 
that are differentially expressed before and after the CRT between Good Responders (graph on the 
left) and Poor responders (graph on the right). 
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8.7 PEPTIDE SEQUENCE IDENTIFICATION 
 
Several peptides have been identified in the MSC elution samples. We easily 
recognized the most intense peaks observed in the MALDI-TOF spectra, using 
common search engines like Mascot.  
In Figure 39 is reported the case of peptide at m/z 1060.6, for which all ion 
fragments have been positively attributed to Bradykinin peptide. The calculated 
threshold score for this peptide was set to 12 by the program.  Since the obtained 
score was 47, this is considered a significant match.  
 
 
 
Similarly, other peptides have been positively recognized by using the search 
engines. All these peptides are naturally occurring in the plasma and, moreover, they 
are produced in vivo by specific proteases.  The peptides identified are listed in the 
table below: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Mascot peptide 
window result for the ion at 
m/z 1060.  The MS/MS 
spectrum is shown with the 
matched fragment ions and 
the ion score associated. 	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Table 13. Peptides identified by using search engines. The table shows the m/z of the spectra, the 
amino acidic sequence and the putative name of the protein from which derived the peptide. 
 
 
Kininogen, C3f, and C4a fragments were identified by two different ion species 
where one is half of the m/z value of the other (e.g. C3f were identified by m/z 
2021.2 and m/z 1011.1). This is due because of the formation of both single charged 
and doubly charged (2+) species during the sample ionization process. We observed 
a Post Translational Modification (PTM) of Bradykinin. The oxidized form of 
proline (P) residue in position 3 of the Bradykinin fragment has been manually 
identified and subsequently it has been confirmed by using the oxidation (P) option 
as the post-translational modification parameter for the search engine. 
The m/z that were not matching with any peptide via on-line search, have been 
identified via de novo sequencing. This is a manual peptides sequencing, based on 
known rules for peptide fragmentation. We used the sequences (or fragment of 
sequences) obtained for protein identification via BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins).  De novo sequencing 
strategy is affected by the quality of MS/MS spectra. For this reason we did not 
obtain reliable identification for some low abundant peptides which produced low 
MS/MS spectra (such as the peptide at m/z 2484, Figure 5, picture on the left). On 
the other hand, sometimes the obtained fragments were not enough to get the 
complete peptide sequence, although we reached good fragmentations (Figure 40, 
picture on the right). 
 
Family Peptide m/z Sequence
Bradykinin 1060.6 RPPGFSPFR
Bradykinin 
oxidized 1076.6 RPP(Ox)GFSPFR
2365.2,
1183 (2+)
2021.2, 
1011.1 (2+)
1896.1,
948 (2+)
Clusterin Clusterin B chain 1530.9 RPHFFFPKSRIV
C3f SSKITHRIHWESASLLR
Complement
Kininogens
Kininogen 
HMW KHNLGHGHKHERDQGHGHQR
C4a NGFKSHALQLNNRQIR
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Figure 40: Tandem mass spectra of peptides at m/z 2484 (on the left) and of peptides at m/z 1919 (on 
the right). 
 
 
Finally, a complete list of all m/z identified in the samples is reported in Table 14. 
This list collects peptides identified using MS/MS data, manual attribution and 
literature references.  
 
Table 14. List of m/z peptides identified and the relative list of attribution name 
 
 
We noticed that few peptides could be different portions of the same protein; this is 
the case for Bradykinin (1060.6) and the Kininogen fragment at m/z 2365.4: both 
peptides derived from High molecular weight-kininogen. However, most of peptides 
recognized with this approach originated from a same protein and they shared the 
same sequence core. As Villaneuva et al noticed, few peptide sequences clustered 
into sets of overlapping fragments lined up within each group at either C- or N-
terminal end and with ladder-like truncations at the opposite ends (Villanueva J.G. 
et al, 2007). In our study many of the recognized peptides were clustered in two 
groups, where the peptide precursors were a fragment of Complement C4a and of 
Complement C3f (Table 15).  
Moreover, most of these peptides derived from proteins or fragment of proteins that 
usually are resident in blood. Bradykinin and full-lengh founder complement C3f 
peptide (2021,3 m/z) are usually generated from various plasma proteins through 
endoproteolytic cleavage: Bradykinin is usually cleaved from high molecular 
m/z Attribution m/z Attribution
948,63 bicharge of 1896 1.847,20 Complement C3f fragment
1.011,15 bicharge of  2021 1.865,22 Complement C3f fragment
1.060,66 bradykinin 1.896,20 Complement C4a fragment
1.076,66 bradykinin oxidized 1.934,23 Complement C3f fragment
1.098,64 Complement C3f fragment 2.021,29 Complement C3f
1.114,65 Complement C3f fragment, + oxygen 2.037,27 Complement C3f + oxygen
1.183,19 bicharge of 2365 2.053,27 Complement C3f +2 oxygen
1.498,91 Complement C4a fragment 2.365,37 Kininogen fragment
1.531,00 Clusterin 2.861,58 Fibrinogen ! fragment
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weight-kininogen by plasma kallikrein while C3f is released by factor I and H after 
prior conversion of C3 to C3b. The full-length peptides that end with Arg or Lys 
amino acid preceded by a hydrophobic amino acid (Val, Leu, Phe) are cleaved by 
trypsin-like protease activity. Then the presence of fragments of peptides with 
ladder-like truncation at the opposite ends could be mainly due to some 
exopeptidase activities  (Table 15 and Table 16). The exopeptidases require a free 
N-terminal amino group, C-terminal carboxyl group or both, and hydrolyze a bond 
not more than three residues from the terminus. The exopeptidases are further 
divided into aminopeptidases, carboxypeptidases, dipeptidyl-peptidases, peptidyl-
dipeptidases, tripeptidyl-peptidases and dipeptidases (MEROPS database, Rawlings 
N.D. et al, 2008). For example, Arg/Lys amino acid could be removed by a 
carboxypeptidase except when it is preceded by Pro amino acid. Further 
exoproteases then could cleave either at the N terminal or C terminal. 
 
Table 15: m/z corresponding to the exopeptidase activity against complement proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
m/z N-term exopeptidase
2021.1 SSKITHRIHWESASLLR
1934.1 SKITHRIHWESASLLR
1847.1 KITHRIHWESASLLR
1098.6 HWESASLLR
m/z C-term exopeptidase
2021.1 SSKITHRIHWESASLLR
1864.9 SSKITHRIHWESASLL
1896 NGFKSHALQLNNRQIR
1498 NGFKSHALQLNNR
Complement C4a
Complement C3f
Complement C3f
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Table 16: Ionic species identified and the C- and N- potential site of cleavage of exopeptidases and 
endopeptidases. 
 
 
Looking at the overall MALDI-TOF spectra that we used in this study and taking 
into account the sequence identification data, we observed that the ionic specie at 
1060,6, which was present in all sample at equally high levels, corresponded to 
Bradykinin. A study of Yi et al), investigating the different spectra between blood 
samples collected using different anti-coagulant reagent and using protease 
inhibitor, showed the abundant presence of Bradykinin associated with EDTA 
sample tube (Yi J. et al, 2006. The founder peptide C3f at m/z 2021.1 was also 
present in all the spectra at high intensities.  
Comparing the peptide profiling of the rectal cancer patients at T0 time point and 
the spectra of healthy subjects, we noticed that among the ionic species that were not 
present in the healthy subject spectra, the amino acids sequences of two were 
positively identified. m/z at 1934.1 was identified as a N-terminal truncated 
fragment of C3f peptide. In particular we observed that this fragment was produced 
by the removal of an N-terminal Ser from the C3f full-length peptide. m/z at 1498.9 
was identified as a fragment of Complement C4a protein. It was a C-terminal 
fragment of a peptide with three more amino acids at m/z 1896.2 that moreover 
resulted down-expressed in healthy subjects. Among the 6 peptides that were 
differentially expressed in both healthy subjects and rectal cancer patients we 
noticed that the one at m/z 1098.6 represented another fragment of C3f that was 
m/z N-cleavage peptide sequence C-cleavage
2021.1 R SSKITHRIHWESASLLR S
1934.1 RS SKITHRIHWESASLLR
1847.1 RSS KITHRIHWESASLLR
1098.6 RSSKITHRI HWESASLLR
m/z N-cleavage peptide sequence C-cleavage
2021.1 R SSKITHRIHWESASLLR S
1864.9 SSKITHRIHWESASLL RS
m/z N-cleavage peptide sequence C-cleavage
1896 STGR NGFKSHALQLNNRQIR GLEE
1498 STGR NGFKSHALQLNNR QIRGLEE
m/z N-cleavage peptide sequence C-cleavage
Bradykinin 1060 MK RPPGFSPFR SS
HMW-Kininogen 2365 EKQR KHNLGHGHKHERDQGHGHQRGHG
m/z N-cleavage peptide sequence C-cleavage
Clusterin 1530 PHR RPHFFFPKSRIV R
Complement C3f
Complement C3f
Complement C4a
	   114	  
truncated at the N-terminal side. Two fragments were produced from the same 
precursor protein; m/z at 2365.4 was fragment of high molecular weight kininogen. 
Another ionic specie that was found increasingly expressed in rectal cancer patient 
was the one at m/z 1530.9 that was identified as a fragment of Clusterin. Moreover 
this peptide was found differentially expressed in relation with the histopathological 
response before and after the CRT and in particular, it was found more expressed in 
Poor responders. Clusterin is an enigmatic protein that has different/opposed 
functions. Several studies reported that CLU gene encoded different protein 
isoforms with distinct subcellular locations and functions: a pro-survival secretory 
form of 80kDa, a pro-survival cytoplasmatic form of 60kDa and a proapoptotic 
nuclear form of 50kDa are the most studied isoforms. The twelve amino acid 
clusterin fragment that we detected in association with the rectal malignancies and 
the histopathological response to CRT is located at the C-terminus of the β chain of 
the secretory form. Clusterin β chain is located at N portion of clusterin protein 
while α chain is the C-terminal part. Chains are separated by a cleavage of Val-Arg-
Xaa bond and the peptide that we detected corresponds to C-terminal portion of β 
chain excluding the Arg at the C-terminal. Beside the clusterin fragment we 
identified amino acid sequence of other three fragments differentially expressed 
between Good and Poor responders, before the CRT: the complement C4a fragment 
(1498.9) and the C3f fragments (1934.1 and 1098.6). Of notice, ionic species at 
1498.9 and 1934.1 were not found in the control samples and 1098.6 was found 
down-regulated in healthy samples. In this analysis the C4a fragment and the 
smaller C3f fragment were associated with Good responders while 1934.1 C3f 
fragments was associated with Poor responders. 
After the CRT, the differences between the histopatological response classes were 
maintained for the fragment of C3f (1934.1) and for clusterin fragment (1530.9) 
even if for the last one there is no statistical significance. m/z at 1183.2 has been 
revealed as a bicharge ion of HMW kininogen fragment. We were not able to 
identify amino acid sequences other ionic species. 
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9 DISCUSSION 
 
In the past decade circulating Low Molecular Weight peptidome has received 
increasing attentions as a powerful source of potential biomarkers that could 
improve diagnosis, monitoring and prognosis of various diseases including cancer. 
This new class of molecules have been recently available for biomarker 
investigation thanks to the technical progresses in clinical proteomic profiling and in 
simplification of complex clinical specimens.  The ability to screen and discover 
multiple circulating molecules simultaneously have been made concrete by the 
recent implementation of Matrix-assisted laser desorption/ionisation time-of-flight 
(MALDI-TOF) coupled with methods of high-abundant blood-resident protein 
depletion. Among different methods of protein depletion, often difficult and time 
consuming, fractionation methods that exploit the properties of nanomaterial have 
emerged. Nanodevices show the skill to reduce the complexity of the sample for 
isolating the low-abundance peptides, improving the ease of sample handling and 
the high throughput of analysis. The aim of the study has been to evaluate the Low 
Molecular Weight region of plasma proteome of locally advanced rectal cancer 
patients in order to find useful biomarkers that could be able to predict 
histopathologic response to neoadjuvant chemo-radio therapy. For improving the 
detection of circulating peptides we has developed a collaboration with the 
Nanomedicine Department of the Methodist Hospital Research Institute (Houston, 
Texas) for exploiting a size-exclusion strategy based on a Mesoporous Silica Chip 
(MSC).  We first performed a characterization of the mechanisms of adsorption and 
of interaction between specific peptides and MSCs by varying the critical 
parameters involved in the process. The ability to precisely control the physical 
(chip thickness, porosity and texture) and chemical properties of the MSC allowed 
to isolate the specific role of each of these features in the overall process of peptide 
absorption, retention, and fractionation. We studied the protein adsorption of MSC 
with different composition and different pore size (4nm, 6nm, 7nm pore size 
diameter) and we selected three different peptide molecules—Angiotensin II, ACTH 
(CLIP) and Aprotinin - for their different characteristics in terms of charge and 
mass, in order to have a broad view of the adsorption process. We studied the 
adsorption behaviour and kinetics of the single specific peptide incubated at 
different pH, in relation to its pI, its molecular weight, and to the different pore size 
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MSCs. Besides the nanostructure surface properties, the peptide adsorption is 
influenced by the conditions under which the experiments are conducted and by the 
nature of the molecular species to be examined. The pH of the solution that is close 
to the pI of the specific peptide favours its adsorption into the pore irrespectively of 
the pore size of MSC. However, the adsorption of peptides changes differently using 
sample solution with different complexity in protein content, where the recovery 
rate was modulated according to the mass of the peptide and the pore size. In this 
contest we observed that the peptide uptake was promoted when the peptide was not 
charged or when it was slightly positive charged. Understanding the influence of 
these factors was essential to control and optimize the process of biomarker 
enrichment and its quantification in order to avoid experimental biases that might 
mask the pathological variations in the sample leading to the erroneous 
interpretation of the results. 
We then focused our attention on the of the peptidomic profiles of patients with 
rectal cancer who received preoperative chemo-radio therapy. Although several 
research groups used serum, we choose to analyze plasma samples for MALDI-MS 
determinations (Smith F.M. et al, 2007).  Serum is obtained after the blood sample 
clotting that requires a certain time and this might interfere with analyte stability. 
Furthermore serum proteins are subjected to proteolytic degradation, enhanced by 
the activation of the coagulation process and blood cell metabolism that occur ex 
vivo. Therefore serum collection procedure and its intrinsic characteristic could 
differentially alter the composition of peptides that could be potential biomarkers 
introducing uncontrolled clinical and analytical inter-individual variations. On the 
other hand, plasma samples are obtained more easily and quickly by simply 
centrifuging blood samples. Yi et al (Yi J. et al, 2006) showed a high presence of 
peaks in serum sample, the majority of these ones ranged from 1000 m/z to 1600 
m/z. However, intrinsic plasma proteolysis is not fully inhibited by the anti-
coagulant reagent added in the blood tubes. Plasma samples that we investigated 
were collected and processed and stored in the same range of time and using the 
same procedure, and we assumed that the partially protease activity could affect the 
spectra reasonably in the same dimension.  
The peptidomic profiling analysis between healthy control subjects and rectal cancer 
patients plasma collected before the pCRT revealed the presence of peptides that 
were peculiar of the rectal cancer patients, demonstrating the diagnostic ability of 
this approach for discriminating the tumour disease. Furthermore, multivariate 
analyses of the ionic species that were observed in both healthy subjects and rectal 
cancer patients, identified several peptides that were differentially expressed 
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according with the pathological status. In particular, the analysis revealed a general 
over-expression in rectal cancer patients for the majority of the specific ionic 
species. Interestingly, analyzing several m/z individually, we observed that while 
Poor responders showed significant higher intensity compare to the controls, the 
good responders showed less pronounced expression differences (m/z at 1530.2, 
1880.9).  
Analyses of peptidomic profile according to the histopathologic response to CRT 
were performed at the three time points collected along the neo-adjuvant treatment 
(before the pCRT: T0, after two weeks from the initiation of the pCRT: T1, after the 
CRT: T2) to identify specific peptide patterns with potential predictive value.  
Unsupervised and supervised principal component analyses, combined with 
individual t-test analysis, were used to investigate the peptidomic differences 
between classes of response.  This approach has allowed the identification of 
different subsets of ionic species that could potentially discriminate the 
histopatologic response, at each time point. In particular, before the chemo-radio 
therapy, we found a set of eight peptidic markers that differentiated the 
histopathologic response; three peptides (m/z 1082.7, 1103. 9, and 1098.6) were 
found increased in the Good responder group whereas five peptides (m/z 1530.2, 
1880.3, 1934.8, 2154.8, 2348.1) were found increased in Poor responder groups. 
The multivariate logistic regression analysis confirmed the correlation of five of 
those peptides revealing a sensitivity of 80% and a specificity of 80%.  Analyses of 
plasma collected after the CRT revealed a panel of six peptidic markers 
differentially expressed, in particular ionic species at m/z 1082.7 and 1103.9 were 
over-expressed in Good responders, and ionic species at m/z 1043.4, 1183.6, 1530.2 
were over-expressed in Poor responders. Five of those were confirmed through the 
multivariate logistic regression, revealing a sensitivity of 80% and a specificity of 
85%. Peptidomic profile analysis at T1 time point identified a set of five peptides 
that showed a better separation between the histopathologic response: ionic species 
at m/z 1082.7 and 1098.6 were increased in Good responders whereas m/z at 1549.5, 
1865.2, and 2348.1 were increased in Poor responders. However the peptide 
intensity differences between the response classes were slightly significant, 
revealing misclassification for several patients. This finding might suggest that 
during the pCRT the peptide intensities could be less powerful in the response 
discrimination. Modulation of gene expression and protein expression as well as 
modulation of a number of pathways and processes such as cell cycle and cell death 
could be occur during the pCRT and this could complicate and alter the mechanisms 
of peptide formation.  Moreover, observing the overall spectra at T1 time point we 
noticed a decreased of intensity for many ionic species compare to the baseline time 
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point (T0). Another limitation for this specific analysis could be the low number of 
plasma patients that we were able to enrol at this time point.  
Comparing the specific peptide pattern that discriminated the histopathologic 
response groups in the three time points, we observed that several peptides that were 
found before the pCRT were also found after the pCRT or at T1 time point, whereas 
other peptides did not maintained its discriminative capacity. In particular we 
observed that the ionic specie at 1082.7 was found significantly expressed in Good 
responder group along all the three time points, indicating that its discriminative 
power is maintained along the therapy, whereas the ionic specie at m/z 1098.6 was 
found at T0 and at T1 time point and m/z at 1103.9 was found before and after the 
pCRT. This suggests that the presence of peptides in blood could be differentially 
affected during the chemo-radio therapy. To deepen this matter we monitored the 
presence and the different fluctuation of the ionic species along the pCRT 
administration, for each class of response. 
Principal component analysis did not showed specific subset of peptides that could 
be peculiar of one time point during the pCRT, whereas ratio of single peptide 
intensity at T1 or T2 time point over the baseline intensity (at T0 time point) 
highlighted fluctuation of several ionic species. As described before, many of these 
m/z ionic species showed a decreasing intensity at T1 time point compare with the 
baseline T0 time point, whereas at T2 time point we noticed an increased intensity 
of many variables compared to T0 and to T1 time point in both Good and Poor 
responders. This trend might suggest that the pCRT could alter the release or the 
production of peptides. Only few peptides showed an increased trend in T1 time 
point and it could be interesting to deepen the analysis in the future. Observing the 
ionic species that showed higher fluctuation during the pCRT we could noticed that 
some m/z ionic species differentially changed accordingly with the histopathologic 
response whereas other ionic species showed tendencies similar for both Good and 
Poor responders, confirming the idea that at the base of the peptidic fluctuations 
there might be different and complex mechanisms that we could not prove in this 
study. 
The identification of the amino-acids sequence of the higher peptides and the 
significant peptides was performed for potentially correlating the specific fragment 
protein to the pCRT response and for promoting possible hypothetical mechanisms 
underlying the different response. However, we could identify only few peptides of 
those observed as potentially involved in the discrimination of the histopathological 
response. Interestingly, the identified peptides were fragments of protein naturally 
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occur in blood or secreted protein. Some of these represented internal fragments of 
the precursor peptide or protein; other represented bioactive molecules or cleaved 
pro-peptides. In particular we identified Bradykinin, Bradykinin oxidized, the 
complement C3f fragment, a fragment of complement C4a, of HMW kininogen and 
of Clusterin. Interestingly, some of these peptides clustered into sets of overlapping 
fragments with ladder-like truncations at opposite ends, in particular we found 2 
overlapped peptides of Complement C4a fragment and many overlapped peptides of 
Complement C3f.   
Among the peptides that were found with high intensities and in the majority of 
spectra, independently to the pathology or to the response to pCRT, we identified 
Bradykinin, Bradykinin oxidized and the complement C3f fragment, indicating the 
absence of their clinical value. In particular, peaks related to Bradykinin were found 
in the study of Yi et al, who observed this peak as peculiar of spectra of plasma 
collected with EDTA. Conversely other ionic species seem to be peculiar of the 
tumour pathology or peculiar of the tumour response to pCRT. In particular, before 
the pCRT, a fragment of complement C4a and two fragment of the Complement C3f 
were showed associated with Good responders while Clusterin fragment 
complement C3f fragment, different from that associated with Good responder, were 
observed related to Poor responders.  After the pCRT, Clusterin and the fragment of 
Complement C3f were maintained for Poor responders whereas in T1 time point 
was maintained the C3f fragment associated to Good responders. Several fragments 
of complement C3f with truncated ends were found associated with the 
histopathological response to CRT. The different peptides of the same precursor 
fragment might be generated by exopeptidase activities that potentially confer 
cancer specific signature. Exoproteases form a heterogeneous group of enzymes that 
play different role in the regulation of biologically active peptides. The small 
number of precursor proteins that are source of these fragments are naturally not 
biomarkers but they could serve as endogenous substrate pool for other kind of 
marker, the proteases. Proteolytic degradative peptides could hold important 
information and utility in cancer detection and in tumour response prediction. 
Fragments that we found differentially expressed in association with the histological 
response could be the indirect proof of the presence of other cancer specific 
molecules. Many studies were performed using serum draw blood in which protease 
activity as well as pathway of complement activation and of coagulation is not 
inhibited, suggesting that the peptidomic pattern might be produced ex-vivo by 
numerous protease that include both endo- and exo-protease (Villanueva J. et al, 
2006; Findeisen P. et al, 2012). Cleavage site of the precursor fragments, from 
which derive the overlapping fragments with ladder-like truncation at the ends, are 
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generally consistent with trypsin- or chymotripsin-like activities of serine protease 
such as kallikreines, plasmin, thrombin, factor I. In this study we could observe 
similar pattern of peptide ladder even if we used plasma sample as starting biologic 
material.  Plasma is made by adding anti-coagulant reagent like EDTA that inhibits 
coagulation and other similar protease activities. Although this inhibition is not 
completely, the ladder-like pattern might be also due to in-vivo tumour specific 
activity. In any case it is important to point out that we found very different control 
spectra comparing to the rectal cancer patient spectra before the treatment and the 
majority of the ionic species found discriminative of the histological response were 
absent or were found differentially expressed from healthy control spectra, 
enhancing the association with the cancer-specific event. Proteases and exo-
proteases play an important role in different biological processes including cell 
differentiation, tissue remodelling, immunity, angiogenesis, apoptosis etc. 
Specifically, in solid tumours, the dysregulation of protease activity is a well-known 
factor that promotes tumour initiation as well as local progression and distant 
metastasis. Complex proteolytic networks interact with other important signalling 
pathways in tumour biology involving the regulation of chemokines, cytokines and 
active molecules (Lopez-otin C. et al, 2008). The tumor-associated proteases are 
either secreted directly by the tumour or originated from the surrounding connective 
tissue and from the infiltrating leucocytes as a result of the communication between 
stroma and tumor. There are mechanisms that concentrate the protease activity in the 
microenvironment such as expression of membrane-anchored proteins, activation of 
soluble proteases or presence of cell-surface receptors activators (Findeisen P. et al, 
2012).  
Many research groups focused on the identification of functional tumour-proteases, 
their putative substrates and their cleavage site, with different techniques 
(Villanueva J.,2008 and 2009). Up to now several databases are available with 
information regarding protease-substrate interaction. (Merops and degradome 
database) (Rawlings N.D  et al, 2008; Quesada V. et al, 2009). However tumor-
associated proteases remain mostly unknown and the disease-related proteolytic 
activities should further be characterized. Recent reports also demonstrated and 
characterized some functional proteases activity in serum and plasma (Findeisen P. 
et al, 2012), but again, little is known about the stability of the proteolytic activity in 
biologic fluid because it is difficult to study specific protease activity in sample in 
which many factors and enzymes could act in parallel. 
Another interesting finding is related to the presence of the proteic fragment at m/z 
1530 that showed an increasing expression from control subjects to poor responders, 
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before the therapy. This corresponded to a fragment of secreted Clusterin β-chain. 
Clusterin is an enigmatic protein which role is controversial because it could be 
present in several isoforms that show different localization and different functions: 
among different isoforms, the secreted isoform is a pro-survival glycoprotein of 
80kDa (sCLU). In the past few years it has become increasingly clear that Clusterin 
isoforms could be involved in numerous physiological processes important for 
carcinogenesis and tumour growth, including apoptotic cell death, cell cycle 
regulation, DNA repair, cell adhesion, tissue remodelling, lipid transportation, 
membrane recycling, and immune system regulation (Shannan B. et al, 2006).  
Furthermore Clusterin has been reported to be a stress inducible gene and it has been 
involved in resistance to therapy. Several controversial data have been published 
on colon cancer discussing its role as tumor suppressor or prosurvival factor in colon 
cancer. In a published paper Andersen et al (Andersen C.L. et al, 2007) found a 
Clusterin expression by neuroendocrine cells in normal colon mucosa whereas CLU 
gene were found de novo synthesized, and often secreted, in 25% of CRCs. Other 
research groups found a progressively increased expression of secretory CLU 
correlated to a significant increase of CLU in serum and stool of patients whereas 
the nuclear pro-apoptotic form was down-regulated (Mazzarelli P. et al, 2009). 
Within the cell, sCLU can bind Bax and prevent it translocation to the mitochondria, 
thereby blocking apoptosis (Zhang H. et al, 2005). Due to its pro-survival functions, 
sCLU overexpression seems to be partially responsible for increased resistance of 
cancer cells to various stresses including radiation (Klokov D. et al, 2005). Outside 
the cell, sCLU seems to act as a molecular chaperone, binding to stress-induced 
unfolded proteins, lipids and other molecules, and works to clear cell debris after 
tissue trauma.  These observations strongly suggest that elevated sCLU levels in 
cancer, as well as induction of sCLU after cytotoxic agent exposures, may result in 
the consequent resistance of cancer cells to therapy, including cancer stem. Goetz et 
al highlighted the complex connection between exogenous or endogenous DNA 
damage and the induction of sCLU, activated by ATM kinase in response to double 
strand break, mediated by IGF-1 and regulated by numerous factors such as p53/NF-
YA, p21, TGF-B1 cells (Goetz E.M. et al, 2011).  
Based on our results, we suggest that low molecular weight peptide analysis is a 
promising approach complementary to the conventional tumour-tissue based tests 
and to the clinical current strategy for predicting the response to multimodality 
preoperative treatment of rectal cancer. 
We highlight the need to identify the other significant ionic species that we were not 
able to identify in the first analysis, such as the m/z at 1082.7 that is found 
associated with Good responders in all three time point along the pCRT.  
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Furthermore, the showed data require to be confirmed by analysing other cases and 
by implementing the study also with patients with inflammatory- non-malignant 
disease for evaluating the protease pattern that could affect this status. It is noticed 
that numerous malignant diseases associated with inflammation are influencing the 
protease pattern in body fluid.  On the other hand these data prepare the ground for 
subsequent investigation on potential peptidases and proteases involved in cancer 
progression and suggested the potential for improving the personalized neo-adjuvant 
therapy.  Further investigations on the specific roles of Clusterin could be interesting 
for understanding its potential relation with tumour therapy resistance and 
eventually thinking about alternative therapy target-specific.  
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10 CONCLUSION 
 
The Ph.D. project has involved the development and the evaluation of blood-based 
approaches for discovering potential biomarkers associated with the 
histopathological response of locally advanced rectal cancer treated with pre-
operative chemo-radio therapy (pCRT). The non-invasive nature and the dynamism 
for which different molecules could be detected in blood, according with 
physiological and pathological states, has given us the possibility to monitor the 
response along the administration of the treatment. For this purpose we investigated 
the circulating cell free DNA and its integrity (cfDNA integrity) along the chemo-
radio treatment, demonstrating a different kinetic of cfDNA integrity in association 
with the histopathological response. The decrement of cfDNA integrity for the 
positive tumour response, during the CRT, could be potentially related to the tumour 
mass reduction and to a possible different mechanism of cfDNA release.  The 
positive association between the presence of tumour with cfDNA concentration and 
with cfDNA integrity, was also confirmed in other studies, performed in different 
cancer types, in which we observed an interesting indication of their potential 
diagnostic and prognostic significance. However, current limitations in clinical 
practice arise by the high inter-individual variability that could be affected by 
numerous technical and biological factors, decreasing the accuracy of the methods. 
More interesting findings have been found by evaluating the low molecular weight 
region of the proteome circulating in blood, in relation to the histopathological 
response to pCRT.  The development of a controlled method of peptide fractionation 
and of peptide analysis has allowed the identification of specific patterns of peptides 
(either before and after the CRT) that correlated with the histopathological response 
to CRT, highlighting the potential utility of this method as a clinical response 
prediction tool. Moreover, the results of this study have opened the way to further 
investigation in different fields that could be involved in modulating the response to 
chemo-radio therapy. In particular, we pointed out the presence of proteolytic 
degradative pattern of peptides that suggested the involvement of potential specific 
functional tumour-protease and exopeptidase activity. In addition, the association of 
a fragment of Clusterin secretory isoform with the Poor response to pCRT, both 
before and after the pCRT, stimulate our interest to future deepen its role with the 
tumour therapy response. Furthermore these data suggested the potential for 
improving the personalized neo-adjuvant therapy and eventually the design of future 
clinical trials.   
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Based on our results, cfDNA and the low molecular weight peptide analysis suggest 
the potential to become promising approaches complementary to the conventional 
tumour-tissue based tests and to the clinical current strategy for predicting the 
response to multimodality preoperative treatment of rectal cancer. 
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